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A fundamental question in developmental biology is how a single 
multipotent cell undergoes cell divisions and fate specification to give rise to 
different cell types. In this process, multiple signaling events and transcription 
factors play critical roles. The understanding of the developmental mechanisms 
is especially important because malfunction of many developmental players 
usually associates with various human diseases.  
I have studied a transcription factor SEM-2, a C. elegans homolog of 
vertebrate SoxC proteins. Mis-regulation of SoxC has been shown to associate 
with multiple types of tumors. However, the molecular mechanism by which SoxC 
gene expression is regulated is not known.  I have determined the function of the 
sole C. elegans SoxC homolog SEM-2 in the M lineage, which produces the 
postembryonic mesoderm. I found that SEM-2/SoxC is both necessary and 
sufficient to promote a proliferating blast cell fate, the sex myoblast fate, over a 
differentiated striated bodywall muscle fate. I have shown that this function of 
sem-2 is directly regulated by PBC/HOX factors in the M lineage, as 
demonstrated by computational, in vivo functional and in vitro electrophoretic 
mobility shift assays (EMSA). I also identified the positional cues that dictate the 
specific expression of sem-2 in the sex myoblast precursors and their 
descendants, which include BMP signaling, Notch signaling and Wnt signaling. 
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Ongoing studies include identifying and analyzing the direct downstream targets 
of sem-2 in promoting the proliferative over differentiative fates by a candidate 
gene approach. 
Another focus of my thesis is on two modulators of BMP signaling in C. 
elegans: DRAG-1, a GPI (glycophosphatidlinositol)-anchored protein that is the 
sole member of the repulsive guidance molecule (RGM) family of proteins, and 
UNC-40, a transmembrane protein that is the sole C. elegans DCC(Deleted in 
Colorectal Cancer)/neogenin ortholog, best studied for its roles in axon and cell 
movement. The vertebrate homologs of both proteins have been found to 
modulate BMP signaling, but the mechanistic details of this regulation are not 
well understood. Using a combination of molecular genetic and biochemical 
analyses, I demonstrated that both DRAG-1/RGM and UNC-40/neogenin are 
positive modulators of BMP signaling at the ligand-receptor level. The role of 
UNC-40/neogenin in modulating BMP signaling is independent of its role in axon 
guidance and does not require its intracellular domain. DRAG-1/RGM physically 
interacts with UNC-40/neogenin, as well as the ligand and the two receptors of 
the BMP pathway. These results suggest a model in which the interaction 
between DRAG-1/RGM and UNC-40/neogenin may help the assembly of the 
ligand/receptor complex at the cell surface to ensure efficient BMP signaling. My 
work demonstrates a direct link between RGM proteins, Neogenin and BMP 
signaling in vivo, and provides a simple and genetically tractable system for 
further mechanistic studies of RGM and Neogenin proteins in regulation of BMP 
pathways. 
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Chapter 1:  Introduction 
One of the fundamental questions in biology is how a single fertilized 
zygote divides into a large population of cells of diverse types to form a functional 
life unit. Cell proliferation, specification, migration and cell death are all critical 
cellular events in this process. Many signaling pathways and transcription factors 
function spatiotemporally in concert to integrate the cellular behaviors during 
development and homeostasis. Many human diseases, either developmental 
diseases or late onset diseases, are due to malfunction of these important 
factors. Therefore, it is beneficial for conquering human diseases to understand 
the molecular mechanisms underlying the regulation and function of signaling 
pathways and transcription factors. In the past several decades, researchers 
have developed multiple model organisms for studying these molecular 
mechanisms.  
C. elegans is an excellent model organism for the study of these 
mechanisms. C. elegans is a multicellular animal that shares conserved genes 
with human. It has appealing advantages in several aspects in comparison to 
other model organisms. First, it has a short life cycle of 3 to 5 days, which is a 
huge advantage over mice, zebrafish, chick, and Xenopus, whose life cycles are 
much longer. This makes it ideal to perform forward genetic screens with C. 
elegans. Second, C. elegans has a small genome of 97Mb (C. elegans 
Sequencing Consortium, 1998), which is smaller than all the other commonly 
used multicellular model organisms. In the genome sequencing era, this 
tremendously reduces the cost and efforts of analyzing sequencing data. Third, 
C. elegans is transparent throughout its life cycle, which allows direct observation 
and manipulation of embryonic and postembryonic development, a task not easy 
to achieve in many vertebrates, especially in mice. Fourth, the cell lineage of C. 
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elegans allows us to study developmental events at single cell resolution, which 
is not always possible in many other multicellular animals. Last, a number of 
genetic manipulation techniques are available in C. elegans, such as powerful 
and effective RNA interference method, various transgenic methods to make 
extrachromosomal arrays, knock in and knock out genes.  
In this chapter, I will start by introducing what we have learned from the 
development of a C. elegans postembryonic mesoderm lineage, the M lineage, 
which is my primary model system. I will then discuss a family of transcription 
factors, Sox, with a focus on the SoxC factors and their roles in increasing or 
reducing proliferation. In the third part, I will introduce the TGF- signaling 
pathway and specifically two groups of TGF- signaling modulators, RGM 
proteins and Neogenin. 
1.1  C. elegans postembryonic mesoderm development 
1.1.1  The M lineage 
The postembryonic M lineage is derived from a single precursor cell, the 
M mesoblast (Sulston and Horvitz, 1977). It is born embryonically and divide 
postembryonically to give rise to all postembryonically derived non-gonadal 
mesodermal cells. The M cell has a reproducible division pattern. It goes through 
one round of dorsoventral division, one round of left-right division and two rounds 
of anterioposterior divisions to give rise to 16 mesoderm cells (Figure 1.1). 
Twelve of these cells will differentiate into the striated muscle-like body wall 
muscles (BWMs). Two of the 16 cells will become non-muscle macrophage-like 
coelomocytes (CCs), which play a role in heavy metal detoxification (Schwartz et 
al., 2010). The remaining two cells, M.vlpa and M.vrpa, or collectively called 
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M.v(l/r)pa, will divide anterioposteriorly once again. The anterior descendants will 
later become progenitor cells, the sex myoblasts (SMs), which will migrate to the 
presumptive vulva region and divide to give rise to all the non-striated sex 
muscles that are used for laying eggs, include type I and type II vulval muscles 
(VM1s and VM2s) and type I and type II uterine muscles (UM1s and UM2s). The 
posterior cells will differentiate into BWMs. The 14 total M lineage-derived BWMs 
will join the 81 embryonically derived BWMs to form the entire musculature used 
for locomotion.  
The M lineage has several advantages for studying mesodermal 
development. First, the M lineage is very reproducible and simple. Second, the 
entire lineage is not essential for the viability of C. elegans, allowing for various 
genetic and experimental manipulations. Third, a variety of cell-type-specific 
reporters are available to follow the M lineage development at single cell 
resolution (Kostas and Fire, 2002, Table 1.1). 
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Table 1.1: M Lineage cell-specific markers 
 
Markers Expression in Cell types 
hlh-8::gfp all the undifferentiated cells in the M lineage 
egl-15::gfp all VM1s 
myo-3::gfp all BMWs and VMs 
Nde-box::gfp all VMs and UMs 
arg-1::gfp VMs 
CC::gfp 4 embryonic-derived CCs and 2 M-derived CCs 
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Figure 1.1: The C. elegans hermaphrodite postembryonic M lineage. 
 
Times indicated are hours post-hatching at 25°C (modified from Sulston 
and Hovitz, 1977). (A) The M lineage fate map showing all the differentiated cell 
types. The corresponding developmental stages are indicated on both sides of 
the figure. (B) A schematic lateral view of developing C. elegans larvae with the 
M lineage cells highlighted. D, dorsal, V, ventral, L, left, R, right, A, anterior, P, 
posterior.  
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The M lineage is a unique model to study mechanisms underlying several 
developmental processes. First of all, we can study asymmetric patterning. The 
M lineage exhibits both dorsoventral and anterioposterior asymmetries: the CCs 
are born on the dorsal side and the SMs are born on the ventral side; yet both 
CCs and SMs are anterior daughters of their respective mother cells. What 
factors regulate these asymmetries? Second, we can study the regulation of 
proliferation vs. differentiation. M.v(l/r)pa cells give rise to two daughter cells of 
entirely distinct fates: the anterior SM cells keep their proliferation ability while the 
posterior BWMs become fully differentiated. What regulates the decision 
between proliferation and differentiation? Third, we can study the different 
mechanisms underlying the formation of striated muscles and non-striated 
muscles. M.v(l/r)pa cells give rise to both striated muscles cells (BWMs) and 
progenitor cells for smooth muscle-like sex muscles. What are the mechanisms 
for the specification of each of these cell types? In the next section, I will 
summarize the molecular mechanisms involved in these events.  
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1.1.2  Mechanisms underlying the specification of M-derived cells 
The specification of M-derived BWMs 
Body wall muscles are derived embryonically and postembryonically 
(Krause and Liu, 2012). Like the embryonically derived BWMs, the specification 
of M-derived BWMs requires the C. elegans homolog of MyoD, HLH-1 (Harfe et 
al., 1998). The lack of hlh-1 expression or function in the M lineage causes fate 
transformation from BWMs and CCs to SMs. However, only a few BWMs are 
affected (Harfe et al., 1998). This suggests that HLH-1 may have redundant 
function with other factors in specifying BWM in the M lineage. One such factor is 
FOZI-1. fozi-1 encodes a zinc-finger protein with a formin homology domain 
(Amin et al., 2007). fozi-1 is expressed similarly to hlh-1 in the M lineage before 
the BWMs are differentiated. A fozi-1 mutant exhibits similar fate transformation 
as hlh-1 mutant: a few BWMs and all M-derived CCs are transformed to SMs. 
Animals that are double mutant for hlh-1 and fozi-1 lose most, if not all, of the M-
derived BWMs. Together with the fact that fozi-1 and hlh-1 do not regulate each 
other’s expression, this suggests that they function redundantly in specifying 
BWMs (Amin et al., 2007). The specification of M-derived BWMs also requires 
MAB-5, an Antennapedia homolog. mab-5 mutants exhibit similar fate 
transformations as hlh-1 and fozi-1 mutants. Double and triple mutant analysis 
indicates that mab-5 functions together with fozi-1, and both function redundantly 
with hlh-1 (Amin et al., 2007; Figure 1.2).   
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Figure 1.2: Genetic regulatory network for patterning the M lineage. 
 
Thick blue lines indicate direct regulation. Black lines represent regulation 
based on genetic evidence, which do not distinguish direct from indirect 
regulation. Grey lines and text indicate lack of expression in the corresponding 
cells.  (A) The dorsal M lineage at the 16-M stage showing the posterior two 
cells. (B) The ventral M lineage at the 16-M stage showing the posterior two cells 
and the two descendants of the anterior cell after its division. 
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M lineage expression of hlh-1 is activated by the HMX homeodomain 
protein MLS-2 (Jiang et al., 2005). mls-2 expression is likely directly activated by 
the PBC homeodomain protein CEH-20 independent of Hox factors (Jiang et al., 
2005;Jiang et al., 2008). The M lineage expression of fozi-1 is also regulated by 
ceh-20. However, this regulation is not mediated by mls-2 (Amin et al., 2007). 
 
The specification of M-derived CCs 
The M-derived CCs are specified by the transient expression of the SIX 
homeodomain protein CEH-34 and its cofactor EYA-1 (Amin et al., 2009; Figure 
1.2). ceh-34 expression in the M lineage is directly activated by FoxF/C factor 
LET-381, which functions in a feed-forward manner with CEH-34 and EYA-1 to 
directly activate genes that are involved in CC differentiation and function (Amin 
et al., 2010). HLH-1 and FOZI-1 factors that specify M derived-BWMs are also 
required to specify M derived-CCs by positively regulating let-381 expression 
(Amin et al., 2010). The expression of ceh-34 and eya-1 is turned on in the 
M.d(l/r)pa cells due to the action of several signaling pathways. The patterning 
along the dorsal-ventral axis requires the Schnurri homolog SMA-9, which 
functions to antagonize a BMP-like pathway to pattern the dorsal M lineage, as 
well as the LIN-12/Notch pathway that patterns the ventral M lineage (Foehr et 
al., 2006;Foehr and Liu, 2008). The expression of ceh-34 and eya-1 in the 
anterior cells (M.d(l/r)pa) requires the Wnt/-catenin asymmetry pathway along 
the anterioposterior axis (Amin et al., 2009;Amin et al., 2010).   
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The specification of SMs 
 The SMs are specified by the SoxC factor SEM-2 (Tian et al., 2011). 
Please refer to section 1.2 for a detailed introduction to Sox factors. sem-2 is 
expressed in the SM mother cells, SMs and their proliferating descendants. sem-
2 is both required and sufficient for the proliferative SM fate over the 
differentiated BWM fate. sem-2 expression is directly activated by the Hox factors 
MAB-5 and LIN-39 and their cofactor CEH-20/PBC (Figure 1.2). The same D-V 
and A-P cues involved in CC specification are also involved in restricting sem-2 
expression in the M lineage (Tian et al., 2011). Notably, the D-V cues likely 
converge on LET-381/FoxF/C, which represses sem-2 expression on the dorsal 
side of the M lineage (Tian et al., 2011; Figure 1.2). My unpublished result 
suggests that SEM-2 may be a cofactor of the Zinc finger transcription factor 
SEM-4/SALL in specifying the SM fate (See Appendix 1). sem-2 and sem-4 
mutants share the same SM to BWM fate transformation. The onset of sem-4 
expression is one division earlier than sem-2 in the M lineage. However, sem-2 
and sem-4 do not regulate each other’s expression in the M lineage (See 
Appendix 1). It will be of great interest to identify the downstream effectors of 
sem-2 and sem-4 for specifying a proliferative blast cell fate.  
The specification of VMs (vulval muscles) and UMs (uterine muscles) 
 The VMs and UMs are non-striated smooth muscle-like cells differentiated 
from the SM descendants. There is very little known about factors that regulate 
the VM and UM fates. The T-box factor MLS-1 is both required and sufficient for 
specifying the uterine muscle fate (Kostas and Fire, 2002). The Meis 
homeodomain protein UNC-62 is required to properly specify UMs and VM2s 
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(Jiang et al., 2009). The Liu lab also discovered a role of the LIN-12/Notch 
signaling pathway in properly specifying VM2s (J. Hale and J. Liu, personal 
communication). In general, specification of the smooth muscles is less well 
studied than that of striated muscles. Therefore, characterizing key factors in the 
specification of VMs and UMs may provide insight into mechanisms involved in 
smooth muscle specification. 
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1.2  SoxC family members and their roles in development and disease  
1.2.1 SoxC molecular features 
Sox family members are found throughout the animal kingdom. They are 
characterized by the presence of a DNA-binding HMG (high mobility group) 
domain (Bowles et al., 2000). Sox family members are divided into groups A-J 
based on homologies in the HMG domain (Bowles et al., 2000). The SoxC family 
of Sry-related HMG box transcription factors is constituted of Sox4, Sox11 and 
Sox12 in vertebrates. There is only a single member of the SoxC family in C. 
elegans and Drosophila (Bowles et al., 2000). SoxC transcription factors are 
conventional transcription factors: they have a SRY-related HMG box (Sox) DNA-
binding domain located in the middle of the proteins and a transactivation domain 
(TAD) located at the C terminus (Dy et al., 2008) (Figure 1.3). The HMG box is 
84% identical at the amino acid level across all vertebrate SoxC proteins (Dy et 
al., 2008). The Sox4 HMG box has high affinity to the minor groove of the 
heptamer motif AACAAAG (van de Wetering et al., 1993). Besides the high 
affinity primary binding sites, Sox4 (and possibly others) is also capable of 
binding to secondary sites that deviate in sequences from the primary site. The 
crystal structure of Sox4 HMG domain binding to DNA indicates that Sox4 is 
capable of binding to primary and secondary sites by the concerted re-
adjustment of the H-bonding pattern of two amino acid side chains (Jauch et al., 
2012). Sox4 HMG box binds to DNA more efficiently than Sox12 in 
electrophoretic mobility shift assays (EMSA) and Sox11 has very low affinity to 
DNA in vitro (Dy et al., 2008).  
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The transactivation domain (TAD) is 67% identical at the amino acid level 
across all the SoxC members. The TAD is highly enriched in proline, serine, and 
acidic residues, which are commonly seen in TADs. Secondary structure 
predictions suggest the formation of a 20-residue alpha helix that is intact in 
Sox11 and disrupted in Sox4 and Sox12 (Dy et al., 2008).  
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Figure 1.3: Structural features of human SoxC proteins and SEM-2.  
 
HMG: high mobility group box DNA-binding domain; TAD, transactivation 
domain. Numbers show the beginning and ending of each domain (Penzo-
Mendez, 2010, for human SoxC proteins).  
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SoxC proteins, like the SoxB1 and SoxE proteins, strongly synergize with 
the POU domain protein Brn1 and Brn2 to activate downstream genes that 
contain adjacent Sox and POU binding sites, including Fgf4 and Nestin (Dy et al., 
2008;Kuhlbrodt et al., 1998;Tanaka et al., 2004). Sox4 also binds to plakoglobin 
in response to WNT3A to inhibit transcriptional activity for some Wnt and Sox4 
downstream genes (Lai et al., 2011). In addition to its role in transcriptional 
regulation, Sox4 was also found to regulate p53 stability and activity in lung non-
small cell carcinoma cells (Pan et al., 2009a). Sox4 regulation of p53 stability is 
dependent on protein-protein interaction that occurs between the Sox4 DNA-
binding domain and the p53 DNA-binding domain and regulatory domain (Pan et 
al., 2009a).  
1.2.2 SoxC expression and mutant phenotypes 
The expression patterns of the SoxC genes are largely overlapping in 
mice. The RNAs for all three genes were found in many regions of the central 
and peripheral nervous system, including the brain, neural tube, retina, olfactory 
epithelium, cochlear epithelium and dorsal root ganglia (Hargrave et al., 1997;Dy 
et al., 2008). The three genes are also co-expressed in the undifferentiated 
mesenchyme, such as skeletal primordia and genital tubercle, and in developing 
organs, such as endocaridial cushions, lung, gut, kidney and pancreas (Sock et 
al., 2004;Dy et al., 2008). The three genes also have gene-specific regions of 
expression. For example, the eyelid primordium and palatal shelf mesenchyme 
express Sox11 and Sox12, but not Sox4; the developing heart endocardial 
cushions express Sox4 and Sox12, but not Sox11; and the developing teeth, 
spleen, thymus and hair follicles predominantly express Sox4 (Dy et al., 2008). 
The expression patterns of the SoxC genes suggest that they may play important 
  
19 
 
roles in development and this is consistent with mouse knockout mutant 
phenotypes. Sox4 null embryos die at embryonic day 14 with heart outflow tract 
defects and incomplete ventricular septation caused by impaired development of 
endocardial ridges (Schilham et al., 1996). Sox11 null mice die at birth from heart 
malfunctions and the phenotypes are similar to, but less severe than, those of 
Sox4 null mutants (Sock et al., 2004). Sox11 and Sox4 null mice also display 
many other developmental defects, such as various craniofacial and skeletal 
malformations, asplenia, and hypoplasia of the lung, stomach, and pancreas 
(Sock et al., 2004). Sox12 null mice have no obvious defects and have a normal 
life span and fertility (Hoser et al., 2008). Interestingly, although the SoxC genes 
are highly expressed in central and peripheral nervous system, no nervous 
system phenotypes were observed in signle mutant, suggesting that they may 
function redundantly there.  
1.2.3 SoxC in promoting differentiation and proliferation 
Overexpression and knockdown experiments of SoxC proteins suggest 
that they have neuronal functions. Neural tube electroporations in chicken 
embryos indicated that Sox4 and Sox11 promote neuronal gene upregulation in 
precursors of CNS neurons (Bergsland et al., 2006), and overexpression of Sox4 
and Sox11 in the mouse has provided evidence for a negative influence of Sox4 
and Sox11 on the differentiation of CNS glia (Hoser et al., 2007;Potzner et al., 
2007).  Recent studies showed that Sox11 is enriched on the promoters of 
neuron-specific genes in embryonic stem cell-derived neurons, suggesting that 
SoxC proteins may be key regulators of neuronal differentiation (Bergsland et al., 
2011). Consistent with this notion, Sox4 and Sox11 exhibit overlapping 
expression in the hippocampal neurogenic lineage. Overexpression of either of 
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them is sufficient to induce neuronal marker expression in adult neural stem cells 
(NSCs), while loss of Sox4 and Sox11 results in loss of expression of neuron-
specific proteins in vivo and in vitro (Mu et al., 2012). Besides their roles in 
neuronal cell differentiation, SoxC factors also play roles in promoting 
proliferation and survival. Cell survival is reduced in the developing spinal cord 
with combined loss of Sox4 and Sox11 proteins, while cell proliferation is not 
affected (Thein et al., 2010). Sox11 regulates survival and axonal growth of 
embryonic sensory neurons (Lin et al., 2011). During development of the 
sympathetic nervous system, Sox11 expression turns on first and is required for 
proliferation in early sympathetic ganglia, whereas Sox4 is prevalent later and 
required for their survival at later stages. Sox4 and Sox11 do not appear to 
function in promoting differentiation as in the central nervous system (Potzner et 
al., 2010). Therefore, depending on the cellular contexts, SoxC factors can 
promote differentiation, proliferation or survival in the nervous system. 
SoxC proteins also function similarly in other cell lineages. Sox4 is 
required for B lymphocyte differentiation as Sox4 null hematopoietic cells grafted 
into wild-type mice remain undifferentiated at the pro-B cell stage (Schilham et 
al., 1996). Sox4(+/-) mice have inhibition of proliferation, differentiation and 
mineralization in primary calvarial osteoblasts (Nissen-Meyer et al., 2007). 
Furthermore, Sox4 null pancreatic explants displayed severely reduced numbers 
of endocrine insulin-producing  cells (Wilson et al., 2005). Similarly, knocking 
down Sox4b in zebrafish embryos results in loss of glucagon-producing alpha 
cells (Mavropoulos et al., 2005). Study of compound mutants of SoxC genes 
suggest that they are redundantly required to control survival of neural and 
mesenchymal progenitors and function at least in part by activating Teads, 
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encoding a transcriptional mediator of the Hippo pathway (Bhattaram et al., 
2010).  
Besides the versatile roles of SoxC factors in mouse development, SOXC 
factors have been implicated in human diseases in recent years. A genome wide 
association study identified SOX4 as a novel gene affecting bone mineral density 
and fracture risk (Duncan et al., 2011). Further experiments will be required to 
elucidate the mechanisms. 
More studies have implicated SoxC genes in cancer. SOX4 or SOX11 
expression is upregulated in medulloblastomas (Lee et al., 2002), 
gliomas(Weigle et al., 2005), non-B cell lymphomas (Wang et al., 2008a), 
epithelial ovarian tumors (Brennan et al., 2009), bladder (Aaboe et al., 2006), 
colon(Andersen et al., 2009), prostate (Liu et al., 2006), and non-small cell lung 
carcinomas (Medina et al., 2009). These genes have been reported to be 
indicators of either good or poor prognosis in cancer patients. However, the roles 
of the SOXC genes in tumors are not fully understood, for example, the role of 
SOX4 in apoptosis is controversial. SOX4 knockdown resulted in apoptosis in 
ACC3 adenoid cystic carcinoma cells (Pramoonjago et al., 2006), while SOX4 
overexpression was shown to promote cell cycle arrest and apoptosis in HCT116 
colon carcinoma cells (Pan et al., 2009b). Overexpression of Sox11 prevented 
tumorigenesis of NSCL61s, a mouse glioma cell line, by inducing their neuronal 
differentiation (Hide et al., 2009). In consistent with that, higher level of SOX4 
and SOX11 expression indicates higher survival rates in medulloblastomas and 
other tumor types (de Bont et al., 2008). Besides the SoxC genes’ possible roles 
in cell survival and differentiation, Sox4 is targeted by microRNA miR-335 to 
inhibit metastatic cell invasion by acting at least in part through the Sox4 target 
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gene Tenascin, a known extracelluar matrix protein implicated in cell migration 
(Tavazoie et al., 2008). 
In summary, SOXC proteins have possible but as yet unclear roles in cell 
survival, apoptosis, differentiation and metastatic invasion, and the different roles 
may depend on the context of different cell lineages or tumor types. Further 
studies are required to elucidate the mechanisms of the involvement of SoxC 
factors in development and diseases, especially cancer. 
 
1.3  The TGF- signaling pathway 
1.3.1  The core TGF- pathway 
 The transforming growth factor (TGF) superfamily of extracellular 
signaling molecules regulates a wide variety of cellular processes, including cell 
fate specification, cell proliferation, cell migration, and cell death throughout all 
developmental stages of multi-cellular organisms (reviewed in Massague et al., 
2000b). Malfunction of the pathway causes many somatic and hereditary 
disorders in humans, including cardiovascular diseases and various types of 
cancers (Massague et al., 2000a;Siegel and Massague, 2003;Gordon and Blobe, 
2008;Massague, 2008). The TGF family of cytokines includes two sub-groups 
defined by sequence similarity and function: the TGF/activin/Nodal subfamily 
and the BMP (Bone morphogenetic protein)/GDF (Growth and differentiation 
factor)/MIS (Muellerian inhibiting substance) subfamily (Shi and Massague, 
2003). The TGF family ligands are generated with a prodomain proceeding the 
mature domain. The prodomain is cleaved by furin protease in the secretory 
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pathway but remains non-covalently bound to the active domain (Miyazono et al. 
1988; Wakefield et al. 1988). Activation of the ligands requires removal of the 
prodomains (Figure 1.4). The active forms of ligands of different subfamilies 
share structural similarities, including a dimer stabilized by hydrophobic 
interactions and an inter-subunit disulfide bond (Shi and Massague, 2003).  
The receptors for TGF cytokines belong to the receptor serine/threonine 
kinase family. TGF receptors fall into two classes:  type I and type II (Attisano et 
al., 1994;Massague, 1992;Massague, 1998).  TGF- and BMP subfamily ligands 
utilized different sets of type I and type II receptors. Both types of receptors are 
type I transmembrane proteins, comprised of an extracellular domain, a 
transmembrane region, and a C-terminal serine/threonine kinase domain. The 
extracellular domains of type I and type II receptors are capable of binding to the 
ligands. Two distinct modes of ligand-receptor interaction exist. BMP ligands 
exhibit a high affinity for the extracellular domains of the type I receptors and a 
low affinity for the type II receptors. The ligand binds to type I receptor first and 
the ligand-type I receptor complex subsequently binds to type II receptors. In 
contrast to the BMPs, TGF and Activin display a high affinity for the type II 
receptors and do not interact with the type I receptors. Therefore, the TGF 
ligand binds tightly to type II receptor first; this binding allows subsequent 
incorporation of the type I receptor. The type I, but not type II, receptors contain a 
characteristic SGSGSG sequence, also known as the GS domain, which is 
located N-terminal to the kinase domain. Once the ligand binding brings the type 
I and type II receptors to close proximity, constitutively active type II receptor 
phosphorylates type I receptor at its GS domain (Figure 1.4).  
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The activated type I receptor is poised to relay the TGF- signal through 
the Smad proteins, which transduce the signal from the cytoplasm to the nucleus 
(Massague, 1998;Massague and Chen, 2000;Massague and Wotton, 
2000b;Massague et al., 2005a; Figure 1.4). There are two classes of Smad 
proteins required for signal transduction: receptor regulated Smads (R-Smads) 
and collaborating Smads (co-Smads). R-Smads are directly phosphorylated and 
activated by the type I receptors. The TGF subfamily uses Smad2 and Smad3, 
while the BMP subfamily transduces through Smads 1, 5, and 8.  
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Figure 1.4: overview of the TGF- signaling pathway 
TGFβ family members are dimeric ligands that remain in latent form by 
binding to their propeptides, or in trapped forms by binding to different ligand 
traps. Only when released from these inactive states, the ligands bind to two 
pairs of type I and type II receptor serine/threonine kinases, forming a hetero-
tetrameric receptor complex. The cytoplasmic region of the type I receptor 
contains a canonical protein kinase domain (purple) C terminal to a regulatory 
region or GS domain (green). Once in close proximity, type II receptor 
phosphorylates the GS domain of type I receptor, which then activate R-Smads 
by phosphorylating the SXS motif at the C terminus of R-Smads. The 
phosphorylation at the C terminus of R-Smads creates a pS-x-pS motif (red P), 
allowing the accumulation of R-Smads in the nucleus and the recognition of this 
motif by Smad4. The Smads complex then recruits DNA-binding cofactors and 
transcription co-activators and co-repressors to confer transcriptional control. 
Modified from Massagué et al. 2005b. 
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The Smad proteins share similar structural features, including the N-
terminal MH1 and the C-terminal MH2 domains. The MH1 domains exhibit DNA 
sequence specific binding activities, and inhibit MH2 domain function.  The MH2 
domain is required for Smad-receptor interaction, Smad-Smad interaction and 
Smad-Smad DNA-binding cofactor interactions. It also directly interacts with the 
cytoplasmic retention proteins and the nuclear pore compex for 
nucleocytoplasmic shuttling. The R-Smads, but not the Co-Smads, exhibit a Ser-
X-Ser (SXS) motif at the C terminus (Figure 1.4). This SXS motif is 
phosphorylated by the activated type I receptor. The phosphorylated C terminus 
provides a binding site for Smad4, the Co-Smad, which is an essential 
component in the assembly of target-specific transcriptional complexes. R-Smad 
translocation does not require the presence of co-Smads.  However, co-Smads 
require the presence of activated R-Smads to travel into the nucleus (Attisano 
and Wrana, 2000;Massague et al., 2005a). The resulting Smad complex 
incorporates different DNA-binding cofactors that confer target gene selectivity 
and affect the recruitment of either transcriptional co-activators or co-repressors 
(Figure 1.4). 
The MH1 domain (approximately 130 amino acids) and the MH2 domain 
(approximately 200 amino acids) are separated by a linker domain, which is not 
conserved in sequence or length (Massague, 1998). However, the linker region 
contains multiple phosphorylation sites that have critical functions. When directed 
to the nucleus by TGF- or BMP signals, the linker region is phosphorylated by 
MAP kinases and cell division cyclin-dependent kinases (CDKs) in response to 
mitogens and stresses to constrain TGF- and BMP signaling (Kretzschmar et al., 
1997;Kretzschmar et al., 1999;Matsuura et al., 2010). Smad proteins can also be 
phosphorylated by cyclin-dependent kinase 8/9 (CDK8/9) and glycogen synthase 
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kinase-3 (GSK3), and these phosphorylations are required for transcriptional 
action and subsequently required for Smad destruction (Aragon et al., 2011). 
1.3.2  The modulation of the TGF- pathways 
The TGF- signaling pathway can be modulated at different levels, including 
receptor activation outside the cell, Smad access to the receptors in the 
cytoplasm, Smad nucleocytoplasmic shuttling, and Smad-dependent 
transcription in the nucleus (Shi and Massague, 2003). I will mainly focus on 
modulations of the TGF- pathway that take place outside the cell. Please refer 
to these excellent reviews for modulation of TGF- signaling at other levels 
(Massague, 1998;Massague and Chen, 2000;Massague and Wotton, 2000a;Shi 
and Massague, 2003; Chen YG, 2009). 
At the level of receptor activation, extracellular secreted proteins, such as 
Noggin, Chordin/Sog, Gremlin, Follistatin, and DAN/Cerberus, have been shown 
to function as ligand binding traps (Balemans and Van Hul, 2002;Shi and 
Massague, 2003) (Figure 1.4). Noggin is the best known BMP antagonist. Noggin 
sequesters the ligands and blocks the ligands from binding to the type I and II 
receptors (Groppe et al., 2002). In Drosophila, Twisted gastrulation (Tsg) forms a 
complex with the Chordin homolog Short gastrulation (Sog). This complex 
sequesters BMPs to attenuate BMP signaling locally but enhances long range 
BMP signaling by transporting BMPs through tissues (O'Connor et al., 2006). 
Crossveinless 2, another Drosophila homolog of Chordin, can activate or inhibit 
BMP signaling through directly binding to the BMP ligands, and the different 
responses are determined by different BMP types and concentrations (Ambrosio 
et al., 2008;Serpe et al., 2008;Zhang et al., 2008).  
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The extracellular matrix (ECM) proteins have also been shown to modulate 
TGF- signaling. glycan, also known as the TGF- type III receptor, mediates 
TGF-2 binding to type II TGF- receptor and also increases the affinity of Inhibin 
to Activin and type II BMP receptors (del Re et al., 2004;Lewis et al., 2000;Wiater 
et al., 2006). A glycosylphosphatidylinositol (GPI)-anchored proteoglycan family 
member in Drosophila, Dally, positively regulates the distribution of Dpp and Wg 
morphogen (Grisaru et al., 2001;Han et al., 2005;Takeo et al., 2005). Cripto, an 
epidermal growth factor-CFC (Cripto/FRL-1/Cryptic) motif-containing GPI-
anchored membrane protein, acts as a co-receptor to mediate the binding of 
Nodal and GDF1 to Activin receptors. Type IV collagens were found to modulate 
Dpp signaling by affecting the formation of Dpp gradient in Drosophila (Wang et 
al., 2008b). RGM (Repulsive Guidance Molecule) proteins are co-receptors for 
BMP signaling (Babitt et al., 2005;Babitt et al., 2006;Xia et al., 2007). A RGM 
interacting protein Neogenin has been implicated in modulating BMP signaling 
(Zhou et al., 2010;Hagihara et al., 2011). RGMs and Neogenin will be the focus 
for sections 1.4 and 1.5, respectively. 
1.3.3  The TGF- pathways in C. elegans 
There are two BMP related TGF- signaling pathways in C. elegans: the 
Sma/Mab pathway, which regulates body size (Savage-Dunn et al., 2003;Suzuki 
et al., 1999;Suzuki et al., 1999), male tail patterning (Savage-Dunn et al., 
2003;Suzuki et al., 1999;Suzuki et al., 1999), and M lineage patterning (Foehr et 
al., 2006), and the dauer pathway, which controls formation of dauer larvae in 
response to stresses (Ren et al., 1996).  These two pathways share the same 
type II receptor DAF-4 (Estevez et al., 1993).  All other components are pathway-
specific.  The Sma/Mab TGF- pathway consists of the ligand DBL-1, the type I 
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receptor SMA-6, the R-Smads SMA-2 and SMA-3, and the co-Smad SMA-4 
(Patterson and Padgett, 2000;Savage-Dunn, 2005; Figure 1.5). The dauer 
pathway consists of the ligand DAF-7, the type I receptor DAF-1, the R-Smads 
DAF-8 and DAF-14, and the co- or anti-Smad DAF-3 (Savage-Dunn, 2005).  In 
addition there are two orphan TGF--like ligands, UNC-129 and TIG-2. UNC-129 
functions in the axon guidance pathway and does not seem to signal through any 
of the identified receptors or Smads (Colavita et al., 1998;Nash et al., 2000). The 
function of TIG-2 is unknown.  
A few signaling components outside of the core Sma/Mab pathway have 
been identified. These include three modulators at the ligand-receptor level. 
LON-2 is a Glypican homolog in C. elegans that negatively regulates Sma/Mab 
signaling possibly by interacting with the ligand DBL-1 (Figure 1.5) (Gumienny et 
al., 2007). Loss-of-function mutation in lon-2 results in long worms. Two proteins 
are positive modulators of the Sma/Mab signaling: CRM-1 is a cysteine-rich 
repeats containing protein (Fung et al., 2007); SMA-10 is a member of the LRIG 
(leucine rich repeats and immunoglobulin-like domains) family of transmembrane 
protein (Gumienny et al., 2010). LON-1 is a downstream target of the Sma/Mab 
pathway (Figure 1). It encodes a pathogenesis-related (PR) protein that regulates 
polyploidization and body length (Maduzia et al., 2002;Morita et al., 2002). LON-1 
is likely also a modulator of the Sma/Mab pathway by interacting with LON-2 and 
CRM-1 (King Chow, personal communication). SMA-9 is a homolog of 
Drosophila Schnurri (Shn) protein (Liang et al., 2003). In C. elegans, SMA-9 is 
known to function as transcription co-factors to convey Sma/Mab signaling (Liang 
et al., 2003). 
 
  
31 
 
Figure 1.5: the Sma/Mab BMP-like pathway in C. elegans 
C. elegans Sma/Mab core pathway includes the ligand DBL-1, type I 
receptor SMA-6, type II receptor DAF-4, R-SMads SMA-2 and SMA-3, and co-
Smad SMA-4.  
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The role of the Sma/Mab pathway in patterning of the C. elegans M 
lineage was discovered in the Liu lab (Foehr et al., 2006). Mutations in sma-9 
cause a dorsal to ventral fate transformation in the M lineage, in addition to the 
small body size phenotype (Liang et al., 2003). The sma-9 M lineage defects can 
be suppressed by mutations in the Sma/Mab pathway, including dbl-1, sma-2, 
sma-3, sma-4, and sma-6.  However, these mutations themselves do not result in 
any M lineage defects (Foehr et al., 2006).  These observations suggest that 
SMA-9 normally antagonizes the Sma/Mab BMP-like pathway to regulate 
dorsal/ventral patterning in the M lineage. Studies of additional sma-9 
suppressors have identified drag-1/Rgm and unc-40/Neogenin. They are the 
focus of Chapters 3 and 4.  
 
1.4  RGM in modulating BMP signaling 
1.4.1  Introduction 
RGM (repulsive guidance molecule) family members include RGMa, 
RGMb and RGMc/Hemojuvelin (Hjv). RGMs also exist in single copy in 
invertebrates, such as C. elegans and sea urchin (Camus and Lambert, 2007). 
The three RGMs share approximately 40-50% identity in primary amino acid 
sequences. They share similarities in predicted protein domains and overall 
structure, as inferred by ab initio molecular modeling (Severyn et al., 2009). 
Specifically, all RGMs have an N-terminal signal peptide, a partial von Willebrand 
type D domain (vWF-type D), which includes a highly conserved autoproteolysis 
site, and a C-terminal GPI (Glycosylphosphatidylinositol)-anchor (Figure 1.6). 
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RGMa and RGMc have a RGD motif (Figure 1.6). RGM proteins also contain a 
number of highly conserved cysteine residues. Studies of vertebrate RGM 
proteins demonstrate that RGMs undergo distinct biosynthetic and processing 
steps. All of them go through autoproteolytic cleavage to generate two fragments 
that are linked by disulfide bonds. RGMc also has a furin pro-protein convertase 
recognition site that is unique to itself. The significance of these processing 
events is beginning to be revealed. RGM proteins are known high affinity binding 
proteins for BMPs (KD ~ 1-5 mm) (Babitt et al., 2005;Babitt et al., 2006;Samad et 
al., 2005; Figure 1.6). Although no role for BMPs has been identified in the 
actions of RGMa, interactions with BMP is mediating at least some of the 
biological effects of RGMc on the regulation of iron homeostasis (Babitt et al., 
2006;Babitt et al., 2007), as well as the roles of RGMb in promoting neurite 
growth and nerve regeneration. As described in Chapter 3, the C. elegans RGM 
protein DRAG-1 is the only studied RGM in invertebrates (Tian et al., 2010). 
DRAG-1 exhibits structure and function similar to vertebrate RGMs. DRAG-1 
protein contains the conserved partial vWF-type D domain, the autocleavage site, 
and all the cysteine residues (Figure 1.6). DRAG-1 is a tissue specific positive 
modulator of the BMP-like Sma/Mab pathway in C. elegans by interacting with 
the ligand and both type I and type II receptors of this pathway (Tian et al., 2010; 
Chapter 5). This section will focus on the current understanding of RGM 
modulation of BMP signaling. 
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Figure 1.6: Structure and function of RGM family members 
 (A) The linear maps of mature RGMa, RGMb and RGMc contain the 
following features: RGD motif (RGMa and RGMc, blue); partial vWF-type D 
domain (yellow); furin recognition and cleavage site (RGMc only, green); 
arrowhead, site of intra-molecular proteolytic cleavage to generate two-chain 
species; red vertical lines, conserved cysteine residues. The squiggle at the C-
terminus of each protein represents the GPI anchor. Modified from Severyn et al., 
2009. (B) RGM proteins are BMP coreceptors. RGM mediates BMP signaling by 
interacting with the ligand and type I and type II receptors and enhancing ligand-
receptor binding. Direct interactions are indicated by red dots. 
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1.4.2  RGMa 
RGMa was the first RGM family member discovered. RGMa is expressed in 
a gradient in the optic tectum in chick embryos and is functionally recognized as 
a repulsive guidance molecule (Monnier et al., 2002). During mouse 
development, RGMa is expressed in the central nervous system in a mostly non-
overlapping fashion with RGMb. RGMa is also expressed in the developing 
mouse cochlea, lung, limb primordia, and gut. In the adult mouse, RGMa 
expression is found in the heart, brain, liver, lung, skin, kidney, testis and gut 
(Corradini et al., 2009). The broad expression pattern of RGMa in developing 
mouse embryo suggests that it likely plays important roles in development, 
especially central nervous system development. In fact, RGMa has been found to 
function in axon guidance in the developing visual system and in axon tract 
formation in the embryonic brain in vivo (Monnier et al., 2002;Matsunaga et al., 
2004;Tassew et al., 2008), as well as in neural tube closure (Kee et al., 2008), 
neuronal differentiation (Matsunaga et al., 2006), cell survival (Koeberle et al., 
2010), cell migration and adhesion (Lah and Key, 2012). Neogenin, as a receptor 
for RGMa, is involved in all the above processes. Recently, RGMa has been 
implicated in some colorectal, prostate, and breast cancers (Li et al., 2011;Li et 
al., 2012;Zhao et al., 2012), as well as associated with inflammation (Nohra et al., 
2010;Mirakaj et al., 2011;Muramatsu et al., 2011).  
RGMa was found to be a BMP coreceptor in vitro (Samad et al., 2005). 
Both overexpression and siRNA knockdown experiments showed that RGMa 
specifically enhances BMP signaling activity through the canonical BMP signaling 
pathway, but not the TGF- signaling pathway (Babitt et al., 2005;Halbrooks et 
al., 2007). The enhancement depends on BMP ligands, because it was blocked 
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by co-transfection of Noggin, a BMP inhibitor, or BMP2 and BMP4 neutralizing 
antibodies (Babitt et al., 2005). Besides the dependent of the ligand, RGMa 
modulates BMP signaling through the classical BMP signaling pathway involving 
type I receptors ALK3 and ALK6 as well as Smad1, 5, and 8, because dominant 
negative forms of ALK3 and ALK6 both blocked the enhanced signaling and 
Smad 1, 5, 8 phosphorylation by RGMa (Babitt et al., 2005). Purified RGMa.Fc 
(the extracellular domain of RGMa fused to the Fc portion of human IgG) protein 
binds directly and selectively to 125I-BMP2 and 125I-BMP4 with a KD of 2.4 nM and 
1.4nM, respectively, but not to BMP7 or TGF-1 ligands  (Babitt et al., 
2005;Halbrooks et al., 2007;Xia et al., 2007). BIAcore assay identified a similar 
direct binding of RGMa.Fc to BMP2 at KD ~ 2.46nM (Babitt et al., 2005;Halbrooks 
et al., 2007). RGMa.Fc binds to the BMP type I receptor ALK6.Fc with or without 
the presence of BMP2. The binding between RGMa and ALK6 increased the 
binding of 125I-BMP2 to ALK6 (Babitt et al., 2005). Another study showed that the 
addition of RGMa not only increased the binding of 125I-BMP2 to the BMP type I 
receptor ALK3.Fc, but also increased the binding of 125I-BMP2 to the type II 
activin receptor ActRIIA.Fc (Xia et al., 2007). A model has therefore been 
proposed in that the addition of RGMa changes the utilization of type II receptors 
from BMPRII alone to both BMPRII and ActRIIA for BMP2 or BMP4 signaling in 
human ovarian granulosa cells and mouse pulmonary artery smooth muscle cells 
(Xia et al., 2007). 
The in vivo evidence is still lacking for RGMa functioning as a BMP co-
receptor. How many of the RGMa mediated processes require its potentiation of 
BMP signaling? BMP signaling occurs in neurons of the adult spinal cord which 
expresses RGMa in mouse; however, it is unknown if RGMa is involved in BMP 
signaling there. In axon guidance process, it has been shown that RGMa-
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neogenin signaling involves activation of the small GTPase RhoA, its 
downstream effector Rho kinase and protein kinase C (PKC) but is independent 
of the BMP signaling (Conrad et al., 2007). It is also of interest to know if 
neogenin, the RGMa receptor that mediates axon guidance and neuronal 
survival, functions together with RGMa to modulate BMP signaling.   
1.4.3  RGMb 
RGMb is currently less well characterized than RGMa. RGMb was first 
identified by using a genomic DNA-binding array to identify genes regulated by 
DRG11, a homeobox transcription factor expressed in embryonic dorsal root 
ganglion (DRG) and dorsal horn neurons (Samad et al., 2004). In the developing 
brain, RGMa and RGMb exhibit non-overlapping expression patterns. RGMb 
expression is also found in the brain, bone, heart, lung, liver, kidney, testis, ovary, 
uterus, epididymis and pituitary in adult mouse (Corradini et al., 2009). Unlike 
RGMa, RGMb does not have any detectable repulsive guidance role in 
embryonic and neonatal DRG neuritis (Samad et al., 2004). However, there is 
evidence supporting its role in the nervous system, immune system and cancer. 
RGMb controls aggregation and migration of neogenin-positive dentate precursor 
cells in vitro and in vivo, and this process might involve RGMb-neogenin 
interaction (Conrad et al., 2010). RGMb also promotes neurite outgrowth and 
peripheral nerve regeneration in vitro and in vivo (Liu et al., 2009;Ma et al., 2011). 
RGMb is an important negative regulator of IL-6 expression in immune cells (Xia 
et al., 2011). Furthermore, RGMb appears to be a negative regulator of breast 
cancer proliferation, adhesion, and migration in vitro (Li et al., 2012). 
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RGMb was the first RGM family member shown to be a BMP co-receptor. 
The reason to test its involvement in BMP signaling is due to the shared 
expression pattern between RGMb and the BMP type I and type II receptors in 
the developing mouse and Xenopus embryos (Babitt et al., 2005). Similar to 
RGMa, RGMb enhanced BMP signaling but not TGF- signaling in LLC-PK1 
(kidney epithelial cells) and in Xenopus embryos (Babitt et al., 2005). siRNA 
treatment of RGMb inhibited BMP signaling (Babitt et al., 2005;Halbrooks et al., 
2007). Like RGMa, RGMb enhancement of BMP signaling is ligand-dependent 
and through the canonical BMP signaling pathway (Babitt et al., 2005). Also like 
RGMa, RGMb.Fc (the extracellular domain of RGMb fused to the Fc portion of 
human IgG) binds directly to 125I-BMP2 (KD ~ 1.4nM). The binding can be 
competed by the addition of unlabeled BMP2 and BMP4, but not BMP7 or TGF- 
ligands (Babitt et al., 2005). BIAcore assay also confirmed that RGMb.Fc binds 
directly to BMP2 with a similar binding affinity (KD ~ 5.43 nM; Babitt et al., 
2005;Halbrooks et al., 2007). RGMb also physically associates with BMP type I 
receptors (ALK2, ALK3, and ALK6) and BMP type II receptors (ActRII and 
ActRIIB) as indicated by co-immunoprecipitation experiment in transfected 
HEK293 cells (Babitt et al., 2005). It has been suggested that RGMb shares the 
ability of RGMa to alter type II receptor utilization by BMP4 ligand from 
unpublished data noted in a review article (Corradini et al., 2009).  
 In one study, RGMb was shown to inhibit BMP signaling in C2C12 
myoblasts. This inhibition by RGMb was dependent on the vWF type D domain. 
Because it can suppress induced BMP signaling by constitutively active Smad1, 
the suppression is likely mediated by a parallel pathway that is activated by 
RGMb (Kanomata et al., 2009). This inhibitory effect of BMP signaling seems to 
be an isolated event, as it has not been observed for RGMa and RGMc in any 
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system or for RGMb in a different system. How RGMb mediates this inhibition 
and its significance of it needs to be studied. 
 The in vivo relevance of RGMb as a BMP co-receptor has just started to 
be discovered. RGMb promotion of axon growth requires BMP signaling. The 
fewer and shorter neurites from cultured neonatal whole DRG explants and 
dissociated DRG neurons in RGMb-/- mutants could be rescued by the addition 
of BMP2. RGMb also promotes, while the BMP inhibitor Noggin inhibits, 
peripheral nerve regeneration in vivo (Ma et al., 2011).  Like RGMa, RGMb also 
directly binds to neogenin (Conrad et al., 2010). It is not known if neogenin 
functions together with RGMb in mediating BMP signaling.  
1.4.4  RGMc/HJV 
HJV and juvenile hemochromatosis 
RGMc was identified by positional cloning for the locus that is associated 
with juvenile hemochromatosis (JH) (Papanikolaou et al., 2004b). JH is a rare 
autosomal recessive disease characterized by high penetrance, early-onset 
systemic iron overload that affects young patients and leads to severe clinical 
complications typically in the first and second decade of life (Camaschella et al., 
2002;De Gobbi et al., 2002;De Domenico et al., 2008a).  
JH is also caused by the lack of functional hepcidin (Roetto et al., 2003).  
Hepcidin is a defensin-like small peptide secreted predominantly from 
hepatocytes (Park et al., 2001;Pigeon et al., 2001). It is essential for iron 
homeostasis. It acts by binding to and degrading Ferroportin, a rate-limiting sole 
iron exporter (De Domenico et al., 2008b). Hepcidin expression is upregulated by 
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high iron level in the body, therefore it is a feedback regulator of iron absorption 
(Kautz et al., 2008a;Pigeon et al., 2001).  
HJV is a key regulator of hepcidin expression 
HJV is both required and sufficient for hepcidin expression. JH patients 
with HJV mutations exhibit a reduction of hepatic hepcidin expression that results 
in severe iron accumulation in liver, heart, and pancreas (Papanikolaou et al., 
2004a). Hjv-/- mice exhibit a similar low hepcidin mRNA expression and iron 
deposition in liver, pancreas, and heart (Huang et al., 2005). Inhibition of HJV 
function by a soluble HJV.Fc reduces hepcidin expression (220 Babitt,J.L. 2007). 
Transfection with HJV cDNA into hepatoma-derived cells increases hepcidin 
mRNA expression and hepcidin promoter activity in a luciferase assay (Babitt et 
al., 2006). Introducing Hjv into the hepatocytes in Hjv-/- mice using adeno-
associated virus 2/8 as a vector is sufficient to completely restore the decreased 
hepatic hepcidin expression and lower the high serum iron level to the wild type 
level (Zhang et al., 2010). 
Consistent with HJV regulating hepcidin expression in the liver, HJV is 
expressed predominantly in the liver, skeletal muscle, and heart (Niederkofler et 
al., 2004;Papanikolaou et al., 2004a;Rodriguez et al., 2007a;Samad et al., 2004). 
The functional significance for skeletal muscle and heart-expressed HJV is 
currently not fully understood. Skeletal muscle-expressed HJV has been 
suggested to be a reservoir for soluble HJV (Zhang, 2010; see section on HJV 
post-translational modification). 
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BMP regulates hepcidin expression 
BMP signaling has been shown to play a role in iron metabolism in liver by 
regulating Hepcidin expression. In vitro studies showed that multiple BMP 
cytokines, including BMP-2, 4, 5, 6, 7, 9 are able to increase hepcidin expression 
through phosphorylated Smad1, 5, and 8 in hepatocytes (Babitt et al., 
2006;Truksa et al., 2006;Andriopoulos et al., 2009a). Liver-specific disruption of 
Smad4, the co-Smad, affected iron homeostasis by decreasing Hepcidin 
expression (Wang et al., 2005).  
HJV is a BMP co-receptor 
The underlying mechanism of HJV regulating hepcidin expression is 
through BMP signaling. Like other RGM family members, HJV functions as a co-
receptor in BMP signaling. Transfection of HJV into hepatocytes enhances BMP, 
but not TGF- signaling activity (Babitt et al., 2005;Babitt et al., 2006;Halbrooks 
et al., 2007;Xia et al., 2008). si-RNA knockdown of HJV reduced BMP2 signaling 
(Babitt et al., 2005;Halbrooks et al., 2007). Similar to RGMa and RGMb, HJV’s 
role in potentiating BMP signaling is dependent on the BMP ligand, because HJV 
signal induction is abolished by the BMP inhibitor Noggin, and by BMP2 and 
BMP4 neutralizing antibodies (Babitt et al., 2006). HJV signals via type I and II 
receptors and the Smads complex. Inhibition of type I receptors (ALK2, ALK3, 
and ALK6) and type II receptors (BMPRII and ACTRII) by si-RNA led to decease 
in HJV-mediated BMP signaling (Xia et al., 2008). Like RGMa and RGMb, 
purified HJV.Fc directly binds to 125I-BMP2 and 125I-BMP4, and this binding can 
be competed away by excess unlabeled BMP2 and BMP4, but not by BMP7 or 
TGF1. HJV.Fc also directly binds to BMP6 (Andriopoulos et al., 2009a). The 
binding affinity of HJV to BMP2 has been estimated by two assays with distinct 
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values: one BIAcore assay showed that dimeric HJV.Fc binds to BMP2 with an 
affinity similar to RGMa and RGMb (KD ~ 4.22nM; Babitt et al., 2005;Halbrooks et 
al., 2007); another BIAcore assay with purified untagged monomeric HJV and 
BMP2 estimated the binding KD to be around 510nM (Yang et al., 2008b). This 
suggests that dimeric form of HJV has a stronger affinity to BMP than the 
monomeric form. HJV has a different binding selectivity to BMP ligands than the 
other RGM family members. Soluble RGMb.Fc and HJV.Fc were assayed for the 
ability of inhibiting selected BMP signaling activity. HJV.Fc is a stronger inhibitor 
to BMP-6 than RGMb.Fc, while RGMb.Fc is a stronger inhibitor than HJV.Fc in 
inhibiting BMP-2 and BMP-4 signaling (Andriopoulos et al., 2009a).  In addition to 
binding to the ligand, HJV can form a complex with type I receptor ALK6 in the 
presence of BMP2 in a co-immunoprecipitation assay (Babitt et al., 2006).  
Consistent with the in vitro data, Hjv-/- mice have reduced hepatic 
hepcidin expression and a decreased level of liver pSmad, an indication of low 
BMP signaling activity. Hepatic expression of Hjv in Hjv-/- mice liver increased 
hepcidin expression and pSmad level (Zhang et al., 2010).  
BMP6 is involved in iron-regulated hepatic hepcidin expression 
BMP6 mRNA expression has been found to correlate to the extent of body 
iron load (Kautz et al., 2008b). Bmp-6-/- mice exhibit a severe loss of hepcidin 
expression and massive iron overload (Andriopoulos et al., 2009b;Meynard et al., 
2009). Exogenous BMP6 by intraperitoneal injection increases hepcidin 
expression and iron metabolism in vivo (Andriopoulos et al., 2009b). The 
expression of BMP6, the inducer of hepcidin expression, is sensitive to iron level 
in the serum. HJV, as a co-receptor to BMP6, however, does not regulate BMP6 
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expression. Hjv-/- mice have increased levels of BMP6 mRNA and reduced 
hepcidin expression that causes severe iron overload (Zhang et al., 2010). The 
increase of BMP6 mRNA level results from iron overload but not Hjv depletion, 
because increase in iron overload in wild type mice also results in a similar level 
of increase of BMP6 mRNA (Kautz et al., 2008a). This also indicates that BMP6 
expression alone cannot induce hepcidin expression in the absence of Hjv, which 
is consistent with the notion that HJV functions as a co-receptor.    
HJV post-translational processing and significance 
HJV protein has three predicted N-glycosylation sites. The muscle-
expressed and liver-expressed HJV proteins are differentially glycosylated, but 
the functional significance for the differential glycosylation is unknown (Fujikura 
et al., 2011). Under reducing conditions, cell membrane localized HJV proteins 
have three major species of 50, 35, and 20kD respectively. Under non-reducing 
conditions, HJV only runs as a single 50kD band, which corresponds to the full-
length form. The 35kD and 20kD species are from an intracellular autoproteolytic 
cleavage event at amino acid 172 in the vWF type D domain between aspartic 
acid and proline in an mildly acidic environment, and these two fragments are 
joined together by disulfide bonds to form a two-chain form (Zhang et al., 
2005;Kuninger et al., 2006a). The autocleavage site is conserved in RGMa and 
RGMb and similar two-chain forms have been observed for RGMa and RGMb 
(Niederkofler et al., 2004; Figure 1.6). The membrane-bound two-chain species 
of Hjv is the predominant isoform (Kuninger et al., 2006a;Silvestri et al., 2007). 
Several JH disease causing mutations appear to affect the autocleavage event. 
These mutations include those that lie in or near the cleavage site, D172E, 
F170C and W191C, as well as one predominant disease causing mutation, 
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G320V (Silvestri et al., 2007;Pagani et al., 2008). It has been found that these 
mutant forms of HJV are retained in the endoplasmic reticulum and have low 
signaling activities. However, other disease causing mutations, such as G99V 
and C119F, that have no effect on HJV autocleavage but have reduced signaling 
activities do reach the plasma membrane (Silvestri et al., 2007). These studies 
suggest that HJV cleavage is essential for their export to the plasma membrane. 
HJV also undergoes active release by furin proprotein convertase. The 
soluble form of cleaved HJV (s-HJV) has a molecular mass of ~40kD (Lin et al., 
2008;Silvestri et al., 2008;Lin et al., 2008) . The cleavage site has been mapped 
to a RNRR sequence that is not conserved in RGMa and RGMb (Silvestri et al., 
2008;Lin et al., 2008; Figure 1.6). Furin is predominantly localized in the trans-
Golgi network (TGN) compartment, with only a small portion of it being on the 
plasma membrane (Thomas, 2002). Consistent with this, it has been shown that 
HJV cleavage occurs in the TGN after it is being endocytosed from the plasma 
membrane (Maxson et al., 2009). Furthermore, the binding of neogenin to HJV 
on the plasma membrane triggers the retrograde trafficking and subsequent 
release of soluble HJV, s-HJV (Zhang et al., 2008). s-HJV is present not only in 
transfected cell lines and cell lines that endogenously express HJV, but also in 
human and rat serum (Kuninger et al., 2004;Lin et al., 2005a;Kuninger et al., 
2006b;Silvestri et al., 2007;Zhang et al., 2007). 
s-HJV inhibits BMP signaling by binding to BMP2, BMP4, and BMP6 to 
suppress hepcidin expression in vitro (Babitt et al., 2006;Lin et al., 2007;Kuns-
Hashimoto et al., 2008b;Andriopoulos et al., 2009a;Nili et al., 2010).  Injection of 
s-HJV decreases hepatic hepcidin mRNA level in vivo (Babitt et al., 2007). s-HJV 
is hypothesized to compete with hepatocyte membrane-bound HJV for BMP 
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ligands, acting as a negative regulator of the BMP-mediated hepcidin expression. 
Because hepcidin expression is positively regulated by body iron load, it is 
reasonable to hypothesize that body iron load may negatively regulate the 
amount of s-HJV. In fact, s-HJV release is negatively regulated by iron level in 
vitro (Lin et al., 2005b;Silvestri et al., 2007;Zhang et al., 2007). In acutely iron-
deficient rats, decreased serum Transferrin and Ferritin saturation is associated 
with decreased hepcidin expression and increased serum s-HJV level (Zhang et 
al., 2007). Therefore, s-HJV is a negative regulator of hepcidin expression in 
response to body iron status.  
A serine protease Matriptase-2, encoded by the gene TMPRSS6, is also 
involved in regulating body iron load (Silvestri et al., 2008). In mice and zebrafish, 
matriptase-2 mutations cause hepatic hepcidin overexpression and iron-deficient 
anemia (Folgueras et al., 2008;Silvestri et al., 2008;Ramsay et al., 2009). In 
humans, mutations in TMPRSS6 cause iron-refractory iron deficiency anemia 
(IRIDA), a familial anemia disorder. The relationship between matriptase-2 and 
HJV has been investigated. matriptase-2 suppresses HJV-induced hepcidin 
expression. Matriptase-2 and HJV are co-expressed in the liver (Velasco et al., 
2002). Moreover, they directly bind to each other in Hela cells (Silvestri et al., 
2008). The binding results in the cleavage of cellular HJV into many fragments 
that are released to the media (Silvestri et al., 2008). However, the in vivo 
situation is more complex. Liver membrane HJV level is decreased rather than 
increased in the Tmprss6-/- mutant mice (Krijt et al., 2011). The expression of 
matriptase can inhibit hepcidin expression that is induced by the addition of HJV, 
although it is controversial if matriptase also decreases BMP-induced hepcidin 
expression (Du et al., 2008;Silvestri et al., 2008). In vivo studies by making 
double mutants between Hjv-/- and Tmprss6-/- or a catalytic mutation 
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Tmprss6mask showed that the double mutants exhibit the Hjv-/- mutant 
phenotypes, suggesting that HJV acts downstream of matriptase-2 in the 
regulation of hepcidin expression (Finberg et al., 2010;Truksa et al., 2009). The 
regulation of matriptase-2 expression has been investigated recently. Tmprss6 
mRNA expression is stimulated by iron loading treatment or BMP6 protein 
injection and is blocked by injection of neutralizing antibody against BMP6 in 
mice (Meynard et al., 2011). Since iron induces hepcidin expression, the 
upregulation of matriptase-2, a negative regulator of hepcidin, by iron indicates 
that matriptase-2 likely represents a negative feedback regulating mechanism to 
balance hepcidin overexpression induced by iron to maintain systemic iron 
homeostasis. 
1.5  Neogenin  
1.5.1  Introduction 
Neogenin is a type I transmembrane protein (Chan et al., 1996). It is 
homologous to DCC (Deleted in Colorectal Cancer). Neogenin and DCC share 
50% identify in amino acid sequence. They have highly conserved extracellular 
domains, including 4 Immunoglobuin (Ig) domains and 6 Fibronectin type III 
(FNIII) domains (Figure 1.7). The intracellular region is less conserved between 
them with only three motifs being conserved: P1, P2, and P3. DCC and neogenin 
have orthologs in Drosophila, zebrafish, Xenopus, chickens and mammals (Cole 
et al., 2007;Wilson and Key, 2007;Yamashita et al., 2007). In C. elegans, a single 
protein UNC-40 resembles both DCC and neogenin (Chan et al., 1996). In 
vertebrates, neogenin has a broad expression pattern compared to DCC. 
Neogenin is found in dividing neurogenic and gliogenic progenitors throughout 
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the embryonic and adult CNS (Vielmetter et al., 1994;Keeling et al., 
1997;Fitzgerald et al., 2006a;Fitzgerald et al., 2006b;Fitzgerald et al., 2007). 
Outside of the nervous system, neogenin protein is found in many developing 
and adult tissues, including heart, gut, lung, liver (Gad et al., 1997;Rodriguez et 
al., 2007b), and limb buds (Hong et al., 2012). In contrast, the expression of DCC 
is primarily restricted to the developing nervous system.  
1.5.2  Neogenin and DCC as receptors for netrins 
Both neogenin and DCC are receptors for netrins, which are a class of 
axon guidance molecules (Figure 1.7). The netrin-binding site on DCC has been 
mapped to the fourth and fifth FNIII domains (FNIII-4, FNIII-5) (Geisbrecht et al., 
2003;Kruger et al., 2004). Because of the high degree of similarity between 
neogenin and DCC in their extracellular region, neogenin is expected to bind to 
netrin via similar domains. In fact, the binding affinity between netrin and 
neogenin was shown to be around 2nM (Wang et al., 1999b), which is simiar to 
the DCC-netrin binding affinity (Keino-Masu et al., 1996). DCC-netrin interactions 
are required for chemoattractant and chemorepellent responses (Kennedy et al., 
1994;Colavita and Culotti, 1998;Hong et al., 1999;Wang et al., 1999a;Qin et al., 
2007). Although less well studied, neogenin has a netrin-dependent role in 
mediating chemoattractant responses to netrin in supraoptic axons in Xenopus 
forebrain (Wilson and Key, 2006). In addition to axon guidance, both DCC and 
neogenin regulate cell-cell adhesion and tissue organization through interactions 
with netrins (Srinivasan et al., 2003;Kang et al., 2004;Park et al., 2004;Jarjour et 
al., 2008;Lejmi et al., 2008). The signal transduction cascades initiated upon 
DCC-netrin interaction have been mapped out in some details, which include 
intracellular tyrosine kinase, second messenger, and rho GTPase pathways 
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(Gomez and Zheng, 2006;Lai Wing Sun et al., 2011;Lin and Holt, 2007;Moore et 
al., 2007;Rajasekharan and Kennedy, 2009;Round and Stein, 2007), intracellular 
signaling downstream of neogenin-netrin is poorly understood. Limited evidence 
suggests that neogenin turns on similar set of downstream signaling events to 
that of DCC (Li et al., 2004;Liu et al., 2004;Xie et al., 2005;Ren et al., 2008). 
However, it is noted that in at least several cases neogenin and DCC have 
differential downstream effects and interaction partners. For example, DCC and 
neogenin, as cargos for myosin X, promote different movements of myosin X (Liu 
et al., 2012); different to DCC, neogenin fails to interact to PLCbut binds to Src 
homology-2 containing inositol-5-phosphatase 1 (SHIP1) in the cytoplasmic 
region in second messenger pathways (Xie et al., 2006;Ren et al., 2008). 
1.5.3  Neogenin is a receptor for RGMs 
Neogenin is not only a receptor for netrins, but also a receptor for RGMs 
(Figure 1.7). Neogenin, but not DCC, directly binds to all three RGM family 
members in vitro. The RGMa-binding site is known to reside within the FNIII 
domains of neogenin (Rajagopalan et al. 2004). Further mapping of the binding 
region indicates that neogenin’s FNIII-(3-4) region is critical for RGMa binding 
(Tassew et al., 2012). Interestingly, the binding affinity of RGMa to neogenin is 
about 10-fold higher than that of netrin to neogenin, suggesting that RGMa may 
be the primary ligand for neogenin in the CNS (Rajagopalan et al. 2004). 
Because the binding of RGMa to neogenin is unaffected by netrin-1 binding, 
these two ligands probably have distinct binding sites (Rajagopalan et al. 2004). 
Unlike for RGMa, the binding site for HJV is mapped to the FNIII-5, FNIII-6 and 
the proximal juxtamembrane region of neogenin, in which FNIII-6 mediates most 
of the interaction, while FNIII-5 alone does not bind HJV (Yang et al., 
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2008a;Yang et al., 2011). The crystal structure of FNIII-5 and FNIII-6 of neogenin 
has been solved (Yang et al., 2011). By comparing neogenin FNIII-6 domain 
(that binds to HJV) to neogenin FNIII-5 domain and DCC FNIII-6 domain (that do 
not bind to HJV), two loops in neogenin FNIII-6 domain are predicted to mediate 
HJV-neogenin interaction (Yang et al., 2011). Efforts have been made to map the 
neogenin binding site in RGMa. In one study, neogenin binding sites in RGMa 
were shown to contain amino acids (aa) 259-295 (Itokazu et al., 2012). However, 
another study indicates a surprising result that the two non-overlapping RGMa N- 
and C- fragments, which are resulted from RGMa autocleavage, could both bind 
to neogenin fragments. Although the neogenin binding sites in HJV haven’t been 
mapped, the most prevalent human JH mutation G320V abolishes neogenin-HJV 
interaction. It may be due to the abolishment of direct interaction or the induction 
of a conformational change in HJV that affects neogenin-HJV interaction (Kuns-
Hashimoto et al., 2008a). It is important to note that HJV can simutaneously bind 
neogenin and BMP2, suggesting that the binding sites for each protein in HJV 
are not overlapping (Yang et al., 2008a).  
 Neognenin-RGMa interaction was first identified to be required for the 
chemorepulsion of temporal retinal axons in the anterior tectum of the chick 
(Monnier et al., 2002). Later, neogenin-RGMa interaction was recognized in 
many of the processes in cultured cells and mice that RGMa regulates, including 
axon tract formation in the embryonic brain (Matsunaga et al., 2004;Monnier et 
al., 2002;Tassew et al., 2008), neural tube closure (Kee et al., 2008), neuronal 
differentiation (Matsunaga et al., 2006), cell survival (Koeberle et al., 2010), cell 
migration, and cell-cell adhesion (Lah and Key, 2012; Figure 1.7). Besides RGMa, 
neogenin also directly binds to RGMb and HJV. RGMb-neogenin interaction 
controls aggregation and migration of a population of dentate precursor cells in 
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vitro and in mice (Conrad et al., 2010). The downstream signaling of RGMa-
neogenin binding appears to be different than that of netrin-neogenin binding. It 
has been shown that RGMa-neogenin-dependent growth cone collapse is 
mediated by rhoA activation of rhoA kinase (ROCK; Conrad et al., 2007;Hata et 
al., 2006). The activated rhoA kinase can phosphorylate the light chain of myosin 
II in an RGMa-dependent manner, leading to F-actin reduction and growth cone 
collapse and subsequent neurite retraction/outgrowth inhibition (Kubo et al., 
2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
53 
 
Figure 1.7: The roles of neogenin in mediating netrin and RGM signaling 
Neogenin is a transmembrane protein with 4 Ig-like domains (half circles), 
6 FNIII domains (black boxes) and three conserved intracellular motifs: P1, P2, 
and P3 (black bars). Neogenin is a multifunctional receptor that mediates 
signaling from the soluble protein netrin and the GPI-anchor proteins RGMs for 
different cellular functions. Modified from Wilson and Key, 2007. 
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1.5.4  Neogenin functions in the BMP signaling pathway 
The broad presence of neogenin outside of the nervous system suggests 
that it may have other functions. One of its functions is modulating BMP signaling. 
Neogenin-deficeint mice that lack functional neogenin have many defects and 
could survive for only one month (Bae et al., 2009;Lee et al., 2010). Neogenin-
deficient mice have reduced hepatic hepcidin expression, severe iron overload, 
and reduced BMP signaling, which are similar phenotypes as those seen in Hjv-/- 
mice. Reduction of hepcidin expression has been observed in hepatoma cells by 
knocking down neogenin with or without ectopic HJV expression (Zhang et al., 
2009). Disruption of neogenin-HJV interaction by a soluble neogenin fragment 
suppresses BMP4 induced hepcidin expression, suggesting that neogenin-HJV 
interaction regulates BMP4-HJV-induced hepcidin expression (Zhang et al., 
2009). It is important to note neogenin and HJV share similar expression patterns 
in the liver, suggesting they may function in the same cells in cis (Lee et al., 
2010). Neogenin-deficient mice are also impaired in endochondral ossification. It 
has been shown that neogenin regulates endochondral bone formation through 
canonical BMP signaling in a cell autonomous fashion (Zhou et al., 2010). 
The mechanism of how neogenin modulates BMP signaling is 
controversial and not well understood. It may also be dependent on cellular 
context. First, neogenin-HJV interaction has been shown to regulate HJV 
secretion in vitro. Knockdown of endogenous neogenin in differentiated myoblast 
and hepatoma cells abolished HJV secretion (Zhang et al., 2005;Zhang et al., 
2007). Inhibition of neogenin-HJV interaction by adding soluble neogenin to the 
media also reduced HJV secretion (Zhang et al., 2008). The direct effects on 
BMP signaling and hepcidin expression haven’t been determined in the above 
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studies; however, we know that soluble HJV is an antagonist of BMP signaling 
and hepcidin expression. As a prediction, enhancing the secretion of a BMP 
signaling antagonist by neogenin would result in decrease in the BMP signaling. 
There is one study showing the opposite result in which neogenin stabilizes HJV 
and inhibits HJV secretion in HEK293 cells (Lee et al., 2010). This latter piece of 
evidence is consistent with the above in vivo observations that neogenin 
positively modulates hepcidin expression and BMP signaling. Second, neogenin 
has been shown to promote the entry of BMP receptors to the lipid rafts 
microdomains, which is necessary for BMP signaling. Because neogenin on its 
own has little direct interaction with the BMP receptors, RGMa appears to act as 
a bridge protein for neogenin to associate with BMP receptors (Zhou et al., 2010). 
Third, in C2C12 cells, neogenin was found to negatively regulate the BMP2-
induced processes of osteoblastic differentiation. It was found that by directly 
binding to BMP ligands and activating RhoA independent of BMP receptors, 
neogenin antagonizes phosphorylation of Smads1/5/8 (Hagihara et al., 2011). 
The negative role of neogenin in BMP signaling may be context dependent and 
requires support from in vivo analysis. Based on these different pieces of 
published data, I illustrate on Figure 1.8 a model of how neogenin might function 
in modulating BMP signaling.  
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Figure 1.8: A model for how neogenin might function in BMP signaling 
Neogenin forms a complex by directly binding to the RGM protein, which 
directly binds to BMP receptors at the extracellular region. The formation of the 
complex can positively modulate BMP signaling, possibly through recruiting BMP 
ligands to the lipid raft microdomains. It is not clear if the intracellular domain of 
neogenin plays a role here. Neogenin also directly binds to BMP ligands via its 
ectodomain. BMP binding activates RhoA which inhibits phosphorylation of 
Smads, therefore, repressing BMP signaling. The mechanism and in vivo 
relevance of this repression is not clear. Red dots represent direct physical 
contacts. 
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1.5.5  Summary 
 Neogenin is a multifunctional receptor with a broad expression pattern. It 
mediates netrin and RGM signaling in axon guidance, neuronal development, 
apoptosis, and survival through differential downstream signaling. Neogenin has 
also been shown to positively modulate BMP signaling in regulating hepcidin 
expression to balance iron metabolism and to affect endochondral ossification. In 
cell cultures, however, neogenin appears to have both positive and negative 
roles in BMP signaling. The direct interaction between neogenin and RGM can 
affect the stability of RGM protein on the plasma membrane and recruit BMP 
receptors to lipid rafts. Neogenin can also directly interact with the BMP ligands, 
instead of promoting BMP signaling, suppressing BMP signaling by activating 
RhoA. There are many unanswered questions: Is modulation of BMP signaling 
involved in the neuronal roles of neogenin? How is BMP signaling mediated by 
neogenin in vivo: does neogenin function by affecting the stability of RGM 
proteins; does neogenin always partner with RGM in modulation of BMP 
signaling; what is the in vivo relevance of neogenin as a negative regulator of 
BMP signaling; does neogenin modulate BMP signaling by acting through any 
intracellular transducers? Furthermore, as a widely expressed protein, does 
neogenin have other roles? Neogenin has recently been shown to be involved in 
digit patterning by regulating the Sonic Hedgehog pathway (Hong et al,. 2012). 
The mechanisms are currently unknown. Based on the many unanswered 
questions and the somehow conflicting observations in cell culture studies, it is 
obvious that in vivo mechanistic studies are in demand and we may be able to 
shed light on its function via studies in model organisms such as C. elegans.  
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1.6  Dissertation Outline 
This dissertation has two major themes, including the description of a 
genetic network important for M lineage development that centered around a sole 
C. elegans SoxC protein, and the characterization of RGM and neogenin proteins 
as modulators of the Sma/Mab BMP-like pathway. 
Chapter 2 describes the identification and characterization of sem-2/SoxC 
as a pro-proliferation factor that is both required and sufficient for the SM (Sex 
Myoblast) fate. My work also revealed the regulatory network that 
spatiotemporally controls sem-2 expression.  
Chapter 3 describes the characterization of the C. elegans RGM protein 
DRAG-1 as a tissue specific BMP coreceptor.  
Chapter 4 describes recent advances the power of DRAG-1 and the C. 
elegans to study vertebrate RGM protein function.  
Chapter 5 describes the characterization of neogenin/UNC-40 as a 
positive modulator of the Sma/Mab signaling pathway.   
Chapter 6 summarizes this work and discusses my thoughts on future 
directions following my studies. 
Appendix I describes the relationship between sem-2/SoxC and sem-
4/SALL in specifying the SM cells. 
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Chapter 2:  The C. elegans SoxC protein SEM-2 opposes differentiation 
factors to promote a proliferative blast cell fate in the postembryonic 
mesoderm1 
2.1  INTRODUCTION  
The group C Sox proteins are Sry-related HMG box (Sox)-containing 
transcription factors (Wegner, 2010). Vertebrates contain three highly conserved 
SoxC genes, Sox4, Sox11 and Sox12, which play important roles in development, 
including cell differentiation, proliferation and survival (Penzo-Mendez, 2009). 
Increasing evidence has also shown that many tumor types in humans are 
associated with significantly elevated level of SoxC gene expression, suggesting 
that mis-regulation of the SoxC genes may contribute to tumor formation (Penzo-
Mendez, 2009). However, the molecular mechanisms underlying these multiple 
functions of the SoxC genes are not fully understood, nor are the molecular 
events that regulate the expression of SoxC genes.  
The nematode C. elegans contains a single SoxC gene, C32E12.5 
(Phochanukul and Russell, 2010), providing an opportunity to determine the 
functions of SoxC genes at single cell resolution. In this study, we show that 
C32E12.5 is the sem-2 gene that is widely expressed and essential for C. 
elegans embryonic development. Furthermore, sem-2 plays a critical role in a 
binary fate decision in the postembryonic mesoderm, the M lineage. The M  
 
1 This chapter was published in Development (Tian C, Colledge C, Shi H, Stern MJ, Waterston 
RH, Liu J. Development. 2011 Mar;138(6):1033-43.) and is reprinted with permission. Mapping 
was performed by Jun Liu, C. Colledge,  who was student of R.H. Waterston, molecular cloning 
was performed by H. Shi, mutation isolation and initial characterization was performed by M.J. 
Stern. 
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mesoblast is an embryonically-born pluripotent precursor cell (Fig. 1A). During 
hermaphrodite larval development, the M cell first divides dorsoventrally, then 
left-right, and then twice anterioposteriorly to produce 16 cells (Sulston and 
Horvitz, 1977). Two of them, M.vlpa and M.vrpa, divide one more time. The 
anterior cells from these final divisions become sex myoblasts (SMs), the 
precursors to all the non-striated egg-laying vulval and uterine muscles. The two 
posterior cells differentiate into striated body wall muscles (BWMs). The SMs 
then migrate to the future vulval region and further proliferate to produce 8 vulval 
muscles (vms) and 8 uterine muscles (ums). We show here that sem-2 is 
required for the binary fate decision between the SMs and BWMs, and is both 
necessary and sufficient to promote the proliferative SM fate as opposed to the 
differentiated BWM fate. This specific function and expression of sem-2 in the M 
lineage is under the direct regulation of Hox/PBC proteins, MAB-5, LIN-39 and 
CEH-20. This finding is intriguing in light of the oncogenic roles of Hox and PBC 
factors (Shah and Sukumar, 2010), suggesting the possibility of Hox regulation of 
SoxC genes during tumorigenesis.   
2.2  MATERIAL AND METHODS 
2.2.1  C. elegans strains 
The following strains were used in this study: LG I: sem-2(n1343); sem-
2(ok2422)/hT2[qIs48]; sys-1(q544)/hT2[qIs48]. LG II: hlh-1(cc561ts). LG III: fozi-
1(cc609); mab-5(e1239) lin-39(n1760)/hT2[qIs48]; ceh-20(os39)/hT2[qIs48]; unc-
32(e189) lin-12(n676n930ts). LG X: sma-9(cc604). Analyses were performed at 
20°C, unless otherwise noted. 
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Integrated lines:  
LW0081: ccIs4438 (intrinsic CC∷gfp) III; ayIs2 (egl-15∷gfp) IV; ayIs6 (hlh-8∷gfp) 
X  
LW1066: jjIs1066[pJKL705.1(hlh-8p::mRFP+unc-119(+)]?; unc-119(ed4) III 
LW1639: mab-5(e1239) lin-39(n1760) III/hT2[qIs48] (I;III); ayIs6(hlh-8p::gfp) X 
LW2466: jjIs1475(myo-3::rfp) I; ccIs4438 (intrinsic CC∷gfp) III; ayIs2 (egl-15∷gfp) 
IV; ayIs6 (hlh-8∷gfp) X 
2.2.2  Isolation, genetic and molecular analysis of sem-2 alleles 
sem-2(n1343) was identified in a Tc1 mutagenesis screen (Desai et al., 
1988). It was mapped using three factor crosses into a small region between 
unc-63 and spe-11, 0.2 map units to the right of unc-63. Cosmids spanning that 
region were tested for rescuing activity. Two cosmids, F47D3 and C32E12, both 
rescued the egg laying defect of n1343. By further truncating the overlapping 
region of the cosmids, the rescuing activity was mapped to C32E12.5. To identify 
the molecular lesion of n1343, PCR reactions were performed using primers 
designed to span the genomic region of C32E12.5. Primer pairs JKL-620 and 
JKL-621 amplified a fragment bigger than expected. Further PCR and 
sequencing identified a Tc1 insertion in the first intron of C32E12.5 (between -
9186 and -9185, Figure 2A).  
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2.2.3  Plasmid constructs and transgenic lines 
Fosmid WRM0623cE02 (Geneservice Ltd) was used to generate the 
gfp::sem-2 translational fusion construct via recombineering (Warming et al., 
2005). gfp sequences from the Fire lab vector pPD95.75 were inserted 
immediately after the ATG start codon. Recombineering was also used to insert 
Tc1 into the gfp::sem-2-containing fosmid generated above between -9186 and -
9185. The insertions were verified by PCR and sequencing.  
sem-2 cDNA from yk657g12 was used to generate pJKL776 (hlh-8p::sem-
2 cDNA::unc-54 3’UTR). 
A 4554bp fragment of the sem-2 1st intron (-11650 to -7097) was cloned 
into L3135 of the Fire lab vector kit to generate pCXT12, which was subsequently 
used to generate deletion constructs pCXT18-22 and pCXT26-33. pCXT33 was 
used to generate pCXT97-99 and pCXT173, carrying mutations in the PBC/Hox 
binding site. sys-1(T23D8.9) and let-381(F26B1.7) RNAi constructs were 
obtained from the Ahringer RNAi library provided by Geneservice Ltd (Kamath et 
al., 2003). sem-2(RNAi) construct pCXT9 was made by subcloning the sem-2 
cDNA fragment from yk657g12 into L4440 (Timmons and Fire, 1998). pNMA49 
and pNMA50 were used for knocking down fozi-1 and mab-5, respectively (Amin 
et al., 2009).  
 Transgenic lines were generated using the plasmids pRF4 (Mello et al., 
1991), pJKL449 (myo-2p::gfp::unc-54 3’ UTR) (Jiang et al., 2009) or LiuFD61 
(mec-7p::mRFP) (Amin et al., 2009) as markers. 
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2.2.4  RNAi 
The T7 Ribomax RNA Production System (Promega) was used to 
generate sem-2 dsRNA using yk404e6 as a template. Synchronized L1 animals 
expressing various M lineage GFP markers were soaked in the dsRNA solution 
at 20˚C for 24-48 hours following the protocol of Maeda and colleagues (Maeda 
et al., 2001). Animals were allowed to recover at 20˚C and adult worms were 
scored for M lineage phenotypes. Water was used as a soaking control. For fozi-
1(RNAi) (Amin et al., 2007), let-381(RNAi) (Amin et al., 2010), mab-5(RNAi) and 
sys-1(RNAi) (Amin et al., 2009), synchronized L1 animals expressing different M 
lineage markers were plated on HT115(DE3) bacteria expressing dsRNA for the 
gene of interest. Bacteria for ingestion were prepared as described by Kamath 
and Ahringer (2003). RNAi by ingestion was performed at 25˚C and animals were 
scored for M lineage phenotypes 24-48h after plating.  
2.2.5  Immunofluorescence staining 
Animal fixation, immunostaining, microscopy and image analysis were 
performed as described previously (Amin et al., 2007). Guinea pig anti-FOZI-1 
(Amin et al., 2007) (1:200) and goat anti-GFP (Rockland Immunochemicals; 
1:1000) were used.  
2.2.6  Electrophoretic Mobility Shift Assays (EMSA)  
6xHis-tagged LIN-39 and CEH-20 fusion proteins were purified as 
previously described (Liu and Fire, 2000). Complementary single-stranded DNA 
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oligos were 3’-end labeled with biotin using the Biotin 3’ End DNA Labeling Kit 
(Pierce) and annealed at room temperature for one hour. Gel shift reactions and 
detection were performed using the LightShift Chemiluminescent EMSA Kit 
(Pierce). Oligonucleotides used are: wt: CXT216/217, canonical: CXT218/219, 
mut 1: CXT220/221, mut 2: CXT222/223, mut 3: CXT224/225. 
2.3  RESULTS 
2.3.1  sem-2(n1343) mutants exhibit a fate transformation of the 
proliferating SMs to differentiated BWMs 
sem-2(n1343) was identified in a Tc1 insertion mutagenesis screen for 
egg-laying defective (Egl) mutants in the mut-2(r459) background (Desai et al., 
1988). Hermaphrodites homozygous for n1343 are 100% Egl (n>200,), lack all 
vulval and uterine muscles required for egg-laying, as monitored by DIC and 
polarized light microscopy, and fail to express egg-laying muscle specific 
reporters, such as egl-15::gfp and ceh-24::gfp (expressed in type I vulval 
muscles, VM1s (Harfe and Fire, 1998b), or in all the egg-laying muscles (Harfe 
and Fire, 1998)) (Figure 2.1C-F, data not shown). To determine the basis for the 
missing egg-laying muscles, we followed the M lineage in n1343 hermaphrodites 
using both Normaski microscopy and the hlh-8::gfp reporter that marks all 
undifferentiated cells of the M lineage (Harfe et al., 1998b). In n1343 
hermaphrodites, the SM mother cells, M.v(l/r)pa as in wild type give rise to two 
daughter cells, M.v(l/r)paa and M.v(l/r)pap. However, the anterior daughters, 
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normally the SMs, exhibit the morphology and identity of their sister cells, the 
body wall muscles (BWM, Figure 2.1A,B and data not shown). These cells also 
fail to migrate anteriorly, never divide, and never differentiate into the egg-laying 
muscles. Therefore, n1343 hermaphrodites exhibit a SM to BWM fate 
transformation. The M lineage phenotype of n1343 animals may reflect a 
complete removal of sem-2 function in the M lineage because n1343 over a 
deficiency of the sem-2 region, sDf4, yielded the same M lineage phenotype as 
homozygous n1343 animals (data not shown). The effect of the sem-2(n1343) 
mutation on SM development appears to be sex specific, since the SMs appear 
unaffected in n1343 males, and n1343 males mate efficiently (data not shown).  
2.3.2  sem-2 encodes the sole C. elegans group C HMG/SRY box-
containing protein  
We mapped sem-2(n1343) to C32E12.5 based on 3-factor mapping and 
cosmid rescue (see Materials and Methods). PCR and sequencing analyses 
showed that n1343 animals contain a Tc1 transposon insertion located 9185bp 
upstream of the predicted ATG of C32E12.5 (Figure 2.2A).  RNAi of C32E12.5 in 
wild-type worms by soaking L1s caused 98% (n=500) of worms to be Egl and 
missing egl-15::gfp expression. RNAi treated worms in the same experiment also 
exhibited a multivulvae phenotype, with 48% being bi-vulvae and 5% having 
three vulvae (n=81, Figure 2.1G,H and data not shown).  
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Figure 2.1: sem-2 is required for proper embryonic and postembryonic 
development.   
 
(A) The wild-type postembryonic M lineage showing all differentiated cell types 
that arise from M [modified from Sulston and Horvitz (1977)]. (B) The M lineage 
of sem-2(n1343) mutants. (C, D) DIC images of a wild-type (C) and a sem-
2(n1343) (D) adult hermaphrodites. All images presented hereafter are oriented 
with dorsal side up and anterior to the left, unless noted otherwise. (E, F) A wild-
type (E) and a sem-2(n1343) animal (F) with CC::gfp and egl-15::gfp. Arrow 
heads indicate the vulva. Both wild-type and n1343 animals have four 
embryonically-derived and two M-derived CCs. (G, H) Vulval phenotypes of sem-
2(RNAi) animals (H) as compared to L4440 control RNAi animals (G). (I-P) 
frames from time-lapse movies of sem-2(ok2422)/+ (I-L) and sem-2(ok2422) (M-
P) worms. Time 0 is when the movie was started. Four time points were selected 
to represent different embryonic stages. M: M mesoblast, d: dorsal, v: ventral, a: 
anterior, p: posterior. 
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The n1343 mutation does not appear to be a null allele of sem-2, since a 
deletion allele of sem-2, ok2422, generated by the C. elegans knockout 
consortium, resulted in 100% embryonic lethality (N>100). ok2422 has most of 
the C32E12.5 coding sequences deleted and is likely a null allele (Figure 2.2A). 
Time-lapse video microscopy showed that ok2422 homozygous embryos 
developed normally until late-comma stage (n=5, Figure 2.1I-P). However, these 
embryos were severely delayed in the elongation process, resulting in noticeable 
morphological defects such as enlarged heads relative to other 1½ fold embryos 
(Figure 2.1O). They eventually all reached to, and were arrested at, the 3-fold 
stage (Figure 2.1L,P). A fosmid (WRM0623cE02) containing C32E12.5 rescued 
the embryonic lethality of ok2422. RNAi soaking of L4s also resulted in 100% 
embryonic lethality (N>200). Thus, C32E12.5 is an essential gene required in 
embryogenesis, vulval and M lineage development, and n1343 is a partial loss-
of-function allele of C32E12.5 specifically affecting M lineage development.  
Sequencing of the cDNA clones for C32E12.5 showed that the C32E12.5 
locus is alternatively spliced with two different splice isoforms. Splice form 1 is 
represented by the cDNA clone yk657g12, in which two small exons separated 
by two large introns, 4.5kb (containing the Tc1 insertion in n1343 animals) and 
7kb respectively, are located upstream of the ATG-containing exon (Figure 2.2A). 
Splice form 2 is represented by two independent cDNA clones yk1577b07 and 
yk1661e08, which have a SL1 splicing leader sequence trans-spliced to the 
ATG-containing exon (Figure 2.2A). Both splice isoforms are predicted to encode 
the same open reading frame that contains 404 amino acids. The predicted 
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SEM-2 protein contains a DNA-binding domain, the SRY/HMG box (residue 92-
156), and a C terminal serine rich region (residue 334-354) that is predicted to be 
the transcriptional activation domain (Figure 2.2B). Based on the homology in the 
SRY/HMG region, SEM-2 is most similar to group C Sox proteins including Sox4, 
Sox11 and Sox12 in vertebrates and Sox14 in Drosophila (Bowles et al., 2000). 
2.3.3  SEM-2/SoxC is a nuclear protein expressed in the SM precursors 
and their descendants 
To understand how sem-2 functions, we generated a N-terminal gfp::sem-
2 translational fusion and examined its expression pattern. This gfp::sem-2 
translational fusion is functional because it rescued the Egl phenotype of n1343 
(1/1 line) and the embryonic lethality of ok2422 (2/2 lines). The GFP::SEM-2 
protein was nuclear localized, consistent with its predicted role as a transcription 
factor (Figure 2.2C,E,F,I,L,O).  
Expression of gfp::sem-2 was first detectable in a subset of cells of the E 
and MS lineages in early gastrulating-stage embryos (Figure 2.2C, D). A similar 
expression pattern has been reported by Broitman-Maduro et al. (2005) using a 
transcriptional reporter of sem-2.  The gfp::sem-2 expression persisted through 
embryonic and larval development in many cell types, including vulval, 
hypodermal and intestinal cells (Figures 2.2E,2.3D).  
To determine the expression pattern of gfp::sem-2 in the M lineage, we 
also labeled the M lineage cells with hlh-8p::rfp or anti-FOZI-1 immunostaining 
(Amin et al., 2007). gfp::sem-2 expression in the M lineage was first detectable at 
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the 16-M stage in the SM mother cells, M.v(l/r)pa (Figure 2.2F-H), and remained 
in both of their daughter cells, M.v(l/r)paa and M.v(l/r)pap (Figure 2.2F-H). The 
presence of GFP::SEM-2 in M.v(l/r)pap was transient: GFP::SEM-2 was not 
detectable after M.v(l/r)pap differentiated into BWMs. However, GFP::SEM-2 
persisted in the nuclei of the SM cells and all their descendants until the 8-SM 
stage, and became undetectable at the 16-SM stage (Figure 2.2L-Q). The 
expression pattern of GFP::SEM-2 is summarized in Figure 2.2R. Thus, sem-2 
expression is turned on in the SM mother cells and is retained in the SMs and 
their descendants.  
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Figure 2.2: sem-2 gene structure and expression pattern.  
 
(A) sem-2 gene structure (not drawn to scale) showing the molecular lesions of 
the sem-2(n1343) and sem-2(ok2422) mutations, two splice forms identified by 
cDNAs, and two translational reporters: gfp::sem-2 and Tc1::gfp::sem-2. Exons 
are in boxes. The coding region is in blue.  (B) A schematic of the predicted 
SEM-2 protein. SEM-2 contains a SRY/HMG box and a serine rich region. (C, D) 
gfp::sem-2 expression (C and the corresponding DIC image (D)) is first 
detectable in embryos at the beginning of gastrulation. (E) Expression of 
gfp::sem-2 in a transgenic larva. (F-Q) Expression of gfp::sem-2 in the M lineage. 
(F-K) Double labeling of wild-type animals with anti-GFP antibodies (F, I) and 
anti-FOZI-1 antibodies (G, J) and the corresponding merged images (H, J) at the 
16-M (F-H) and 18-M (I-K) stages, showing the expression of gfp::sem-2 in the 
SM mother cell (M.vlpa) and the SM cell (M.vlpaa). Expression is also seen in the 
equivalent cells on the right side (not shown). (L-Q) Ventral views of wild-type 
animals carrying gfp::sem-2 (L, O) and hlh-8::rfp (M, P) and the corresponding 
merged images (N, Q) at the 2-SM (L-N) and 4-SM (O-Q) stages. (R) Summary 
of GFP::SEM-2 expression in the M lineage. GFP::SEM-2-expressing cells are in 
green. 
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2.3.4  M lineage expression of sem-2 is specifically disrupted in n1343 
mutants  
Since sem-2 is an essential gene, the exclusive M lineage defects 
observed in sem-2(n1343) mutants suggest that the Tc1 transposon insertion 
may specifically affect sem-2 expression in the M lineage. To test this hypothesis, 
we introduced the Tc1 transposon back into the functional gfp::sem-2 
translational fusion, at the same insertion site as found in n1343 mutants (Figure 
2.2A), and examined the function and expression of this reporter: Tc1::gfp::sem-2. 
Tc1::gfp::sem-2 rescued the embryonic lethality of ok2422 mutants (1/1 line). 
However, it failed to rescue the Egl phenotype of n1343 mutants (4/4 lines, 
n>100). Thus Tc1::gfp::sem-2 is functional outside of the M lineage, but not 
functional in the M lineage. When we examined its expression pattern, we found 
that Tc1::gfp::sem-2 was not expressed in the M lineage at all (Figure 2.3A-C,E-
G and data not shown), while its expression outside of the M lineage was largely 
unaffected (Figure 2.3D,H). We also forced the expression of sem-2 cDNA in the 
M lineage of n1343 animals using the M lineage specific hlh-8 promoter and 
found that it rescued the missing egg-laying muscle phenotype in sem-2(n1343) 
animals, as determined by the reappearance of egl-15::gfp expression (6/6 lines). 
Together these observations demonstrate that the Tc1 insertion located in the 
4.5kb intron specifically disrupts the M lineage expression of sem-2, and that 
sem-2 is required within the M lineage for proper SM fate specification. 
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2.3.5  SEM-2/SoxC is sufficient to promote the SM fate 
We then tested whether sem-2 is sufficient to promote non-SM cells to 
adopt the SM fate. To this end, we used the hlh-8 promoter to force sem-2 cDNA 
expression in all the undifferentiated M lineage cells in wild-type animals. We first 
assayed for the effect of sem-2 misexpression on the CC and BWM fates using 
an intrinsic CC specific reporter CC::gfp and a BWM specific reporter myo-3p::rfp 
(see Materials and Methods). Wild-type worms have 4 embryonically-derived and 
2 M lineage-derived CCs (Figure 2.3I). Among animals carrying the hlh-8p::sem-
2 construct, 62.5% had no M-derived CCs (Figure 2.3J,K) and 14.1% had only 
one M-derived CC (n=64). The animals that lack M-derived CCs also lacked, on 
average, 10 of the 14 BWMs derived from the M lineage (n=9, Figure 2.3M,N). In 
contrast, 40.6% of the animals carrying hlh-8p::sem-2 (n=64) had extra hlh-
8::gfp-expressing SM-like cells and later, extra egl-15::gfp-expressing type I 
vulval muscle-like cells (Figure 2.3J). In most cases the vulval muscles born from 
animals misexpressing sem-2 were not attached to the vulva properly or not even 
located in the vulval region, and were therefore not likely to be functional (Figure 
2.3J,K). Taken together, the loss of M-derived BWM and CCs and the 
appearance of excessive SM- and vulval muscle-like cells are strongly 
suggestive of a transformation of some (if not all) of the M lineage cell types to 
SMs. Thus, sem-2 is not only necessary, but also sufficient, to promote the SM 
fate.  
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Figure 2.3: sem-2 is both required and sufficient in the M lineage for 
specifying the SM fate.  
 
(A-H) Transgenic worms carrying gfp::sem-2 (A-D) or Tc1::gfp::sem-2 (E-H) at 
the 2-SM stage. gfp::sem-2 (A-C), but not Tc1::gfp::sem-2 (E-G), is expressed in 
the SM cells (one focal plane shown) labeled by hlh-8::rfp (B, F, with merged 
images shown in C and G). Both transgenes are expressed in vulval and 
hypodermal cells (D, H, ventral views). (I-N) wild-type (I, L) or transgenic worms 
carrying hlh-8p::sem-2 cDNA (J-K, M-N) that also express cc::gfp, which labels 
CC, and egl-15::gfp, which labels type I vulval muscles (I-K), as well as myo-
3::gfp, which labels BWMs (L-N).  Compared to wild-type animals, animals 
expressing hlh-8p::sem-2 cDNA often have extra type I vulval muscles that are 
disorganized (enlargement boxes in J,K), lack M-derived CCs (J,K) and some M-
derived BWMs (arrows in M-N indicate regions with missing M-derived BWMs). 
Arrowheads point to M-derived CCs. * denotes the location of the vulva.  
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2.3.6  The M lineage specific expression of sem-2/SoxC is is controlled 
by elements in the 4.5 kb intron.   
The M lineage specific function of sem-2 in promoting the SM fate coupled 
with the presence of the Tc1 insertion in the 4.5kb intron and the loss of M 
lineage specific expression of Tc1::gfp::sem-2 suggest that the 4.5kb intron may 
contain element(s) specifically required for sem-2 expression in the M lineage. To 
test this hypothesis, we first placed the 4.5kb intron (Figure 2.2A) directly 
upstream of the gfp coding sequence, but observed no gfp expression in 
transgenic lines carrying the construct (2 lines, n>100). However, the 7kb intron 
of sem-2 alone was capable of driving reporter expression in hypodermal, 
intestinal and vulval cells that express sem-2 even in the n1343 mutants (data 
not shown). Taking into account the two types of sem-2 transcripts (Figure 2.2A), 
these observations suggest that the 7kb intron likely has the promoter 
responsible for the transcription of splice form 2 in hypodermal, intestinal and 
vulval cells, while the 4.5kb intron has no promoter activity on its own.  
To further test whether the 4.5kb intron contains any M lineage specific 
enhancer(s), we placed the entire 4.5kb intron sequence upstream of the Dpes-
10 basal promoter and gfp, followed by the unc-54 3’UTR (pCXT12, Figure 2.4A). 
We observed M lineage specific expression of the reporter (6/8 lines, Figure 
2.4B-G), suggesting the presence of M lineage specific enhancer element(s) 
within the 4.5kb intron. However, the gfp expression pattern from this reporter 
differs from that of the translational gfp::sem-2 reporter described earlier; while 
GFP::SEM-2 was only found in the SM mother and the SM lineage cells, 
  
80 
 
transgenic lines carrying the pCXT12 reporter showed gfp expression in all the 
undifferentiated cells in the M lineage, including the early M lineage and the SM 
lineage (Figure 2.4B-G). We reasoned that either additional cis-element(s) are 
involved in restricting sem-2 expression to specific cells within the M lineage, or 
the SEM-2 protein is unstable in the early M lineage. To this end, we tested 2.8kb 
sequences upstream of the 4.5kb intron, 2kb sequences of the 3’ UTR, and the 
entire 7kb second intron by placing each of them in cis with the 4.5kb intron. 
None of them was able to restrict the expression of the 4.5kb intron::gfp reporter 
in the early M lineage (Figure 2.4H). Despite this, our data demonstrate that the 
4.5kb intron contains enhancer(s) positively involved in directing sem-2 
expression in the M lineage. 
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Figure 2.4: The 4.5kb intron of sem-2 contains an M lineage enhancer 
element.  
 
(A) Schematic of deletion series of the sem-2 4.5kb intron in the enhancer 
analysis. GFP expression was scored in F2 animals in at least 3 independent 
lines per construct. Expression is represented as + (consistent expression), - (no 
detectable expression). * denotes the location of Tc1 insertion in the n1343 allele 
(also in panel H). (B-G) Examples showing lateral views (one focal plane) of 
worms expressing GFP driven by the pCXT12 reporter (B,E) in the M lineage 
(labeled by hlh-8::rfp, C,F) at the 4-M stage (B-D) and the 2-SM stage (E-G). (H) 
Constructs used to identify possible cis-negative elements in the sem-2 locus. + 
indicates the presence of reporter expression. 
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2.3.7  M lineage expression is under the direct control of Hox factors, 
MAB-5 and LIN-39, and their cofactor CEH-20 
To identify the M lineage specific enhancer(s) within the 4.5kb intron, we 
generated a series of deletions in pCXT12 (Figure 2.4A), and found a 598bp 
region (-11650 to -7097) that is sufficient to drive reporter expression in the M 
lineage (Figure 2.4A). Alignment of this 598bp region in C. elegans and its 
homologous sequences in three related Caenorhabditis species, C. briggsae, C. 
remanei and C. brenneri, which are farther away to C. elegans than mouse to 
human, identified several blocks of highly conserved sequences (data not shown) 
that include a site “TGATATATCG” (Figure 2.5A). This site closely matches the 
consensus PBC/Hox binding sequence “TGATNNAT(G/T)(G/A)”, with “TGAT” 
being the PBC binding site and “AT(G/T)(G/A)” being the Hox binding site (Chan 
and Mann,1996;Mann and Affolter, 1998). Interestingly, the Tc1 transposon 
insertion site in the sem-2(n1343) mutants disrupts the putative PBC half site 
(Figure 2.5A). Furthermore, inserting Tc1 into the same location as in n1343 
mutants in the reporter construct pCXT33 completely blocked the M lineage 
expression of the reporter (pCXT173, 6/6 lines, n>100). We further tested the 
importance of the putative PBC/Hox binding site by making clustered mutations 
in each half site and testing the consequences of the mutations on the M lineage 
enhancer activity. Mutating the PBC half site (mut1) completely abolished the M 
lineage expression of the reporter (100%, n=45, Figure 2.5B). Mutations in the 
putative Hox binding site (mut2 and mut3) also led to the loss of the M lineage 
enhancer activity in all (100%, n=26, for mut2) or most (93.7%, n=63, for mut3) of 
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the transgenic animals (Figure 2.5B). Thus the putative PBC/Hox binding site, 
disrupted by the Tc1 insertion in n1343 mutants, is required for sem-2 M lineage 
activity. 
Previous studies have found that two Hox factors, MAB-5 and LIN-39, and 
their cofactor, the PBC homolog CEH-20, play essential roles in M lineage 
development (Liu and Fire, 2000; Jiang et al., 2009). Both mab-5 and ceh-20 are 
expressed throughout the M lineage (Salser, 1995; Jiang et al., 2009), while lin-
39 is expressed in the SM lineage (Wagmaister et al., 2006). Furthermore, MAB-
5 and LIN-39 together and CEH-20 are required for the proper specification and 
differentiation of M-derived CC, BWMs and SMs (Jiang et al., 2009). We 
therefore tested whether these three factors are required for the sem-2 M lineage 
activity using the minimal pCXT33 reporter. We introduced pCXT33 into the 
double null mutant lin-39(n1760) mab-5(e1239) and a strong loss-of-function 
mutant ceh-20(os39) (Liu and Fire, 2000; Arata et al., 2006; Jiang et al., 2009). 
gfp reporter expression was detected in the M mesoblast in 98.3% (n=56) of lin-
39(n1760) mab-5(e1239)/++ animals (data not shown) and 92.6% (n=54) of ceh-
20(os39)/+ animals (Figure 2.5L, M). However, gfp expression was detected in 
the M mesoblast in only 4.9% (n=82) of lin-39(n1760) mab-5(e1239) animals and 
in 8.3% (n=72) of ceh-20(os39) animals (Figure 2.5N, O, and data not shown). 
Thus, the PBC/Hox factors MAB-5, LIN-39 and CEH-20 are necessary for the 
sem-2 M lineage enhancer activity. 
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To test whether MAB-5, LIN-39 and CEH-20 may directly regulate sem-2 
expression in the M lineage, we used the Electrophoretic Mobility Shift Assay 
(EMSA) to test whether recombinant LIN-39 and CEH-20 proteins can 
cooperatively bind to the putative PBC/Hox binding site in vitro. We were not able 
to generate recombinant full-length MAB-5 proteins in vitro (Liu and Fire, 2000). 
As shown in Figure 2.5, LIN-39 alone, or together with CEH-20, binds 
oligonucleotides with a canonical ANTP/EXD composite site (Knoepfler et al., 
1996) or oligonucleotides containing the putative PBC/Hox site in the sem-2 M 
lineage enhancer (Figure 2.5B,C). In contrast, mutating the PBC half site (mut1) 
completely abolished the composite binding of LIN-39 and CEH-20 proteins 
without affecting LIN-39 binding alone (Figure 2.5C). Similarly, mutating the Hox 
half site (mut2) completely abolished the binding of LIN-39 alone or both LIN-39 
and CEH-20. Consistent with the in vivo reporter assay result, mut3 significantly 
reduced, but did not completely abolish, the binding of LIN-39 alone or LIN-39 
and CEH-20 together (Figure 2.5C). The composite binding of LIN-39 and CEH-
20 to the putative PBC/Hox binding site can also be competed away using 
excess of unlabeled oligonucleotides containing the wild-type binding site (Figure 
2.5C). Taken together, our data suggest that sem-2 is directly regulated by the 
Hox factors MAB-5 and LIN-39 and their cofactor CEH-20 in the M lineage. 
Consistent with our finding, ChIP-seq experiments by modENCODE showed that 
LIN-39 directly binds to this Hox-PBC site in vivo 
(http://intermine.modencode.org). 
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Figure 2.5: sem-2 is a direct target of Hox/PBC factors in the M lineage.  
 
(A) Alignment of the conserved intronic regions that include the putative 
Hox/PBC binding site (box region) from C. elegans, C. remanei, C. brenneri and 
C. briggsae using clustalW. C. brenneri has two copies of the sem-2 gene. * 
marks the Tc1 insertion site in sem-2(n1343). Blue color indicates identity among 
the four species. (B) Summary of in vivo transgenic reporter assays and in vitro 
EMSA results. The putative PBC (red) and Hox (blue) binding sites are in capital 
letters. Mutated sites are in lower case. +++: strong binding or robust reporter 
expression, ++: moderate binding, +/-: faint expression in 4 of 63 animals 
examined, -: no binding or no detectable reporter expression. (C) EMSA using 
indicated oligonucleotides, purified LIN-39 and CEH-20 protein, and un-labeled 
competitor wild-type oligonucleotides in 2000-fold excess. The top and bottom 
arrows indicate the sizes of LIN-39/CEH-20/DNA and LIN-39/DNA complexes, 
respectively. (L-O) pCXT33 expression in ceh-20(os39)/+ (L,M) and ceh-20(os39) 
(N,O) animals. (L,N) GFP, (M,O) DIC. Arrow: M mesoblast. 
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2.3.8  SEM-2/SoxC acts downstream of signaling pathways required for 
proper SM fate specification 
Previous studies have shown that LIN-12/Notch signaling is required for 
promoting the SM fate on the ventral side, while the antagonism of TGF- 
signaling by SMA-9 is required for the CC fate on the dorsal side, of the M 
lineage (Greenwald et al., 1983; Foehr et al., 2006; Foehr and Liu, 2008). We 
therefore tested whether SM fate and sem-2 expression in the M lineage is under 
the control of these dorsoventral patterning mechanisms. As shown in Figure 
2.6A-C, no gfp::sem-2 expression was observed in M.v(l/r)pa cells at the 16-M 
stage (n=44) in unc-32(e189) lin-12(n676n930ts) animals at the restrictive 
temperature, in which the SMs are transformed to CCs (Greenwald et al, 1983; 
Foehr and Liu, 2008). In contrast, gfp::sem-2 expression was detected in both 
M.d(l/r)pa and M.v(l/r)pa as well as their descendants at the 16-M stage (n=18, 
Figure 2.6D-F) and the 18-M stage (n=4) respectively in sma-9(cc604) mutants, 
which show a M-derived CC to SM fate transformation (Foehr et al., 2006). 
Furthermore, sem-2 is required for specifying the dorsal SMs in sma-9(cc604) 
mutants, as both the endogenous and the ectopic SMs in sma-9(cc604) mutants 
were lost upon sem-2(RNAi) treatment (97.3%, n=75) or in sem-2(n1343); sma-
9(cc604) double mutants (100%, n>200). Thus, the M lineage expression of sem-
2 is downstream of both LIN-12 and SMA-9.  
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Figure 2.6: The M lineage expression of sem-2 is under the control of 
multiple signaling pathways and transcription factors.  
 
(A-O) sem-2 M lineage expression in lin-12(n676n930ts) animals at the restrictive 
temperature (A-C), sma-9(cc604) (D-F), let-381(RNAi) (G-I), sys-1(RNAi) (J-L) 
and fozi-1(RNAi) (M-O) animals. Arrowheads indicate cells with gfp::sem-2 
expression. The animal shown in (M-O) is at the 2-SM stage. (P-S) fozi-1 is 
ectopically expressed in M.vlpaa in sem-2(n1343) animals (R-S) compared to 
wild-type animals (P-Q), as shown by -FOZI-1 immunostaining (P, R) and the 
corresponding DAPI staining images (Q, S). Arrows point to M.vlpaa. Similar 
expression is also seen in the equivalent cells on the right side for A-L and P-S. 
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We have recently shown that the FoxF/C forkhead transcription factor 
LET-381 also functions downstream of SMA-9 and LIN-12 to promote CC fate 
specification (Amin et al., 2010). let-381 is expressed in M.d(l/r)pa and their 
mothers and let-381(RNAi) leads to the fate transformation of M-derived CCs to 
the SM mother cells (Amin et al., 2010). In let-381(RNAi) animals, gfp::sem-2 
was detected in both M.d(l/r)pa and M.v(l/r)pa as well as their descendants 
(Figure 2.6G-I, n=23/45). Furthermore, no SMs were produced in sem-2(RNAi) 
let-381(RNAi) animals (94.1%, n=118), suggesting that sem-2 functions 
downstream of let-381. Thus the exclusive ventral expression of sem-2 in the M 
lineage is due to the negative regulation of LET-381, whose own expression is 
repressed by LIN-12 on the ventral side and activated by SMA-9 on the dorsal 
side (see Figure 2.7).  
Along the anterior-posterior axis, the Wnt/-catenin asymmetry pathway is 
required for proper M lineage fate specification at the 16-M stage (Amin et al., 
2009). Specifically, SYS-1/-catenin is enriched in the nuclei of posterior cells 
and mutations of sys-1 lead to a posterior-to-anterior fate transformation and the 
production of extra SMs and CCs, while POP-1/TCF has a reciprocal localization 
and loss-of-function phenotypes (Amin et al., 2009). Because sem-2 expression 
is first detected only in M.v(l/r)pa cells but not their posterior sister cells M.v(l/r)pp 
at the 16-M stage, we looked to see if sem-2 expression in the M lineage is under 
the control of the Wnt/-catenin asymmetry pathway. As shown in Figure 2.6J-L, 
gfp::sem-2 was expressed in both M.v(l/r)pa and M.v(l/r)pp (33.3%, n=26) and all 
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the endogenous and ectopic SMs (85.7%, n=14) in sys-1(RNAi) animals. sem-2 
is also required for both the endogenous and the ectopic SMs produced in sys-
1(q544) animals, as sem-2(RNAi) sys-1(q544) animals produced no SMs at all 
(100%, n=20). Thus sem-2 acts downstream of, and is negatively regulated by, 
SYS-1. 
2.3.9  sem-2 exhibits mutually repressive interactions with fozi-1 and 
hlh-1. 
Previous studies have shown that the MyoD homolog HLH-1 functions 
redundantly with the zinc finger protein FOZI-1 to specify M-derived BWMs and 
CCs while repressing the SM fate (Harfe et al., 1998a; Amin et al., 2007). We 
found that gfp::sem-2 was expressed in both the endogenous and the ectopic 
SMs in fozi-1(RNAi) animals (98.6%, n=70, Figure 2.6M-O) and hlh-1(RNAi) 
animals (100%, n=25). Furthermore, no SMs were produced by sem-2(RNAi) 
fozi-1(cc609) animals (100%, n=71) or sem-2(RNAi) hlh-1(cc561ts) animals at 
the restrictive temperature (100%, n=30). These observations suggest that sem-2 
expression is repressed in the M-derived BWMs and CCs by HLH-1 and FOZI-1. 
Because the SMs are transformed to BWMs in sem-2(n13430) mutants, 
we also examined whether fozi-1 and hlh-1 are expressed in the ectopic BWMs 
in n1343 animals. As shown in Figure 2.6P-S, fozi-1, which is transiently 
expressed in all M-derived BWMs prior to their differentiation in wild-type animals 
(Figure 2.6P-Q), is expressed in the ectopic BWMs in sem-2(n1343) animals 
(Figure 2.6R-S). Similar results were also obtained for hlh-1 expression in sem-
  
93 
 
2(n1343) animals (data not shown). Since the expression of sem-2 in the SM 
mother cells (M.v(l/r)pa) overlaps with those of hlh-1 and fozi-1, the above results 
suggest that the BWM-specifying factors FOZI-1 and HLH-1 and the SM-
specifying factor SEM-2 mutually repress each other’s expression to maintain 
their proper expression pattern in the respective daughter cells derived from the 
SM mothers.   
2.4  DISCUSSION 
2.4.1  SEM-2/SoxC acts as a switch in a binary fate decision to promote 
a proliferative fate over a differentiated muscle fate  
We have demonstrated that the single SoxC protein SEM-2 is both 
necessary and sufficient to specify the SM fate in the C. elegans postembryonic 
mesoderm. SMs are precursors that have the potential to proliferate and then 
differentiate into 16 non-striated egg-laying uterine and vulval muscles. 
Disrupting sem-2 expression specifically in the M lineage leads to a 
transformation of SMs to cells that differentiate into striated BWMs. sem-2 is 
specifically expressed in Mv(l/r)pa, a bi-potent precursor cell that asymmetrically 
divides to give rise to a SM and a BWM. sem-2 expression is retained in the SM, 
perdures in its descendants that remain proliferative and ceases when these 
cells switch from a proliferation state and differentiate into mature egg-laying 
muscles (Figure 2.2R). Forced over-expression of sem-2 throughout the M 
lineage led to the loss of M-derived BWMs and CCs and the gain of extra SMs 
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(Figure 2.3J-N). These experiments demonstrate that SEM-2 is both necessary 
and sufficient for promoting the egg-laying muscle precursor SM fate while 
antagonizing the sem-2-expressing cells from differentiating into BWMs. 
Consistent with this, ectopic sem-2 expression was detected in mutant animals 
with extra SMs and removing sem-2 in these animals blocked the formation of 
both ectopic and normal SMs.  
sem-2 is also broadly expressed during embryogenesis and essential for 
embryonic development. sem-2 null mutant embryos were arrested at the 3-fold 
stage. Time-lapse movies showed that this arrest is preceded by delays in 
hypodermal migration.and elongation. Besides the embryonic phenotype, RNAi 
knockdown of sem-2 postembryonically caused a multivulval (Muv) phenotype, 
which may result from a fate specification defect or a proliferation defect in the 
vulval precursor cells. Further characterization of the embryonic and vulval 
phenotypes of sem-2 mutants will help shed light on how sem-2 functions in 
these processes. 
2.4.2  A model for the specification of the non-striated muscle 
precursors, the SMs 
Our findings provide an example of how lineage information and positional 
information are integrated to activate the cell type specific expression of a cell 
fate determinant, in this case, sem-2, in the specification of the sex myoblast 
cells. The M lineage expression of sem-2 is controlled by a cis-acting M lineage 
enhancer located in the 4.5kb intron (Figure 2.4A). Disruption of this site by the 
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transposon Tc1 in n1343 animals specifically disrupted the expression and 
function of sem-2 in the M lineage without affecting its expression in other cells. 
We showed that the Hox factors MAB-5 and LIN-39 and their cofactor, the PBC 
protein CEH-20, directly bind this site to activate sem-2 expression in the M 
lineage (Figure 2.5B,C). However, these three genes are also expressed in other 
cell types in C. elegans (Costa et al., 1988; Wagmaister et al., 2006; Jiang et al., 
2009). In fact, it has been shown that MAB-5/CEH-20 and/or LIN-39/CEH-20 
complexes directly activate the expression of hlh-8 throughout the M lineage 
before terminal differentiation (Liu and Fire, 2000); of egl-18, elt-6, eff-1 and lag-2 
in the developing vulva (Koh et al., 2002;Shemer and Podbilewicz, 2002;Takacs-
Vellai et al., 2007), and of egl-1 in the P11 lineage and the VC neurons (Liu et al., 
2006;Potts et al., 2009). A Hox independent role of CEH-20 has also been found 
in the activation of mls-2 in the early M lineage (Jiang et al., 2008). Thus, 
additional factors must cooperate with Hox/PBC proteins to refine the cell type 
specific expression of Hox/PBC targets.    
Our results demonstrate that, in addition to the Hox factors and CEH-20, 
the integration of dorsal-ventral (D/V) and anterior-posterior (A/P) positional 
information is critical in dictating the specific localization of sem-2 within the M 
lineage. Previous studies have shown that LIN-12/Notch signaling and SMA-9, 
which antagonizes the Sma/Mab TGF-signaling pathway, work independently 
to control D/V patterning of the M lineage and that they both regulate the 
expression of the FoxF/C transcription factor LET-381 for its dorsal M lineage 
expression (Foehr et al., 2006; Foehr and Liu, 2008; Amin et al., 2010). We 
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showed that the proper pattern of sem-2 expression is due to the presence of 
LIN-12/Notch signaling and the absence of SMA-9 along the D/V axis. 
Furthermore, sem-2 functions downstream of let-381 and is negatively regulated 
by let-381 in the dorsal M lineage (Figure 2.6G-I). Currently it is not clear whether 
this negative regulation of sem-2 by let-381 is direct or not.  
Along the A/P axis at the 16-M stage, POP-1/TCF functions as a repressor 
in M.v(l/r)pa due to low nuclear levels of SYS-1/-catenin and is converted to an 
activator in M.v(l/r)pp due to high nuclear levels of SYS-1/-catenin (Kidd et al., 
2005;Liu et al., 2008; Amin et al., 2009). We showed that sys-1(RNAi) caused 
ectopic expression of gfp::sem-2 and ectopic production of SMs (Figure 2.6J-L). 
Since sem-2 is expressed in M.v(l/r)pa where POP-1 acts as a repressor, these 
results suggest that POP-1 must activate the expression of a repressor of sem-2 
in M.v(l/r)pa to restrict sem-2 expression along the anterior-posterior axis in the 
M lineage. We hypothesize that an additional factor(s) must be present either in 
M.v(l/r)aa to repress sem-2 expression or in M.v(l/r)pa to promote sem-2 
expression in order to ensure specific expression of sem-2 in M.v(l/r)pa (see 
model in Figure 2.7).   
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Figure 2.7: A Model for sem-2 regulation and SM fate specification.  
 
A proposed model on how sem-2 expression in the M lineage is regulated 
(see discussion). * denotes a putative transcriptional repressor of sem-2. Thick 
blue lines represent direct regulatory relationships, black lines represent 
relationships based solely on genetic data, and do not distinguish between direct 
and indirect. Gray lines and text indicate a lack of expression in the indicated cell. 
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Immediately after the SM mother cell M.v(l/r)pa divides, both its daughter 
cells express gfp::sem-2 (Figure 2.2I-K). However, gfp::sem-2 perdures in the 
anterior SM lineage, but not in the posterior BWMs. hlh-1 and fozi-1 exhibit a 
reciprocal expression pattern: they are turned off in the SMs, but remain 
expressed in the BWMs (Harfe et al., 1998a; Amin et al., 2007). The initiation of 
the asymmetric expression of sem-2 vs. hlh-1 and fozi-1 may be due to the 
nuclear POP-1 and SYS-1 asymmetry along the anterior-posterior axis (Amin et 
al., 2009). Once initiated, sem-2 and hlh-1 and fozi-1 appear to mutually repress 
each other to maintain their proper expression, as sem-2 is expressed in all the 
ectopic SMs in hlh-1 and fozi-1 mutant or RNAi animals, while fozi-1 and hlh-1 
are expressed in the ectopic BWMs in sem-2(n1343) animals. 
2.4.3  An evolutionarily conserved role of SoxC family members in cell 
fate specification and cell proliferation 
SEM-2 is a member of the SoxC subfamily, which includes Sox14 in 
Drosophila and Sox4, 11 and 12 in vertebrates (Bowles et al., 2000). Drosophila 
Sox14 exhibits a dynamic expression pattern during development and regulates 
dendrite severing and other unknown processes essential for fly metamorphosis 
(Sparkes et al., 2001;Kirilly et al., 2009;Ritter and Beckstead, 2010). Functional 
studies on vertebrate SoxC members have shown that SoxC proteins play 
essential roles in multiple lineages such as oligodendrocytes, B lymphocytes, 
osteoblasts and others to regulate cell fate specification, cell differentiation and 
cell survival (Penzo-Mendez, 2009). In humans, Sox4 overexpression has often 
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been detected in cases of prostate cancer (Dhanasekaran et al., 2001;Ernst et al., 
2002;Lapointe et al., 2004;Liu et al., 2006;Luo et al., 2001;Magee et al., 
2001;Rhodes et al., 2002;Welsh et al., 2001). Sox4 is also overexpressed in 
many other types of cancers, including leukemias (Andersson et al., 2007), 
melanomas (Talantov et al., 2005), glioblastomas (Sun et al., 2006), 
medulloblastomas (Lee et al., 2002), bladder cancer (Aaboe et al., 2006) and 
lung cancer (Friedman et al., 2004). Similarly, Sox11 is highly expressed in 
medulloblastomas (Lee et al., 2002), gliomas (Weigle et al., 2005); non-B cell 
lymphomas (Wang et al., 2008) and epithelial ovarian tumors (Brennan et al., 
2009). However, the underlying mechanism by which the Sox proteins may 
contribute to cancer is not known. We have found that sem-2 is specifically 
expressed in the proliferating SM mother cells, the SMs and their descendants 
prior to terminal differentiation (Figure 2.2R). Furthermore, increasing sem-2 level 
throughout the M lineage is sufficient to transform other M lineage cells into 
proliferating SM-like cells, even though they express normal levels of CC- and 
BWM-specifying and differentiating factors. Thus it appears that increasing sem-
2 level is sufficient to tip the balance between proliferative and differentiative 
factors and allows for proliferation. This pro-proliferation function of SEM-2 may 
be a conserved role of the group C Sox proteins. 
Hox and PBC proteins have also been implicated in tumorigenesis. There 
are numerous examples of Hox gene overexpression in various tumor types 
(Argiropoulos and Humphries, 2007;Shah and Sukumar, 2010). Given our finding 
that sem-2 expression in the M lineage is directly activated by Hox-PBC proteins 
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and that there is overexpression of Sox4 and Sox11 in a variety of cancers, it is 
possible that the oncogenic activity of Hox genes in some cases is due to their 
direct activation of SoxC gene expression.   
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Chapter 3:  The RGM protein DRAG-1 positively regulates a BMP-like 
signaling pathway in Caenorhabditis elegans2 
3.1  INTRODUCTION 
Bone morphogenetic proteins (BMPs) belong to the transforming growth 
factor-β (TGFβ) superfamily of ligands and the BMP signaling pathway plays 
roles in multiple developmental and homeostatic processes (Wu and Hill, 2009). 
Malfunction of the pathway causes many somatic and hereditary disorders in 
humans, including cardiovascular diseases and cancer (Gordon and Blobe, 
2008; Massagué, 2008). All BMP family members share a common mode of 
signal transduction (Shi and Massague, 2003). Upon binding of the BMP ligands, 
the type II receptor phosphorylates the type I receptor, which then 
phosphorylates the receptor-regulated Smads (R-Smads). These activated R-
Smads then complex with common-mediator Smads (co-Smads) and enter the 
nucleus where the complex participates in regulation of downstream gene 
expression. Multiple levels of regulation, including extracellular regulation, ensure 
proper spatiotemporal control of BMP signaling in the right cellular context 
(Massague and Chen, 2000; Balemans and Van Hul, 2002; Moustakas and 
Heldin, 2009; Umulis et al., 2009). In particular, a family of repulsive guidance 
molecules (RGMs) has recently been found to bind different BMPs with high  
2 This chapter was published in Development (Tian C, Sen D, Shi H, Foehr ML, Plavskin Y, 
Vatamaniuk OK, Liu J. Development. 2010 Jul;137(14):2375-84.) and is reprinted with permission. 
Mapping was performed by Y. Plavskin, M.L. Foehr, and D. Sen, molecular cloning was 
performed by H. Shi, fractionation experiment was supervised by O.K.Vatamaniuk. 
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affinity and acts as BMP co-receptors in tissue culture experiments (Samad et al., 
2005; Babitt et al., 2005, 2006).   
RGM family proteins are GPI (glycophosphatidylinositol)-linked 
membrane-associated proteins (Corradini et al., 2009; Severyn et al., 2009). 
Vertebrates have four RGMs: RGMa, RGMb (DRAGON), RGMc (haemojuvelin 
or HJV) and RGMd (Camus and Lambert, 2007). RGMa, RGMb/DRAGON and 
RGMc/haemojuvelin can bind selected BMP molecules as well as type I and type 
II BMP receptors to enhance BMP signaling in tissue cultures (Babitt et al., 2005, 
2006; Samad et al., 2005; Xia et al., 2008, 2010; Andriopoulos et al., 2009). 
Over-expression of mouse RGMb/DRAGON in Xenopus embryos can augment 
Smad1-induced mesodermal and endodermal marker expression (Samad et al., 
2005). Several lines of in vivo evidence suggest that RGMc/haemojuvelin acts as 
the co-receptor for BMP-6 in regulating iron metabolism in mice (Babitt et al., 
2007; Xia et al., 2008; Andriopoulos et al., 2009). However, there is as yet no 
evidence showing that RGMa and RGMb/DRAGON are required for modulating 
BMP signaling in vivo.   
In this study, we describe the identification and functional characterization 
of the sole C. elegans RGM homolog DRAG-1 in modulating a BMP-like 
signaling pathway. There are two TGFβ-related pathways in C. elegans, a TGFβ-
like pathway that controls dauer formation and a BMP-like Sma/Mab pathway 
that regulates body size, male tail formation, mesoderm development and innate 
immunity (Savage-Dunn, 2005; Foehr et al., 2006; Moustakas and Heldin, 2009; 
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Partridge et al., 2010). The ligand of the Sma/Mab pathway is a BMP-like 
molecule DBL-1 (Morita et al., 1999; Suzuki et al., 1999). Additional members of 
this pathway include the type I receptor SMA-6 (Krishna et al., 1999), type II 
receptor DAF-4 (Estevez et al., 1993), and Smads SMA-2, SMA-3 and SMA-4 
(Savage et al., 1996).  Loss-of-function mutations in any of these pathway 
members cause small body size and male tail sensory ray formation defects.  
The Sma/Mab pathway also plays a role in patterning the C. elegans 
postembryonic mesoderm. The hermaphrodite postembryonic mesodermal M 
lineage arises from a single pluripotent precursor cell, the M mesoblast. During 
larval development, the M mesoblast divides to produce a dorsal lineage that 
gives rise to macrophage-like coelomocytes (CCs) and striated bodywall muscles 
(BWMs), and a ventral lineage that produces BWMs and the sex muscle 
precursor cells, the sex myoblasts (SMs) (Sulston and Horvitz, 1977; Figure 
3.1C). We have previously shown that mutations in the schnurri homolog sma-9 
lead to a dorsal to ventral fate transformation in the M lineage (Foehr et al., 2006; 
Foehr and Liu, 2008). Furthermore, mutations in the core components of the 
Sma/Mab pathway suppress the dorsoventral patterning defects of sma-9 
mutants, suggesting that SMA-9 functions by antagonizing Sma/Mab signaling to 
pattern the postembryonic mesoderm along the dorsoventral axis.  
Among suppressors of the sma-9 phenotype, we detected a mutation in a 
novel locus that we have named drag-1. drag-1 mutants exhibit only a subset of 
phenotypes seen in the Sma/Mab pathway mutants. We show that drag-1 
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encodes the sole RGM homolog in C. elegans. We also show that DRAG-1 is a 
membrane-localized protein that functions at the ligand-receptor level in the 
Sma/Mab pathway to regulate body size and mesoderm patterning. Using a 
novel Sma/Mab responsive reporter, we demonstrate that DRAG-1 positively 
modulates Sma/Mab signaling. Our work establishes a direct link between RGM 
proteins and BMP signaling in vivo and provides a simple and genetically 
tractable system for mechanistic studies on RGM protein regulation of BMP 
pathways in vivo. 
3.2  MATERIAL AND METHODS 
3.2.1  C. elegans strains 
Strains were kept at normal conditions, as described by Brenner (Brenner, 
1974). Analyses were performed at 20°C, unless otherwise noted. The following 
mutations and integrated transgenes were used: Linkage group II (LGII): sma-
6(jj6); LGIII: daf-7(m62), daf-7(e1372), daf-4(m72), sma-3(jj3), lon-1(e185), 
ccIs4438(intrinsic CC::gfp); LGIV: daf-1(m40), daf-1(m213); LGV: dbl-1(wk70); 
LGX: lon-2(e678), sma-9(cc604), sma-9(cc606), sma-9(wk5). Other strains used: 
VF1: unc119(ed3); gfEx[phmt-1p::gfp, unc-119(+)] (Schwartz et al., 2010); 
VF12.3: hmt-1(gk161) III; gfIs1[hmt-1::gfp, unc-119(+)]. 
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3.2.2  Molecular analysis of drag-1 
The molecular lesion of jj4 was identified by sequencing PCR fragments 
spanning the entire genomic region of Y71G12B.16.  
 To determine the drag-1 cDNA sequence, the ProQuest cDNA library 
(Invitrogen) was used for PCR amplification using primers ForwLongpPC-86 
(corresponding to vector sequences—5’ 
TATAACGCGTTTGGAATCACTACAGGGATGTTTAATACCAC 3’) and DS147 
(complementary to sequences spanning the predicted stop codon of drag-1—5’ 
TCAGCATAACAATGATAAAAGAGCAAAAAAAAAG 3’). The PCR fragments 
were cloned into the pCR-Blunt II-TOPO vector (Invitrogen). Three of the 10 
resulting clones sequenced contained the entire Y71G12B.16 ORF as well as 
additional 5’ UTR sequences. One clone (pDS9.10) has 32bp of 5’ UTR 
sequences immediately upstream of the ATG (Y71G12B.16b, Genbank: 
HM154524), while the other two (pDS9.5 and pDS9.6) contain 60bp 5’ UTR 
sequences (Y71G12B.16a, Genbank: HM154523).  
3.2.3  Plasmid constructs and transgenic lines 
drag-1 reporter constructs 
4kb of the drag-1 upstream sequence (-3977 to -1), sequences from 
immediately downstream of the ATG till the end of the first intron of drag-1 (4 to 
1123), the entire drag-1 protein coding region and 1 kb of the drag-1 downstream 
sequences were PCR amplified using N2 genomic DNA as template. The PCR 
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products were used to generate the following reporter constructs for analyzing 
the expression pattern of drag-1: 
pDS14: 4kb drag-1p::4xNLS::gfp::unc-54 3’ UTR; 
pDS15: 4kb drag-1p::drag-1 1st intron::4xNLS::gfp::unc-54 3’ UTR (Transgenic 
animals carrying either pDS14 or pDS15 gave identical gfp expression patterns, 
data not shown).  
pDS27: 4kb drag-1p::drag-1 genomic ORF::1kb drag-1 3’ UTR  
pCXT15: 4kb drag-1p::drag-1 1st intron::drag-1 cDNA::unc-54 3’UTR  
pJKL849: 4kb drag-1p::drag-1 genomic ORF::gfp::1kb drag-1 3’ UTR. GFP from 
the Fire lab vector pPD95.75 (http://www.addgene.org) was inserted between 
aa395 and aa396 of the drag-1 coding region, just prior to the cleavage site of 
the putative C-terminal pro-peptide.  
Constructs for tissue specific expression of drag-1 
pJKL928: myo-2p::drag-1 cDNA::unc-54 3’ UTR 
pJKL931: elt-2p::drag-1 cDNA::unc-54 3’ UTR 
pJKL933: elt-3p::drag-1 cDNA::unc-54 3’ UTR 
pJKL935: rol-6p::drag-1 cDNA::unc-54 3’ UTR 
pDS20: hlh-8p::drag-1 cDNA::unc-54 3’ UTR  
pCXT148: hlh-8p::drag-1 cDNA::1 kb drag-1 3’ UTR 
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Constructs for structure-function analysis of drag-1 (derived from pJKL849) 
pCXT92 (DelC::GFP): drag-1::gfp with the putative C-terminal pro-peptide 
(aa387-408) deleted  
pCXT115 (DelN::GFP): drag-1::gfp with the N-terminal signal peptide (aa2-23) 
deleted 
pCXT116 (DelNC::GFP): drag-1::gfp with both the N-terminal signal peptide 
(aa2-23) and the C-terminal pro-peptide (aa387-408) sequences deleted 
pCXT94 (LIN-12TM::GFP): drag-1::gfp with the C-terminal pro-peptide (aa387-
408) replaced by the LIN-12 transmembrane domain (aa907-934 of LIN-12, 
Yochem et al., 1988) 
Other reporters: 
pJKL840: sma-6p::nls::rfp::lacZ::unc-54 3’ UTR (containing 3kb of the sma-6 
promoter (-3094 to -1)) 
Generating transgenic animals 
Transgenic animals were generated using the plasmids pRF4 (Mello et al., 
1991), pC1 (pha-1 rescuing construct, Granato et al., 1994), pJKL449 (myo-
2p::gfp::unc-54 3’ UTR, Jiang et al., 2009) or LiuFD61(mec-7p::mRFP, Amin et 
al., 2009) as markers. 
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3.2.4  Reverse Transcription-PCR (RT-PCR) 
Total RNA was extracted from mixed stage wild-type and drag-1(jj4) 
worms using a RNA extraction kit (Qiagen). Reverse transcription was performed 
using the Superscript III First Strand Synthesize kit (Invitrogen) following the 
manufacturer’s instructions. Primers used for amplifying the wild-type and jj4 
cDNAs are CXT49 (annealing to exon 1, forward) and CXT50 (annealing to exon 
3, reverse). The resulting PCR fragments were purified and sequenced using 
primer CXT67.  
3.2.5  Body size measurement  
Hermaphrodite animals at the gravid adult stage were collected and 
treated with hypochlorite. The resulting embryos were allowed to hatch in M9 
buffer at 16°C. Synchronized L1s were plated onto NGM plates and allowed to 
grow for 24h, 48h, 72h or 96h respectively before they were washed off the 
plates, treated with 0.3% sodium azide, and mounted onto 2% agarose pads. 
Images of the worms were taken on a Leica DMRA2 compound microscope with 
a Hamamatsu Orca-ER Camera using the Openlab software (Improvision). Body 
length of each animal was measured using Openlab software. Subsequent 
statistics analyses were performed using Microsoft Excel.  
3.2.6  Dauer formation assays 
Frequency of dauer formation was assessed under non-dauer-inducing 
conditions as described (Vowels and Thomas, 1992). Five to 10 adult 
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hermaphrodites were placed on a 6cm NGM plate at the test temperature. After a 
short period of egg-lay (less than 12 hours at 25°C), the parents were removed 
from the plates and their progeny were allowed to develop at a given temperature. 
When the non-dauer worms became young adults, the numbers of dauers and 
non-dauers on each plate were counted. 
3.2.7  Immunofluorescence staining 
Animal fixation, immunostaining, microscopy and image analysis were 
performed as described previously (Amin et al., 2007). Guinea pig anti-FOZI-1 
(1:200) and goat anti-GFP (Rockland Immunochemicals; 1:1000) were used. All 
secondary antibodies were from Jackson ImmunoResearch Laboratories and 
used at a dilution of 1:50 to 1:200.  
3.2.8  Fractionation experiment 
Transgenic worms used in the fractionation experiment were generated in 
the pha-1(e2123ts) mutant background and maintained at 25°C. Worms were 
harvested in M9 and re-suspended in lysis buffer [50mM Tris-HCI, pH=7.5; 10% 
glycerol; 10mM 2-mercaptoethanol, 1mM phenylmethylsulfonyl fluoride and 1 
Complete Mini Protease Inhibitor Cocktail Tablet (Roche)/50ml lysis buffer] so 
that the ratio of worm volume to buffer volume was 1:1. Worms were sonicated 
until around 90% of the worms were lysed as assessed by microscopy. Debris 
was cleared by centrifugation at 4000xg for 10min at 4°C. The supernatants were 
centrifuged at 115,000xg for 1h. The resulting supernatant was the soluble 
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fraction. The pellet, which contains microsomal membrane proteins, was further 
cleared from soluble proteins by two more rounds of centrifugation 
(115,000xg)/resuspension in lysis buffer. The resulting pellet was reconstituted in 
the same volume of lysis buffer as the soluble fraction. Micro BCA Protein Assay 
Reagent Kit (Pierce) was used to measure the protein concentration. 30mg/lane 
of samples were loaded onto a 7% SDS-PAGE. GFP fusion proteins were 
detected by Western blotting using goat anti-GFP antibodies (Rockland 
Immunochemicals; 1:1000). 
3.2.9  Generating the RAD-SMAD and BAD-SMAD reporters: 
Oligonucleotides containing the wild-type (RAD-SMAD) or mutant (BAD-
SMAD) Smad binding sites and StyI restriction sites at each end were treated 
with T4 polynucleotide kinase, annealed and ligated. Concatenated 
oligonucleotides were cloned into the Fire lab vector L3135 
(http://www.addgene.org). Upon conformation of plasmid sequence, their DNA 
was injected into N2 worms using mec-7p::mRFP as a co-injection marker. The 
RAD-SMAD transgene was then integrated into the genome via gamma-
irradiation. Seven integrated lines were obtained, out-crossed and mapped to 
specific chromosomes. All lines showed similar GFP expression patterns. Two of 
them, LW2433: jjIs2433[pCXT51(RAD-SMAD) + LiuFD61(mec-7p::mRFP)] X and 
LW2436: jjIs2436[pCXT51(RAD-SMAD) + LiuFD61(mec-7p:: mRFP)] (I or IV) 
were used for subsequent analysis. The BAD-SMAD transgenes were kept in 
high efficiency extra chromosomal lines. 
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3.3  RESULTS 
3.3.1  drag-1 mutants exhibit a subset of the phenotypes seen in 
mutants in the Sma/Mab pathway  
 
In a mutagenesis screen for suppressers of the sma-9(cc604) M lineage 
phenotype (Foehr et al., 2006), we isolated the Sma/Mab pathway mutants as 
well as a single locus, recessive mutation jj4. Unlike sma-9(cc604) animals, 
which lack both M-lineage derived CCs (Figure 3.1A,D), 98.5% (n=201) of jj4; 
sma-9(cc604) animals had both M-derived CCs (Figure 3.1B,C). jj4 also 
suppressed the M lineage phenotypes of two other sma-9 alleles, cc606 and wk5 
(data not shown), suggesting that this suppression is not allele specific. Like the 
Sma/Mab pathway mutants, jj4 mutants by themselves did not have any M 
lineage defect when separated from the cc604 mutation (Figure 3.1C). However, 
jj4 mutants were smaller than wild-type N2 worms throughout larval development, 
although they were not as small as the dbl-1(wk70) null mutants (Figure 3.1E-G). 
Unlike the Sma/Mab pathway mutants, jj4 mutant males could mate and did not 
exhibit any male tail patterning defects (Figure 3.1H,I). Thus, jj4 mutants exhibit 
some, but not all, phenotypes of the Sma/Mab pathway mutants.  
We mapped the jj4 mutation to the left arm of chromosome I, a region not 
previously known to contain any genes involved in body size regulation. Thus jj4 
represents a novel locus required to regulate body size. We named the locus 
drag-1 (see below).  
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Figure 3.1: drag-1 mutants exhibit body size and mesodermal defects.  
 
All images are ventral/lateral views with anterior to the left. CC::gfp labels 
all the coelomocytes (CCs) , including embryonically-derived CCs (*) and M-
derived CCs (red arrowheads). (A-D) Mesoderm phenotype. sma-9(cc604) 
mutants (A, D) show a dorsal to ventral fate transformation in the postembryonic 
mesoderm lineage, the M lineage, thus lacking M-derived CCs, compared to 
wild-type (C) or drag-1(jj4); sma-9(cc604) double mutants (B, C). (E-F) A wild-
type adult (E) and drag-1(jj4) adult (F) at the same stage. (G) Growth curves of 
wild-type (N2), drag-1(jj4), drag-1(tm3773) and dbl-1(wk70) worms. Fifty to 85 
animals were examined for each strain at each time point. By student t test, the 
body lengths of drag-1(jj4) and drag-1(tm3773) animals are significantly different 
(p<0.0001) from the body lengths of wild-type and dbl-1(wk70) animals at 24, 48, 
72 and 96h. (H, I) Tails of a wild-type male (H) and a drag-1(jj4) male (I). SM, sex 
myoblast. a, anterior; d, dorsal; l, left; p, posterior; r, right; v, ventral.  
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3.3.2  drag-1 functions in the Sma/Mab pathway, possibly at the ligand-
receptor level, to regulate body size  
Because drag-1(jj4) mutants and the Sma/Mab pathway mutants share 
similar phenotypes in body size and mesoderm patterning, we tested whether 
drag-1 functions in the Sma/Mab pathway. We generated double mutants 
between jj4 (a putative null, see below) and mutations in various Sma/Mab 
pathway components (Figure 3.2A) and measured their body sizes.  
As shown in Figure 3.2B, double mutants between jj4 and the sma-3(jj3) 
null mutation were as small as sma-3(jj3) single mutants. Similarly, jj4; sma-6(jj1) 
and jj4; dbl-1(wk70) double mutants were as small as sma-6(jj1) and dbl-1(wk70) 
single mutants (both are null mutants), respectively. These observations suggest 
that jj4 is likely compromised for Sma/Mab pathway function, rather than affecting 
a pathway that functions in parallel to the Sma/Mab pathway, in regulating body 
size.  
To further characterize the role of drag-1 in the Sma/Mab pathway, we 
generated the following double mutants: jj4; lon-1(e185), jj4; lon-2(e678) and jj4; 
dbl-1(ctIs40).  e185 is a strong loss-of-function mutation in lon-1, a known 
downstream target of the Sma/Mab pathway (Maduzia et al., 2002; Morita et al., 
2002). e678 is a null mutation in lon-2, which encodes a member of the glypican 
family of heparan sulfate proteoglycans and acts as a negative regulator of the 
Sma/Mab pathway (Gumienny et al., 2007). dbl-1(ctIs40) is a strain that over-
expresses dbl-1 (Suzuki et al., 1999). As shown in Figure 3.2B, jj4; lon-1(e185) 
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mutants were as long as lon-1(e185) mutants. However, jj4; lon-2(e678) and jj4; 
dbl-1(ctIs40) double mutants showed intermediate body size between jj4 single 
mutants and lon-2(e678) or dbl-1(ctIs40) single mutants. These results suggest 
that drag-1 is likely to act upstream of lon-1, but in parallel to lon-2 and dbl-1. 
Taken together, our genetic epistasis results are consistent with drag-1 
functioning at the ligand/receptor level in the Sma/Mab pathway to regulate body 
size.  
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Figure 3.2: drag-1 likely functions at the ligand-receptor level in the 
Sma/Mab pathway to regulate body size. 
 
(A) A simplified schematic of the Sma/Mab pathway (see text for details). 
(B) Body length of wild-type (N2) and various mutant worms at 96hr post plating 
(see Materials and Methods). Similar results were observed using worms at 24hr, 
48hr and 72hr post plating (data not shown). drag-1(jj4); lon-2(e678) and drag-
1(jj4); dbl-1(ctIs40) worms show significantly different body length compared to 
lon-2(e678) and dbl-1(ctIs40) worms, respectively. Error bars represent 95% 
confidence intervals for the mean body length. The significance of difference 
between double mutant and the corresponding single mutant was statistically 
analyzed via student t test.  ***, p<0.0001. 
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3.3.3  drag-1 interacts genetically with the dauer pathway 
In addition to the Sma/Mab pathway, C. elegans has another TGFβ 
pathway that regulates dauer development (Savage-Dunn, 2005). drag-1(jj4) 
animals did not exhibit any constitutive or deficient dauer phenotypes on their 
own (Table 3.1). Animals carrying a deletion allele of drag-1, tm3773 (see below), 
did not exhibit any dauer phenotypes either (Table 3.1).  However, drag-1(jj4) 
enhanced the dauer-constitutive (Daf-c) phenotype of certain daf-7 and daf-1 
alleles at the permissive temperature. daf-7 and daf-1 encode the ligand and the 
type I receptor of the dauer pathway, respectively (Georgi et al., 1990; Ren et al., 
1996). As shown in Table 3.1, while drag-1(jj4) did not affect the Daf-c phenotype 
of daf-7(m62) animals at all temperatures tested, drag-1(jj4) moderately 
enhanced the Daf-c phenotype of daf-7(e1372) mutants at 16˚C. Similarly, drag-
1(jj4) moderately enhanced the Daf-c phenotype of daf-1(m213) mutants at 16˚C, 
but significantly enhanced the Daf-c phenotype of daf-1(m40) mutants at both 
16˚C and 20˚C. The allele specific and moderate enhancement of Daf-c 
phenptypes of daf-7 and daf-1 mutants by drag-1(jj4) are consistent with low 
levels of crosstalk between the Sma/Mab and the dauer pathways, as suggested 
by previous observations on the genetic interactions between sma-6 and daf-7 
and daf-1 mutations (Krishna et al., 1999).   
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Table 3.1: Enhancement of Daf-c phenotypes of daf-1 and daf-7 mutants by 
the drag-1 mutation 
  
15˚C 
 
20˚C 
 
25˚C 
n % Daf-c (pop) n % Daf-c (pop) n % Daf-c (pop) 
drag-1(jj4)  3 0 (476)  3 0 (395)  3 0 (275) 
drag-1(tm3773)  3 0 (167)  3  0 (381)  3 0 (209) 
daf-7(m62)   5 79.5±2.9 (317)   6 80.0±12.2 
(384) 
 5 100 (373) 
drag-1(jj4); daf-7(m62)  5 80.0±3.5 (177)   6 77.1±3.7 (357)  5 100 (502) 
daf-7(e1372)  5 63.3±2.7 (296)   5 73.3±10.7 
(516)  
 5 100 (613) 
drag-1(jj4); daf-7(e1372)  5 68.7±3.5 
(422)*  
 5 81.5±6.3 (636)   5 100 (627) 
daf-1(m40)  4 3.1±1.3 (378)  6 20.5±7.3 (991)   5 100 (570) 
drag-1(jj4); daf-1(m40)  5 27.9±9.6 
(187)* 
 5 95.1±3.4 
(570)*  
 5 100 (470) 
daf-1(m213)  5 0 (302)  5 80.9±6.4 (606)  5 100 (780) 
drag-1(jj4); daf-1(n213)  5 2.1±1.9 (459)*  5 81.5±8.9 (255)  5 100 (1096) 
n: the number of plates scored at each temperature; 
% Daf-c: the mean and standard deviation of the dauer formation percentage for 
n plates; 
pop: total number of worms on n plates scored; 
*: p<0.05, as calculated by t test, between double mutant and the corresponding 
daf single mutant at the specified temperature.  
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3.3.4  drag-1 encodes the C. elegans homolog of the RGM family 
proteins 
drag-1(jj4) was mapped to the left arm of chromosome I between 
Y92H12A.3 and Y71G12B.24 via snip-SNP mapping (Wicks et al., 2001). RNAi 
injection for 15 likely candidates among the 24 predicted genes located in this 
region showed that Y71G12B.16(RNAi) led to a small body size phenotype and 
the suppression of the sma-9(cc604) M lineage phenotype. For simplicity, we will 
refer to the suppression of the sma-9(cc604) M lineage phenotype by jj4 as the 
SOSMLP phenotype of jj4 in the remainder of the manuscript. Several additional 
lines of evidence indicated that jj4 is a loss-of-function allele of Y71G12B.16. 
First, DNA fragments containing the genomic DNA sequence of Y71G12B.16 
rescued both the small body size and the SOSMLP phenotype of jj4 mutants 
(Figures 3.3C,D and 3.5O). Second, sequencing of Y71G12B.16 in jj4 mutants 
revealed a T to A single nucleotide mutation in the splicing donor site in the first 
intron (Figure 3.3C). RT-PCR analysis (see Materials and Methods) showed that 
this mutation led to the production of three aberrant drag-1 transcripts, all 
producing mutant peptides containing the first 16 amino acids of DRAG-1 
followed by 9-49 additional random amino acids (data not shown). Third, a 
deletion allele of drag-1, tm3773, led to the same body size and SOSMLP 
phenotypes as jj4 mutants (Figures 3.1G, 3.3D and 3.5O).  
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Figure 3.3: drag-1 encodes a putative GPI-anchor protein of the RGM family.  
 
(A) A schematic of the DRAG-1 protein, showing the various conserved 
motifs drawn in scale. (B) Alignment between DRAG-1 (the bottom line) and its 
human RGM homologs RGMa (GenBank: AAI51133.1), RGMb (GenBank: 
NP_001012779.2) and RGMc (GenBank: NP_998818.1) in regions between the 
N-terminal signal peptide and the C-terminal pro-peptide. Notice the highly 
conserved vWF type D domain (solid underline) and hydrophobic region (dashed 
underline). The RGD motif (boxed in red) is present in RGMa and RGMc, but not 
in RGMb and DRAG-1. (C) Diagrams of the drag-1 genomic, cDNA and GFP 
tagged constructs. The locations of the jj4 and tm3773 molecular lesions are 
shown. (D) Body size measurement of worms of various genotypes at 72hr post-
plating. Length is presented as the mean +/- standard deviation. * indicates the 
length of the drag-1 worms carrying a particular transgene is significantly 
different from that of the corresponding drag-1 single mutant. p<0.0001. 
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We isolated two cDNA variants for Y71G12B.16, Y71G12B.16a and 
Y71G12B.16b, which share the same coding sequences and differ only in the 
lengths of their 5’ UTRs (see Materials and Methods). The predicted 
Y71G12B.16 protein is 408aa long. It contains a predicted N-terminal signal 
peptide, a partial von Willebrand factor D (vWF type D) domain, a hydrophobic 
region and a C-terminal region that meets the criteria of a pro-peptide that is 
cleaved off and replaced by a glycosylphosphatidylinositol (GPI) anchor during 
post-translational processing (Chatterjee and Mayor, 2001; Bohme and Cross, 
2002). Blast search showed that Y71G12B.16 has homologs in sea urchins, 
tunicates, mollusks and vertebrates, but not in Drosophila. The vertebrate 
Y71G12B.16 homologs belong to the RGM (Repulsive Guidance Molecule) 
family that includes RGMa, RGMb (aka DRAGON), RGMc (aka hemojuvelin) and 
the recently identified RGMd (Camus and Lambert, 2007; Corradini et al., 2009). 
Y71G12B.16 appears to be a distant member of the RGM family (Camus and 
Lambert, 2007), sharing 22%, 21% and 18% identity to Human RGMb, RGMa 
and RGMc respectively, in the region flanked by the N-terminal signal peptide 
and the C-terminal pro-peptide (Figure 3.3B). In particular, Y71G12B.16 and 
human RGMb/DRAGON share 46% identity in the vWF type D domain and 40% 
identity in the hydrophobic region. Like RGMb/DRAGON, Y71G12B.16 lacks the 
RGD (Arg-Gly-Asp) motif found in RGMa and RGMb proteins (Figure 3.3B). We 
therefore named Y71G12B.16 DRAG-1. Like C. elegans, other invertebrates 
including sea urchins, tunicates and mollusks also contain a single RGM-related 
protein in each genome (Camus and Lambert, 2007). 
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RGM proteins can function as BMP co-receptors (Babitt et al., 2005, 2006; 
Samad et al., 2005). Our genetic evidence described above suggests that 
DRAG-1 may also function as a co-receptor in the Sma/Mab pathway in C. 
elegans.  
3.3.5  drag-1 is expressed in the same cell types as the Sma/Mab 
pathway type I receptor sma-6 
To test the hypothesis that DRAG-1 may function as a co-receptor for the 
Sma/Mab pathway, we first asked whether drag-1 is expressed in the same cells 
that express core components of the Sma/Mab pathway. A drag-1 genomic 
construct (pDS27), which contains the entire drag-1 genomic region including 
4kb 5’ sequences and 1kb 3’ sequences, fully rescued the body size defects of 
both drag-1(jj4) and drag-1(tm3773) mutants (Figure 3.3C,D). Similarly, a drag-1 
cDNA construct (pCXT15) (see Materials and Methods), with the genomic coding 
region of drag-1 replaced by drag-1 cDNA and the drag-1 3’ UTR replaced by 
unc-54 3’ UTR, also rescued the body size defects of drag-1(jj4) mutants (Figure 
3.3C,D). These results suggest that the regulatory elements required for drag-1 
function in regulating body size likely reside in the upstream sequences used in 
pCXT15. We then generated a transcriptional drag-1p::gfp fusion pDS15 using 
these upstream sequences (see Materials and Methods). Transgenic lines 
carrying pDS15 showed GFP expression in pharyngeal, hypodermal and 
intestinal cells (Figure 3.4A-C), the same cells that express sma-6 in 
hermaphrodites (Krishna et al., 1999; Yoshida et al., 2001). In fact, transgenic 
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lines carrying both drag-1p::gfp and sma-6p::mRFP showed co-localization of the 
two reporters in all three tissues described above (Figure 3.4A-C, E-G, I-K). 
Therefore, drag-1 is expressed in the same cell types as sma-6 in 
hermaphrodites. However, drag-1p::gfp is not expressed in the male tail cells that 
express sma-6p::mRFP (Figure 3.4D, H and L), consistent with the lack of male 
tail defects in drag-1(jj4) mutant males.  
The same expression pattern of drag-1 was also observed using a 
functional translational DRAG-1::GFP fusion (pJKL849), which has GFP inserted 
right before the putative cleavage site upstream of the C terminal pro-peptide 
sequence (Figure 3.3B). This reporter is fully functional as it rescued both the 
body size and the SOSMLP of jj4 mutants (Figures 3.3D, 3.5D,O). Just like the 
drag-1p::gfp transcriptional fusion, DRAG-1::GFP was present in pharyngeal, 
hypodermal and intestinal cells (Figure 3.4M-O). Robust expression in the M 
lineage was also detected from 1-M to 4-M stage (Figure 3.4Q-S).  DRAG-
1::GFP signal was reduced (40%, n=20) or undetectable (60%, n=20) at the 8-M 
stage (Figure 3.4T), and completely undetectable beyond the 8-M stage (Figure 
3.4U and data not shown). The M lineage expression pattern of drag-1 is 
consistent with previous findings that sma-9 functions prior to the 8-M stage for 
proper M lineage development (Foehr et al., 2006). 
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3.3.6  drag-1 functions in the same cells as the Sma/Mab pathway 
receptors and Smads to regulate body size and mesoderm patterning 
The Sma/Mab pathway receptors and Smad proteins have been shown to 
function in the hypodermal cells to regulate body size (Yoshida et al., 2001; 
Wang et al., 2002). Because drag-1 is expressed in the same tissues as sma-6 in 
hermaphrodites, we tested whether drag-1 also functions in hypodermal cells to 
regulate body size. We forced the expression of drag-1 cDNA in pharyngeal 
muscles [using the myo-2 promoter (Okkema et al., 1993)], intestine [using the 
elt-2 promoter (Fukushige et al., 1998)], and in hypodermal cells [using both the 
elt-3 and rol-6 promoters (Kramer and Johnson, 1993; Gilleard et al., 1999)], and 
tested the ability of each transgene to rescue the small body size of jj4 mutants. 
As a control, drag-1 cDNA under the control of its own promoter could rescue the 
small body size phenotype of jj4 mutants (Figure 3.4P). As shown in Figure 3.4P, 
forced expression of drag-1 in hypodermal cells rescued the small body size 
phenotype of jj4 mutants, while expression in the pharynx and intestine did not. 
Thus, drag-1 functions in the same cells as the Sma/Mab receptors and Smad 
proteins to regulate body size.  
 Previous studies have shown that sma-9 and the Sma/Mab pathway 
function within the M lineage to regulate dorsoventral patterning of the M lineage 
(Foehr et al., 2006). We therefore forced the expression of drag-1 within the M 
lineage in drag-1(jj4); sma-9(cc604) double mutants using the hlh-8 promoter 
(Harfe et al., 1998). This M lineage-specific expression of drag-1 (using pCXT148) 
is sufficient to rescue the SOSMLP phenotype of jj4 mutants (24.5%, n=106), i.e., 
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to reverse the M lineage phenotype of drag-1(jj4); sma-9(cc604) mutants to that 
of sma-9(cc604). Thus, drag-1 also functions in the same cells as sma-9 and the 
Sma/Mab pathway to regulate M lineage development.  
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Figure 3.4: drag-1 is expressed and functions in the same cell types as the 
Sma/Mab pathway components.  
 
Images shown are side views with anterior to the left and posterior to the 
right. drag-1p::gfp (A-D) and sma-6p::rfp (E-H) co-localize in pharyngeal (A, E, I), 
hypodermal (B, F, J) and intestinal (C, G, K) cells, but do not co-localize in the 
male tail (D, H, L). (I-L) are merged images of (A-D) and (E-H) respectively. (M-N) 
DRAG-1::GFP or (O) LIN-12TM::GFP (see Figure 3.5 for details) localization in 
pharyngeal (M), hypodermal (N) and intestinal (O) cells, as visualized by anti-
GFP antibody staining. Note that the GFP signal (green) is located outside of the 
nucleus (blue, stained with DAPI), both at the cell surface and inside the cell. 
Arrow heads, hypodermal cells; arrow, pharynx. (P) Tissue-specific rescue of the 
body size phenotype of drag-1(jj4) mutants. Body size was measured in adult 
worms at 72hr post-plating. Transgenic worms were distinguished from non-
transgenic ones by the presence of mec-7p::rfp. The lengths of drag-1(jj4) and 
non-transgenic worms of each group were normalized to 1. The relative lengths 
of wild-type and various transgenic animals compared to their corresponding 
non-transgenic controls are presented. Between 30 and 80 animals were 
measured for each genotype. Error bars represent 95% confidence intervals for 
the mean of relative body length. The significance of difference between 
transgenic and the corresponding non-transgenic animals was statistically 
analyzed via student t test.  ***, p<0.0001. (Q-U) The M lineage expression 
pattern of drag-1 using LIN-12TM::GFP (green, see Figure 3.5 for details). Anti-
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FOZI-1 antibody staining (red) was used to mark M lineage cells from the 4-M to 
the 12-M stage (S-U). Only one focal plane was shown for the 8-M (T) and 12-M 
(U) stage worms. DRAG-1::GFP is present from the 1-M to the 4-M stage (O-S), 
becomes fainter at the 8-M stage (T) and undetectable after the 8-M stage (U).  
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3.3.7  DRAG-1 localizes to and functions at the cell membrane 
The translational DRAG-1::GFP reporter described above allowed us to 
examine the sub-cellular localization pattern of DRAG-1. As shown in Figures 
3.4M-O, 3.5B-C, DRAG-1::GFP was present outside of the nucleus but localized 
to the cell surface as well as inside the cell. To determine if DRAG-1 protein is 
membrane-associated, we performed cell fractionation experiments to separate 
the soluble fraction and the membrane fraction using lysates from mix-staged 
worm populations (see Materials and Methods). As controls, we used worms 
expressing GFP alone under the control of the hmt-1 promoter, and worms 
expressing the HMT-1::GFP fusion under the control of the hmt-1 promoter 
(Schwartz  et al., 2010; see Materials and Methods). HMT-1 is a transmembrane 
half-molecule ATP-binding cassette transporter required for heavy metal 
detoxification (Vatamaniuk et al., 2005). As shown in Figure 3.5N, GFP was only 
detected in the soluble fraction, while HMT-1::GFP was only detected in the 
membrane fraction. In the same experiment, DRAG-1::GFP was only detected in 
the membrane fraction. This result, in combination with results from 
immunostaining, demonstrates that DRAG-1 is a membrane protein, as predicted 
for a putative GPI-anchor protein. 
 To determine whether DRAG-1 functions at the cell membrane, we 
generated transgenic lines expressing DelC::GFP, which has the C-terminal pro-
peptide deleted from DRAG-1 (Figure 3.5A). DelC::GFP showed reduced signal 
at the cell surface (Figure 3.5E,F), and became partially soluble in cell 
fractionation experiments (Figure 3.5N). We then checked the functionality of 
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DelC::GFP and found that it could rescue both the body size and the SOSMLP 
phenotypes of drag-1(jj4) mutants, but the rescuing efficiency was reduced when 
compared to wild-type DRAG-1::GFP (Figures 3.5D,G,O). These data together 
suggest that the putative C-terminal pro-peptide is important, but not essential, 
for DRAG-1 membrane localization and function.  
The membrane localization and function of DRAG-1::GFP and DelC::GFP 
appeared to require that the proteins enter the secretory pathway via their N-
terminal signal peptide. DelN::GFP and DelNC::GFP with their N-terminal signal 
peptide deleted (Figure 3.5A) failed to rescue the drag-1(jj4) mutant phenotypes 
(Figure 3.5J, O), and showed drastically reduced level of expression (Figure 
3.5H,I,N), possibly due to the mis-targeting and subsequent degradation, of the 
mutant protein.  
 To directly test whether DRAG-1 functions at the cell membrane, we 
replaced the putative C-terminal pro-peptide sequence of DRAG-1 with the 
transmembrane domain of a well-characterized transmembrane protein LIN-12, 
LIN-12TM::GFP (Figure 3.5A). LIN-12TM::GFP was solely detected in the 
membrane fraction (Figure 3.5N), showed cell surface localization (Figure 
3.5K,L), and fully rescued the body size and SOSMLP phenotypes of drag-1(jj4) 
mutant (Figure 3.5M,O). Thus DRAG-1 is not only present, but also functions, at 
the cell membrane. 
 
 
  
134 
 
Figure 3.5: drag-1 is localized to and functions at the cell membrane.  
 
(A) Schematics of various DRAG-1 deletion constructs (see Material and 
Methods). (B-M) GFP localization (B, E, H, K, arrowheads point to the surface of 
the pharynx), the corresponding DIC images (C, F, I, L), and body size 
measurement (D, G, J, M) of animals containing the specific transgenes. (B, C, D) 
DRAG-1::GFP, (E, F, G) DelC::GFP (abbreviated as DelC), (H, I, J) DelNC::GFP 
(abbreviated as DelNC), and (K, L, M) LIN-12TM::GFP (abbreviated as LIN-
12TM). In panels D, G, J and M, Blue bars: drag-1(jj4) animals carrying the 
transgene; grey bars: drag-1(jj4) non-transgenic animals. the Y axis shows the 
relative body length, with the lengths of non-transgenic worms of each group 
being normalized to 1. Between 30 and 70 animals were measured for each 
genotype. Error bars represent 95% confidence intervals for the mean of relative 
body length. The significance of difference between transgenic and the 
corresponding non-transgenic animals was statistically analyzed via student t test.  
***, p<0.0001. **, p<0.001. (N) Western blots probed with anti-GFP antibodies 
showing the localization of DRAG-1::GFP fusions via fractionation experiments. * 
refers to non-specific bands recognized faintly by the anti-GFP antibodies. (O) 
Rescue of the mesodermal phenotype of jj4 mutants by various drag-1::gfp 
constructs.  
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3.3.8  DRAG-1 positively modulates Sma/Mab signaling as indicated by 
a Sma/Mab-responsive reporter  
The phenotypes of drag-1 mutants described above suggest that DRAG-1 
positively modulates Sma/Mab signaling. To test this hypothesis, we generated a 
Sma/Mab-responsive reporter as there are no existing phospho-Smad antibodies 
or appropriate Smad::GFP reporters or anti-Smad antibodies that allow us to 
directly monitor the output of Sma/Mab signaling. 
Previous work has shown that individual Smad complexes are capable of 
binding to three abutting Smad boxes (or Smad binding site: GTCT) with high 
affinity (Johnson et al., 1999). Furthermore, abutting Smad boxes organized in 
the RLR orientation (R, rightward and L, leftward) are bound by Smad complexes 
with higher affinity than those organized in the RLL or RRR orientation (Johnson 
et al., 1999). We decided to place multiple copies of the Smad boxes organized 
in the RLR orientation upstream of the minimal pes-10 promoter and gfp (Figure 
3.6A), and tested whether the expression of the gfp reporter is responsive to 
Sma/Mab signaling. We named the reporter as RAD-SMAD (Reporter acting 
downstream of Smad). The expression pattern of the gfp reporter was examined 
using two different integrated transgenic lines carrying RAD-SMAD (see 
Materials and Methods), which showed similar expression patterns. We detected 
GFP signal from late embryogenesis until adulthood. GFP signal was detected in 
intestinal and hypodermal cells, including those from the P lineages (Figure 3.6B) 
and cells in the male tail (data not shown). The expression level of the reporter 
appeared rather dynamic during development, with stronger intestinal expression 
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in embryos and L1s but fainter in adults, and stronger hypodermal expression in 
L2 and L3 stages (data not shown). No gfp expression was detected in dauer 
animals either in the wild-type background or the daf-7(e1372) background (data 
not shown).  
To test the specificity of the RAD-SMAD reporter, we generated two 
reporters carrying different mutations in the Smad boxes, BAD-SMAD1 and BAD-
SMAD2 (Bad reporter of Smad) (Figure 3.6A). Transgenic worms carrying either 
reporter showed no gfp expression in any cells (Figure 3.6C, I, and data not 
shown). This result indicates that the Smad boxes are directly responsible for 
RAD-SMAD reporter expression.  
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Figure 3.6: A RAD-SMAD reporter directly and positively responds to 
Sma/Mab signaling in vivo.  
 
(A) Schematics of the RAD-SMAD, BAD-SMAD1 and BAD-SMAD2 
reporters, with the oligonucleotide sequences shown on top. Mutated sequences 
in the BAD-SMAD1 and BAD-SMAD2 reporters are shown in red lower case. (B, 
D-H) Expression of the RAD-SMAD GFP reporter in wild-type (B, D), lon-2(e678) 
(E), drag-1(jj4) (F), sma-3(jj3) (G) and dbl-1(wk70) (H) worms at the L2 stage. 
Arrowheads in B point to hypodermal cells derived from the P lineages. (C, I) The 
BAD-SMAD1 GFP reporter shows no expression. Hypodermal cells are shown in 
(D-I). Pictures were taken at the same exposure. (J) Quantification of hypodermal 
RAD-SMAD GFP signals in various mutants. In each mutant background, the 
pixel intensities of GFP signals from 10 hypodermal nuclei in 10 different worms 
(20 worms for WT) at the L2 stage were measured by the OpenLab software. 
The signal intensity in wild-type worms was set to 1 and compared to the signal 
intensity in each mutant background. Error bars represent 95% confidence 
intervals for the means of relative intensity. The significance of difference 
between wild-type and each mutant was statistically analyzed via student t test. 
*** p<0.0001; * p<0.01. 
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To test if the expression level or pattern of the RAD-SMAD reporter are 
regulated by Sma/Mab signaling, we crossed the two integrated RAD-SMAD 
reporters (jjIs2433 and jjIs2436) into different Sma/Mab pathway mutants and 
saw similar results with both reporters. As shown in Figure 3.6D-E and 3.6G-H, 
RAD-SMAD expression in all cell types was down-regulated in dbl-1 and sma-3 
null mutants, but up-regulated in lon-2 null mutants. In fact, quantification of the 
GFP signal intensity in various mutants correlated well with the body sizes of 
each mutant (Figure 3.6J, compared to the body size of each mutant in Figure 
3.2). These results demonstrate that RAD-SMAD positively responds to 
Sma/Mab signaling.  
As shown in Figure 3.6F and 3.6J, RAD-SMAD expression was 
significantly down-regulated in drag-1(jj4) mutants. Furthermore, the degree of 
reporter down-regulation in jj4 mutants was smaller than that in sma-3(jj3) and 
dbl-1(wk70) mutants, again correlating very well with the body sizes of these 
mutants. These observations indicate that DRAG-1 is a positive regulator of the 
Sma/Mab pathway. 
3.4  DISSCUSION 
3.4.1  DRAG-1 is a cell type-specific modulator of BMP signaling in C. 
elegans 
Previous studies have shown that RGM proteins can enhance BMP, but 
not TGFβ, signaling in tissue cultures by binding to selected BMP molecules as 
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well as type I and type II BMP receptors (Babitt et al., 2005, 2006; Samad et al., 
2005). However, except for RGMc/Haemojuvelin, there is no evidence showing 
that RGMa and RGMb/DRAGON are essential for regulating BMP signaling in 
vivo (Babitt et al., 2005, 2006; 2007; Samad et al., 2005; Xia et al., 2008; 2010; 
Andriopoulos et al., 2009). Our data demonstrate that the sole RGM homolog 
DRAG-1 is an integral member of the BMP-like Sma/Mab pathway in C. elegans: 
1) drag-1 mutants share similar body size and SOSMLP phenotypes as mutants 
in all the core members of the Sma/Mab pathway, 2) DRAG-1 is a membrane-
localized protein that functions at the ligand-receptor level in the Sma/Mab 
pathway to regulate body size, 3) drag-1 is expressed and functions in the same 
cells as the receptors and Smad proteins of the Sma/Mab pathway to regulate 
body size (in hypodermal cells) and mesoderm patterning (in the M lineage). 
Both the mutant phenotypes and the reduced level of Sma/Mab pathway reporter 
(RAD-SMAD) expression in drag-1 loss-of-function mutants suggest that DRAG-
1 positively regulates Sma/Mab signaling in C. elegans. DRAG-1 appears to 
function specifically in the BMP-like Sma/Mab pathway, but not the TGFβ-like 
dauer pathway, as drag-1 mutants do not have any defects in dauer formation. 
The genetic interaction between drag-1(jj4) and certain daf-7 and daf-1 alleles 
(Table 3.1) could be due to the fact that both the Sma/Mab pathway and the 
dauer pathway share the same type II receptor DAF-4 and thus exhibit low levels 
of crosstalk. Consistent with this notion, previous studies have also shown 
genetic interactions between sma-6 and daf-7 and daf-1 mutations (Krishna et al., 
1999) .  
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Interestingly, DRAG-1’s function in modulating Sma/Mab signaling is cell-
type specific. Like other core members of the Sma/Mab pathway, drag-1 
functions in both body size regulation and mesoderm patterning. However, drag-
1 is not expressed in the male tail and drag-1 mutants do not have any male tail 
patterning defects. It has been previously suggested that body size and male tail 
development require different Sma/Mab signaling thresholds, with the male tail 
requiring a lower level of signaling activity, because a hypomorphic sma-6(e1482) 
allele has small body size but wild-type male tail morphology (Krishna et al., 
1999). Our studies on drag-1 are consistent with this hypothesis, and further 
demonstrate that drag-1 functions to augment the level of Sma/Mab signaling 
activity in the hypodermal cells to ensure proper body size regulation.  
3.4.2  RAD-SMAD, a Sma/Mab-responsive reporter in C. elegans 
The activity of TGFβ signaling can be monitored by the phosphorylation or 
nuclear entry of Smads, or the expression of direct TGFβ downstream genes 
(Schmierer and Hill, 2007; Wrighton et al., 2009). However, there are no existing 
phospho-Smad antibodies, appropriate Smad::GFP reporters or anti-Smad 
antibodies, or direct Sma/Mab target genes that allow us to directly monitor the 
activity of Sma/Mab signaling in C. elegans. In this study, we generated a 
Sma/Mab signaling reporter RAD-SMAD that appears to directly reflect Sma/Mab 
signaling activity in C. elegans: 1) the reporter is active in cells that have been 
reported to be responsive to Sma/Mab signaling, 2) mutations in the Smad 
binding sites abolished reporter expression, and 3) the level of RAD-SMAD 
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reporter expression correlated with the level of Sma/Mab signaling in various 
Sma/Mab pathway mutants. The RAD-SMAD reporter appears to specifically 
reflect Sma/Mab signaling, as no reporter expression was observed in dauer 
animals either in the wild-type background or the daf-7(e1372) background. We 
also noticed that the RAD-SMAD reporter is not expressed in the M lineage, 
where DRAG-1 and other Sma/Mab pathway components are expressed and 
function (data not shown). At present, we cannot rule out the possibility that the 
expression level of RAD-SMAD in the M lineage is too low to detect. An 
alternative explanation is that expression of Sma/Mab pathway targets in the M 
lineage requires additional transcriptional input. A likely candidate for the 
additional transcription factor is the Schnurri (SHN) protein SMA-9 (Liang et al., 
2003; Foehr et al., 2006), as previous studies in Drosophila have identified 
composite Smad-SHN binding sites that contain additional nucleotide sequences 
in between the two Smad binding sites (Pyrowolakis et al., 2004; Gao et al., 
2005). Despite this caveat, the RAD-SMAD reporter will be a useful tool for C. 
elegans researchers wishing to monitor the direct transcriptional output of the 
Sma/Mab signaling pathway.  
In summary, our work demonstrates that DRAG-1 acts in a cell-type 
specific manner to modulate the BMP-like signaling pathway in C. elegans, and 
establishes a direct link between RGMb/DRAGON proteins and BMP signaling in 
vivo. Because RGM proteins are not present in Drosophila, our work further 
provides a simple genetic system for mechanistic studies on RGM protein 
regulation of BMP pathways in vivo. 
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Chapter 4:  C. elegans DRAG-1 as a model to study RGM protein function 
4.1  Introduction 
DRAG-1 belongs to the RGM protein family (Tian et al., 2010). RGMs 
have an N-terminal signal peptide, a partial von Willebrand type D domain (vWF-
type D), which includes a highly conserved autocleavage site, and a C-terminal 
GPI (Glycosylphosphatidylinositol)-anchor (Monnier et al., 2002;Camus and 
Lambert, 2007;Corradini et al., 2009;Severyn et al., 2009). Vertebrate RGMa and 
RGMc proteins have a RGD motif (Figure 4.1). RGM proteins also contain a 
number of highly conserved cysteine residues (Figure 4.1). 
RGM proteins have been shown to function as BMP coreceptors in cell 
culture and in vivo. RGMs are high affinity binding partners of BMP ligands with 
KD of several nM (Babitt et al., 2005;Halbrooks et al., 2007;Xia et al., 2007). In 
cultured cells, RGM proteins selectively bind to a subset of BMP type I and type 
II receptors (Babitt et al., 2005). Addition of RGMs increased BMP ligand 
receptor binding (Xia et al., 2007). In vivo data suggests that RGMc/HJV 
functions in modulating BMP6 signaling to regulate the expression of hepcidin 
(Andriopoulos et al., 2009;Meynard et al., 2009), a key small peptide secreted 
predominantly from hepatocytes essential for iron homeostasis (Park et al., 
2001;Pigeon et al., 2001). RGMb functions in neurite outgrowth and peripheral 
nerve regeneration by modulating BMP signaling in mice and in cell culture (Ma 
et al., 2011). The in vivo relevance for RGMa functioning in the BMP signaling 
pathway is not clear. 
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RGMc/HJV was identified by positional cloning of the locus that is 
associated with juvenile hemochromatosis (JH) (Papanikolaou et al., 2004). JH is 
a rare autosomal recessive disease characterized by the early-onset of severe 
iron overload that affects young patients typically in their first to third decade of 
life (Camaschella et al., 2002;De Domenico et al., 2008;De Gobbi et al., 2002). 
JH is also caused by the lack of functional hepcidin (Roetto et al., 2003). Several 
dozens JH-associated mutations in RGMc/HJV have been identified (Nagayoshi 
et al., 2008;Robson et al., 2004). An understanding of the mechanism of the 
disease came from studying some of the missense mutations in cell culture. 
These studies examined the G99V mutation in that mutated a residue in the RGD 
motif, the D172E mutation of a key residue for RGM autocleavage, and G320V, 
which is the predominant disease-causing mutation. G99V mutated RGMc failed 
to bind to BMP-2, while D172E or G320V mutated RGMc failed to bind to 
neogenin, an RGM interacting protein that is essential for RGM’s function (Kuns-
Hashimoto et al., 2008; See Chapter 5). Besides protein-protein interaction, a link 
has been made between affecting the autocleavage event and protein secretion. 
Some mutations that lie in or near the cleavage site, D172E, F170C and W191C, 
as well as G320V abolished the autocleavage event, and these mutated proteins 
were retained in the endoplasmic reticulum and resulted in low BMP signaling 
activities (Pagani et al., 2008;Silvestri et al., 2007).  
C. elegans has a single RGM protein DRAG-1. DRAG-1 positively 
modulates BMP-like Sma/Mab signaling in regulating body size and M lineage 
patterning (Tian et al. 2010). DRAG-1 is a membrane-associated protein that 
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functions at the ligand-receptor level to modulate the Sma/Mab pathway in a cell-
type-specific manner. Study of DRAG-1 provides a direct link between RGM 
proteins and BMP signaling in vivo and a simple and genetically tractable system 
for mechanistic studies of RGM protein regulation of BMP pathways. In this 
Chapter, I first show that vertebrate RGMs can replace DRAG-1 in C. elegans 
Sma/Mab signaling, suggesting a high degree of functional conservation in RGM 
and BMP signaling in C. elegans. I then used DRAG-1 as a qualitative and 
quantitative in vivo model to test three JH mutations that were studied previously 
in cell cultures (Kuns-Hashimoto et al., 2008). Consistent with previous results, 
all three mutations affect DRAG-1 function in Sma/Mab signaling, but they do so 
to different degrees. Lastly, I demonstrated DRAG-1 physical interaction with 
Sma/Mab pathway ligand and receptors. This suggests that DRAG-1 may 
function by simultaneously interacting with both the ligand and receptors.  
4.2  Material and Methods 
4.2.1  C. elegans strains 
Strains were kept under normal conditions, described by Brenner (1974). 
Analyses were performed at 20°C, unless otherwise noted. The following 
mutations and integrated transgenes were used: Linkage group I (LGI): drag-1 
(jj4); LGX: sma-9(cc604).  
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4.2.2  Plasmid constructs and transgenic lines 
Constructs for testing vertebrate RGM function in C. elegans 
pCXT14: drag-1p (4kb of drag-1 upstream sequence (-3977 to -1), sequences 
from immediately downstream of the ATG till the end of the first intron of drag-1 
(4 to 1123))::full length mouse Rgmb coding sequence::unc-54 3’UTR. 
pCXT161: drag-1p (same as above)::drag-1 signal sequence:: mRgmb mature 
region::drag-1 C- signal sequence::unc-54 3’UTR, has aa23–aa375 of DRAG-1 
replaced by aa59–aa414 of mouse Rgmb in pCXT15 (Tian et al., 2010). 
pCXT185: drag-1p (same as above)::drag-1 signal sequence:: hHJV mature 
region::drag-1 C- signal sequence::unc-54 3’UTR, has aa23–aa375 of DRAG-1 
replaced by aa38–aa398 of human RGMc/HJV in pCXT15 (Tian et al., 2010). 
Constructs for interaction analysis of DRAG-1 
pCXT239: pCMV::signal peptide::FLAG-drag-1 mature region, with a FLAG tag in 
the N- and a stop codon C-terminal to aa22-aa360 of DRAG-1 in pSecTag. 
pCXT241: pCMV::signal sequence::dbl-1 prodomain::FLAG-dbl-1 mature region, 
has aa32–stop codon of DBL-1 in pSecTag construct, FLAG tag is inserted 
between aa238 and aa239. 
pJKL964: pCMV::signal sequence::c-Myc-His-sma-6 full length, has aa27–stop of 
SMA-6 in pSecTag construct with c-Myc-His tagged on the N terminus after the 
signal sequence. 
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pCXT230: pCMV::signal sequence::Myc-His-daf-4 EXD, TM and partial ICD, has 
aa33–aa468 of DAF-4 in pSecTag construct with c-Myc-His tagged on the N 
terminus after the signal sequence. 
pJKL962: pCMV::signal sequence::Myc-His-drag-1 mature domain, with a c-Myc-
His tag in the N- and a stop codon C-terminal to aa22-aa360 of DRAG-1 in 
pSecTag construct. 
Generating transgenic animals 
Transgenic animals (except for the ones generated by MosSCI) were 
generated using the plasmids pJKL449 (myo-2p::gfp::unc-54 3’ UTR, Jiang et al., 
2009) as markers. 
4.2.3  Body size measurement  
Hermaphrodite animals at the gravid adult stage were collected and 
treated with hypochlorite. The resulting embryos were allowed to hatch in M9 
buffer at 16°C. Synchronized L1s were plated onto NGM plates and allowed to 
grow for 72h before they were washed off the plates, treated with 0.3% sodium 
azide, and mounted onto 2% agarose pads. Images of the worms were taken on 
a Leica DMRA2 compound microscope with a Hamamatsu Orca-ER Camera 
using the Openlab software (Improvision). Body length of animals whose vulva 
development is at early Charismas tree stage was measured using Openlab 
software. Subsequent statistics analyses were performed using Microsoft Excel.  
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4.2.4  MosSCI technique 
Insertion lines were generated using direct gonadal injection method using 
ttTi5605 Mos site and pglh-2 driving Mos transposase following protocols in 
Frokjaer-Jensen et al. (2008).  
Constructs used in this study: 
pCXT208: pJKL849 (Tian et al., 2010) was modified to delete sequences 
encoding intron 3, because the repetitive sequences make it extremely hard for 
cloning. The new construct is pCXT183. 3.9kb drag-1p::drag-1 genomic 
sequence without 3rd intron::gfp::1.7kb drag-1 3’ UTR was moved from pCXT183 
with restriction enzymes HpaI and StuI to pCFJ151 digested by XhoI and blunted 
(Frokjaer-Jensen et al., 2008). 
pCXT221: G68V (ggt to gtt) mutation was made in pCXT183. The genomic 
sequence was then moved in the same way as shown above to pCFJ151.  
pCXT222: D117E (gat to gaa) mutation was made in pCXT183. The genomic 
sequence was then moved in the same way as shown above to pCFJ151.  
pCXT223: G272V (gga to gta) mutation was made in pCXT183. The genomic 
sequence was then moved in the same way as shown above to pCFJ151.  
PCR verifications for insertions: 
PCR pair to verify the N terminus of the insertion: 
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CXT310: gcgggatcatttcttactag. Sense, anneals to genomic sequence till 0bp 
upstream of Mos insertion site.  
CXT226: cctgaatttgtaaatactcttc. Reverse, anneals to drag-1 promoter sequence  
in pCXT208.  
PCR pair to verify the C terminus of the insertion. 
CXT312: caaggacttggataaattggc. Sense, anneals to C-terminal homology arm in 
pCFJ151. 
CXT311: gtgtatctgcattaaccaata. Reverse, anneals to genomic sequence till 0bp 
downstream of Mos insertion site. 
4.2.5  Co-immunoprecipitation  
Medium was collected from HEK293T cells that were transiently 
transfected by constructs carrying FLAG-tagged or Myc-tagged DRAG-1 mature 
region (pCXT239 or pJKL962 respectively) and FLAG-tagged DBL-1 mature 
domain (pCXT241) for five days. Cell lysates were harvested 48h post 
transfection from HEK293T cells that are transiently transfected by constructs 
carrying Myc-tagged SMA-6 (pJKL964) and Myc-tagged DAF-4 (pCXT230). Anti-
c-Myc conjugated sepharose or anti-FLAG M2 conjugated sepharose was used 
to incubate with media or cell lysates expressing one protein for 4 hour at 4°C, 
and then with media or cell lysates expressing a second protein for 4 hours. The 
beads were then subjected to 5 time wash with 50 mM Tris, pH 8.0, 150 mM 
NaCl, and 1% Triton X-100. The presence of DRAG-1 in the immunoprecipitates 
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was detected by western blotting using mouse anti-FLAG (M2) antibodies 
(4mg/ml, 1:10000) or anti-c-Myc (9E10) antibodies (2mg/ml, 1:5000). 
4.3  Results 
4.3.1  Vertebrate RGMs are functional in C. elegans 
DRAG-1 shares high degree of homology to the vertebrate RGM proteins 
in its mature protein domain but not the N- and C- terminal signal sequences 
(Figure 4.1). DRAG-1 functions in a similar fashion to its vertebrate homologs in 
modulating the BMP-like Sma/Mab signaling (Tian et al., 2010). I therefore asked 
if C. elegans DRAG-1 provides a good system for studying RGM protein function. 
I started by testing if vertebrate RGMs are functional in C. elegans. As in Chapter 
3, I will refer to the suppression of the sma-9(cc604) M lineage phenotype by jj4 
as the SOSMLP phenotype of jj4 in the remainder of Chapter 4 and 5. As a 
control, a construct carrying drag-1 promoter driving drag-1 cDNA is functional to 
rescue both the small body size and the SOSMLP phenotypes (Table 4.1). 
However, the rescue of SOSMLP by this cDNA construct is only 17.9%, which is 
incomplete rescue because the rescue efficiency of the drag-1 genomic construct 
is 100% (Table 4.1). The rescue of small body size is much better by this cDNA 
construct (Figure 4.2). This could be due to the lack of an M lineage enhancer in 
the promoter; this may also be due to the general lower expression level of drag-
1 in the cDNA construct compared to the genomic construct and to the possibility 
that different processes have different sensitivity to Sma/Mab signaling.  To 
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examine whether vertebrate RGM could function similarly to drag-1 in C. elegans, 
I replaced the drag-1 cDNA with the mouse Rgmb cDNA. However, this construct 
failed to rescue in both the body size rescue and the SOSMLP rescue assays 
(Table 4.1 and Figure 4.2). Because of the lack of homology in the N- and C- 
terminal signal sequences, I reasoned that Rgmb signal sequences were not 
recognized by C. elegans system and that the Rgmb protein might not be 
properly localized in C. elegans. Therefore, I generated a hybrid drag-1-Rgmb 
gene with drag-1 N- and C- terminal signal sequences and mouse Rgmb mature 
protein sequences under the control of drag-1 promoter. The hybrid drag-1-Rgmb 
transgene was able to rescue both the small body size and the SOSMLP of sma-
9 in a comparable degree as drag-1 cDNA itself (Table 4.1 and Figure 4.2). I also 
tested a hybrid drag-1-human RGMc/HJV cDNA construct and showed that it 
functions as well as drag-1 cDNA control in rescuing the SOSMLP (Table 4.1). I 
am currently testing RGMc/HJV construct using the body size assay. In summary, 
these results indicate that after proper processing, vertebrate RGMs are 
functional in C. elegans to a similar degree as drag-1 cDNA construct. Therefore, 
drag-1 could potentially be a good model to study human RGM function in vivo. 
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Table 4.1: Rescue of the SOSMLP by drag-1 with various constructs. 
 
Transgenes in sma-9(cc604); drag-1(jj4) The extent of suppression 
drag-1::gfp genomic 100% (N=43) 
drag-1 cDNA 17.9% (N=106) 
Rgmb cDNA 0.9% (N=107) 
drag-1-Rgmb hybrid cDNA 14.6% (N=82) 
drag-1-HJV hybrid cDNA 23.4% (N=143) 
Mos-SCI drag-1:gfp 98.8% (N=498) 
Mos-SCI G68V in drag-1::gfp 20.7% (N=554) 
Mos-SCI D117E in drag-1::gfp 99.2% (N=515) 
Mos-SCI G272V in drag-1::gfp 5.1% (N=414) 
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Figure 4.1: Comparison between DRAG-1 and vertebrate RGM proteins. 
 
Alignment between DRAG-1 (the bottom line) and its human RGM homologs 
RGMa (GenBank AAI51133.1), RGMb (GenBank NP_001012779.2) and RGMc 
(GenBank NP_998818.1). The purple shaded area is the N- and C- terminal 
signal sequences predicted for drag-1 sequence. The green shaded area 
represents the highly conserved vWF type D domain. The RGD motif (boxed in 
red) is present in RGMa and RGMc, but not in RGMb and DRAG-1. The black 
vertical dotted line represents the autocleavage site that is conserved in all four 
RGM proteins. Red underlines represent highly conserved Cysteine residues. 
Blue underline represents the motif that is sufficient for DRAG-1-UNC-40 
interaction (See Chapter 6). The arrows point to the mutated residues in human 
JH disease with molecular lesion shown on top of the arrows.  
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Figure 4.2: Body size rescue of drag-1(jj4). 
 
Body size was measured in adult worms at 72 hours post-plating. Transgenic 
worms were distinguished from non-transgenic ones by the presence of myo-
2::gfp in the former. The lengths of drag-1(jj4) and non-transgenic worms of each 
group were normalized to 1. The relative lengths of wild-type and various 
transgenic animals compared with their corresponding non-transgenic controls 
are presented. Between 12 and 44 animals were measured for each genotype. 
Error bars represent 95% confidence intervals for the mean of relative body 
length. The significance of difference between transgenic and the corresponding 
non-transgenic animals was statistically analyzed via Student's t-test. ***, 
P<0.0001; N.D., not significantly different. 
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4.3.2  Assessment of human HJV mutations using C. elegans DRAG-1 
as a model 
Several dozen human JH disease mutations are identified in RGMc/HJV 
(Nagayoshi et al., 2008;Robson et al., 2004). Missense mutations associated 
with JH disease are shown in Figure 4.1. Most of the residues carrying whose 
mutation in human causes JH disease are conserved in DRAG-1 (Figure 4.1). 
Several of the missense mutations have been characterized in vitro for their 
function (Kuns-Hashimoto et al., 2008). However, there haven’t been in vivo 
studies to assess their consequences. To provide a qualitative and quantitative 
assessment of these human mutations, I used DRAG-1 as an in vivo model to 
test human mutations in three conserved DRAG-1 residues: G68 (G99 in human 
HJV) that is located in an RGD motif that is present in RGMa, HJV, but not in 
RGMb or DRAG-1; D117 (D172 in human HJV) that is located in the critical 
residue for the conserved “GDPH” motif for RGM autocleavage; G272 (G320 in 
human HJV) that is the most frequently mutated residue in JH patients (Figure 
4.1). I generated the G68V, D117E, and G272V mutations in functional drag-
1::gfp genomic constructs (Tian et al., 2011). I used the newly developed Mos-
mediated single copy insertion (Mos-SCI, (Frokjaer-Jensen et al., 2008)) 
technique to insert the mutation-carrying constructs as well as a wild type drag-
1::gfp construct into the same genomic locus as single copy. Two insertion lines 
were generated for each of the wild type, D117E, and G272V constructs and one 
insertion line was generated for G68V construct. The insertions were PCR 
verified (See Material and Methods). Western blotting showed that proteins from 
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each insertion line are expressed at a similar level and the same size (Figure 
4.3A). Assuming that each line has one copy of transgene insertion per 
chromosome, the point mutations do not affect the protein stability. Fractionation 
experiments showed that neither wild type DRAG-1::GFP nor the three mutated 
forms of DRAG-1::GFP are mainly or totally localized to the membrane fraction, 
with very little of G68V mutated DRAG-1::GFP became soluble (Tian et al., 2010, 
Figure 4.3B). Thus, the mutations do not affect DRAG-1 protein membrane 
association.   
The insertions were then crossed into the drag-1(jj4) background to test 
for rescue of small body size phenotype and into the drag-1(jj4); sma-9(cc604) 
background to test for the rescue of the SOSMLP. The results were similar in 
both assays between the two independent inserted lines for each of wild type, 
D117E, and G272V (data not shown). Results were thus averaged; they are 
summarized in Table 4.1 and Figure 4.3C. In both assays, wild type drag-1::gfp is 
fully functional: it rescues the small body size to wild type levels and rescues the 
SOSMLP close to 100%. Among G68V, D117E, and G272V mutated drag-1::gfp 
transgenes, G272V is the least functional: it failed to rescue the small body size 
of drag-1(jj4) mutant, and it only rescued 5.1% of the SOSMLP. G68V is 
moderately functional: it significantly rescued the small body size phenotype and 
rescued the SOSMLP in 20.7% of the worms. Interestingly, D117E significantly 
rescued the small body size but not nearly to the wild type level and fully rescued 
the SOSMLP. One explanation for this result is that body size is likely more 
sensitive to DRAG-1 protein function and Sma/Mab signaling activity than M 
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lineage patterning. Together, these results suggest that the three mutations 
affect DRAG-1 protein function to different levels, with G272V being the most 
impaired and with D117E being the least impaired. 
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Figure 4.3: JH disease mutations in DRAG-1 affect DRAG-1 function to 
different degrees. 
 
(A) Western blotting showing similar expression level of different DRAG-1::GFP 
forms in Mos-SCI lines with actin as a loading control (see Materials and 
methods). (B) Wild type and mutant forms of DRAG-1::GFP are associated with 
the membrane fraction (see Materials and methods). (C) Body length of wild-type 
(N2) and various mutant worms at 72 hours post-plating (see Materials and 
methods). Error bars represent standard deviation. The significance of difference 
between double mutants and the corresponding single mutants was statistically 
analyzed via Student's t-test. P values are shown. 
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4.3.3  DRAG-1 physically interacts with the Sma/Mab ligand DBL-1, type 
I receptor SMA-6, and type II receptor DAF-4. 
Vertebrate RGM proteins physically associate with the BMP receptors and 
directly bind to the BMP ligand with high affinity in mammalian cell culture. I 
therefore tested whether DRAG-1 binds to Sma/Mab ligand and receptors. Flag-
tagged DRAG-1 mature domain and Myc- tagged SMA-6 mature region or Myc-
tagged DAF-4 mature region that lacks aa 439-end were transfected into 
mammalian HEK293T cells (Figure 4.4A). Immunopreciptation (IP) using anti-
FLAG successfully pulled down both Myc-SMA-6 and Myc-DAF-4 proteins, 
suggesting that DRAG-1 physically interacts with both SMA-6 and DAF-4 (Figure 
4.4C). DBL-1, like the other TGF- family ligands, goes through proprotein 
convertase cleavage between its prodomain and mature domain to release the 
active mature domain. Therefore, I generated a construct expressing FLAG-
mature DBL-1 by inserting the FLAG tag before the DBL-1 mature domain and 
after the proprotein cleavage site in DBL-1 prodomain (Figure 4.4A). The FLAG-
mature DBL-1 transfected HEK293T media contained the mature FLAG-DBL-1 of 
the expected size, while the cell lysate contained the full length unprocessed 
form of DBL-1 prodomain-FLAG-mature DBL-1 (Figure 4.4B). Anti-c-Myc 
conjugated sepharose was first incubated with DRAG-1 that was expressed as a 
Myc-DRAG-1 form in HEK293T cells, and then with HEK293T media containing 
DBL-1. IP pulled down FLAG-mature DBL-1 (Figure 4.4D). Thus DRAG-1 also 
physically interacts with the ligand DBL-1. As a positive control, type I receptor 
SMA-6 physically interacted with the ligand DBL-1 while type II receptor DAF-4 
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failed to bind to DBL-1 (Figure 4.4E). This is consistent with previous finding that 
BMP ligands have higher affinity to the type I receptors than type II receptors 
(Attisano et al., 1994;Massague, 1992;Massague, 1998). These results and 
previous studies (Tian et al., 2010; Chapter 3) support the hypothesis that 
DRAG-1 is likely a Sma/Mab pathway co-receptor. For confirmation, however, I 
am currently examining all of these pairs of interactions with reciprocal IPs. 
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Figure 4.4: DRAG-1 physically interacts to the Sma/Mab receptors SMA-6 
and DAF-1 and the ligand DBL-1. 
 
(A) Schematics of all the constructs used in this study, with ss representing the 
N-terminal signal sequence, TM representing the transmembrane domain, EXD 
representing the extracellular domain, and ICD representing the intracellular 
domain. (B) Western blotting of FLAG-DBL-1 in media and cell lysates showed 
different molecular sizes indicative of protein processing. Co-IP experiment using 
the above constructs showed that SMA-6 and DAF-4 (B) and mature domain of 
DBL-1 (C) all bind to DRAG-1 mature domain. As controls, SMA-6, but not DAF-4, 
binds to DBL-1 (D). 
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4.4  Discussion 
  In this study, I established that DRAG-1 and vertebrate RGMs share 
functional similarities. DRAG-1 has cysteine residues at positions identical to 
vertebrate RGMs, suggesting that similar pairs of disulfide bonds might form 
between comparable cysteine residues, leading to a highly similar protein 
structure. Human JH disease missense mutations are located in the residues that 
are conserved in DRAG-1. Furthermore, examination of three of the human 
mutations introduced into DRAG-1 in C. elegans showed that the mutations have 
quantitatively and qualitatively different impacts on DRAG-1 protein function. The 
most prevalent human mutation, corresponding to G272V in DRAG-1, has the 
most abolishment on DRAG-1 function. This mutation (G320V in human 
RGMc/HJV) abolished RGMc interaction with neogenin protein in cell culture 
(See Chapter 5, Zhang et al., 2009). This is consistent with the notion that 
neogenin is involved in the BMP signaling (Zhang et al., 2009;Zhou et al., 2010; 
Lee et al., 2010). As will be discussed in Chapter 5 of this thesis, I showed that C. 
elegans neogenin UNC-40 functions in modulating Sma/Mab signaling. Therefore, 
I will test if C. elegans G272V, the corresponding RGMc G320V mutation in 
DRAG-1, disrupts DRAG-1 interaction to UNC-40 and if the disruption of this 
interaction affects Sma/Mab signaling.  
 I also established that C. elegans DRAG-1 physically interacts with the 
Sma/Mab ligand DBL-1 and both type I receptor SMA-6 and type II receptor 
DAF-4 in HEK293T cells. Similar results were published in mammalian cultured 
cells showing that all three RGMs were able to directly bind to BMPs and 
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physically associate with both type I and type II receptors (Babitt et al., 
2005;Babitt et al., 2006). Because of the profound similarity in protein sequences 
between DRAG-1 and its vertebrate homologs, DRAG-1 may interact with the 
Sma/Mab ligand and receptors through some conserved motifs, rendering 
DRAG-1 suitable for mapping out critical motifs for the interactions.  
 Therefore, C. elegans has a highly conserved BMP-like Sma/Mab 
signaling system that includes a highly conserved role for the RGM protein 
DRAG-1, and together with the worm’s easily distinguishable and nonessential 
Sma/Mab pathway phenotypes, which makes C. elegans a great tool to study 
BMP signaling and RGM protein function. The recent availability of the single 
copy insertion technique, Mos-SCI, makes C. elegans even more powerful to 
quantitatively assay for protein function (Frokjaer-Jensen et al., 2008). In this 
study, I used transgenes introduced by the Mos-SCI method to compare the 
function of DRAG-1 proteins carrying different point mutations using two assays, 
the rescue of small body size of drag-1(jj4), and the rescue of SOSMLP. Results 
from both assays suggest that G272V mutation is the least functional, G68V 
mutation is intermediate functional, and D117E mutation is the most functional. 
An unexpected and yet interesting finding come out from these comparisons is 
that I found that different tissues respond to differently to the mutations, which 
may be due to different levels of Sma/Mab signaling. This wouldn’t have been 
identifiable by conventional transgenic techniques, which cannot be used for 
quantitative comparison of transgenes because of high copy numbers of 
transgenes that lead to severe overexpression. Specifically, D117E mutation 
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couldn’t rescue the small body size phenotype based on a moderate cutoff 
(p<0.1%) but fully rescued the sma-9 M lineage suppression. One reasonable 
explanation from this study is that M lineage patterning requires lower level of 
Sma/Mab signaling than body size regulation.  
The next step of the project is to determine why the mutations, especially 
the G272V mutation, affect DRAG-1 protein function. Two directions will be the 
main focus: to determine if the mutated DRAG-1 proteins fail to bind to its crucial 
partners, and to investigate if the mutations affect DRAG-1 subcellular 
localization (See Chapter 6).  
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Chapter 5:  UNC-40/neogenin functions independently of netrin signaling in 
modulating the BMP-like Sma/Mab signaling in C. elegans 
5.1  INTRODUCTION 
Bone morphogenetic proteins (BMPs) belong to the transforming growth 
factor-β (TGFβ) superfamily of ligands. BMP signaling pathway plays important 
roles in development and disease (Wu and Hill, 2009). The BMP signal 
transduction mode is relatively simple (Shi and Massague, 2003). The signal 
activation starts with the formation of the BMP ligand-type I,II receptor  complex. 
Once in close proximity, the constitutively active type II receptor phosphorylates 
the type I receptor, which then phosphorylates the receptor-regulated Smads (R-
Smads). These activated R-Smads then complex with common-mediator Smads 
(co-Smads) and enter the nucleus. The R-Smad-co-Smad complex is then joined 
by transcription cofactors in regulation of downstream gene expression. Multiple 
levels of regulation, including extracellular regulation, are critical to ensure proper 
spatiotemporal control of BMP signaling (Balemans and Van Hul, 
2002;Massague and Chen, 2000;Moustakas and Heldin, 2009;Umulis et al., 
2009).  
The repulsive guidance molecule (RGM) protein family, including RGMa, 
RGMb, and RGMc (hemojuvelin or HJV), as the name suggests, was initially 
originally identified because of a role in axon guidance (Monnier et al., 2002). 
Since then, members of the family have also been shown to function as BMP co-
recetors by in vitro and in vivo studies in vertebrates (Babitt et al., 2005;Babitt et 
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al., 2006;Samad et al., 2005). All three RGM proteins physically interact with 
selective BMP ligands and receptors to enhance BMP signaling in cell cultures 
(Babitt et al., 2005;Babitt et al., 2006;Samad et al., 2005;Xia et al., 2007;Xia et al., 
2008). In mice, RGMc acts as the BMP6 co-receptor in regulating expression of 
hepcidin, a peptide that regulates iron metabolism (Park et al., 2001;Pigeon et al., 
2001;Andriopoulos et al., 2009;Babitt et al., 2007;Meynard et al., 2009). 
Mutations in RGMc/HJV in humans cause juvenile hemochromatosis, an iron 
overload disease with a reduction in hepatic hepcidin expression (Papanikolaou 
et al., 2004a;Papanikolaou et al., 2004b). The single RGM family member in C. 
elegans, DRAG-1, functions similarly as a co-receptor of the BMP-like Sma/Mab 
pathway (Tian et al., 2010). 
Neogenin, a member of the DCC (deleted in colorectal cancer) family, 
regulates neuronal axon guidance by serving as a receptor for the guidance cue 
netrin (Keino-Masu et al., 1996) as being a receptor for the repulsive cue RGM 
(Rajagopalan et al., 2004;Cole et al., 2007). In addition to those roles, recent in 
vitro and in vivo evidence has shown that neogenin also modulates BMP 
signaling. Neogenin-RGM interaction is required for the activation of hepcidin 
expression downstream of BMP signaling in mice and cultured cells (Zhang et al., 
2009;Lee et al., 2010). Neogenin also positively regulates BMP-induced 
endochondral bone formation in mice (Zhou et al., 2010). In cell cultures, 
neogenin has been shown to recruit BMP receptors to lipid rafts where the 
signaling occurs (Zhou et al., 2010). Neogenin has also been shown play 
negative roles in modulating BMP signaling in cell cultures: it facilitates the 
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secretion of soluble RGMc, a negative regulator of BMP signaling (Zhang et al., 
2005;Zhang et al., 2007); neogenin-BMP ligand interaction also activates RhoA 
signaling events that antagonize Smad activation (Hagihara et al., 2011). 
However, none of the negative roles of neogenin in modulating BMP signaling 
were identified in vivo. Therefore, an in vivo genetic model is valuable for 
understanding how neogenin modulates BMP signaling. 
C .elegans contains a single protein, UNC-40, that is homologous to both 
DCC and neogenin (Hong et al,. 1996). In this study, I examined the role of UNC-
40 in modulating the BMP-like Sma/Mab pathway. There are two BMP-related 
pathways in C. elegans, a dauer pathway that controls dauer formation and a 
Sma/Mab pathway that regulates body size, male tail formation, mesoderm 
development and innate immunity (Foehr et al., 2006;Partridge et al., 
2010;Savage-Dunn, 2005). The ligand of the Sma/Mab pathway is a BMP-like 
molecule DBL-1 (Morita et al., 1999;Suzuki et al., 1999). Additional members of 
this pathway include the type I receptor SMA-6 (Krishna et al., 1999), type II 
receptor DAF-4 (Estevez et al., 1993), and the Smad proteins, SMA-2, SMA-3 
and SMA-4 (Savage et al., 1996). Loss-of-function mutations in any of these 
pathway members cause small body size and male tail sensory ray formation 
defects. 
The Sma/Mab pathway also plays a role in the C. elegans postembryonic 
mesoderm development. The postembryonic mesodermal M lineage arises from 
a single precursor cell, the M mesoblast. During hermaphrodite postembryonic 
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development, the M cell divides to produce a group of dorsal cells that include 
the macrophage-like coelomocytes (CCs) and striated bodywall muscles (BWMs), 
and a group of ventral cells that includes BWMs and the sex muscle precursor 
cells, the sex myoblasts (SMs; Fig. 1C; Sulston and Horvitz, 1977). We have 
previously shown that mutations in the schnurri homolog sma-9 lead to a dorsal-
to-ventral fate transformation in the M lineage (Foehr et al., 2006;Foehr and Liu, 
2008). Furthermore, mutations in the core components of the Sma/Mab pathway 
suppress the dorsoventral patterning defects of sma-9 mutants, suggesting that 
the Sma/Mab signaling is antagonized by SMA-9 to pattern the postembryonic 
mesoderm along the dorsoventral axis. 
In this study, I identified UNC-40 as a positive modulator of the Sma/Mab 
pathway. I showed that the role of UNC-40 in the Sma/Mab pathway is 
independent of the netrin cue UNC-6 and the netrin receptor UNC-5. I 
demonstrated that UNC-40 binds to and synergizes with the RGM protein DRAG-
1 via its extracellular domain to mediate Sma/Mab signaling. Surprisingly, the 
intracellular domain of UNC-40 is not required in this process. 
5.2  MATERIALS AND METHODS 
5.2.1  C. elegans strains 
Strain handling is the same as in Chapter 2, 3, and 4. The following 
mutations and integrated transgenes were used: Linkage group I (LGI): drag-
1(jj4); unc-40(e1430); unc-40(tr115); unc-40(ev457); unc-40(ev546); unc-
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40(e271); unc-40(ur304); LGII: sma-6(jj6); LGIII: lon-1(e185), ccIs4438(intrinsic 
CC::gfp); LGIV: unc-5(e53); LGV: dbl-1(wk70); LGX: lon-2(e678); sma-9(cc604); 
unc-6(ev400).  
5.2.2  Constructs for interaction analysis of UNC-40 
pCXT239: pCMV::signal peptide::FLAG-drag-1 mature region, with a FLAG tag in 
the N- and a stop codon C-terminal to aa22-aa360 of DRAG-1 in pSecTag. 
pCXT245: pCMV::signal peptide::c-MycHis-unc-40 FNIII 5-6, with a cMycHis tags 
in the N- and a stop codon C-terminal to aa852-aa1081 of UNC-40 in pSecTag.  
5.2.3  Body size measurement  
Hermaphrodite animals at the gravid adult stage were collected and 
treated with hypochlorite. The resulting embryos were allowed to hatch in M9 
buffer at 16°C. Synchronized L1s were plated onto NGM plates and allowed to 
grow for 48h before they were washed off the plates, treated with 0.3% sodium 
azide, and mounted onto 2% agarose pads. Image taking and data analysis are 
the same as in Chapter 4.  
5.2.4  Immunofluorescence staining 
Animal fixation, immunostaining, microscopy and image analysis were 
performed as described previously (Tian et al., 2011). Guinea pig anti-FOZI-1 
(1:200; Amin et al., 2007), mouse monoclonal anti-AJM-1 (clone MH27, 1:100), 
rat anti-MLS-2 (1:200; Jiang et al., 2005) and goat anti-GFP (Rockland 
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Immunochemicals; 1:1000) were used. All secondary antibodies were from 
Jackson ImmunoResearch Laboratories and used at a dilution of 1:50 to 1:200.  
5.2.5  RAD-SMAD reporter assay 
 
Hermaphrodites carrying the RAD-SMAD reporters (jjIs2437) were treated 
with hypochlorite. The resulting embryos were allowed to hatch in M9 buffer at 
16°C. Synchronized L1s were plated onto NGM plates and allowed to grow for 48 
hours. The resulting L3 animals were anesthetized. Images of the hypodermal 
cells were taken at 40x magnification on a Leica DMRA2 compound microscope. 
Fluoresence intensity of the nuclei and background was measured in pairs using 
the Openlab software. Five nuclei/background pairs were measured for each 
worm. The value of nuclei signal minus background signal was averaged for 
each worm. The middle 60% of the means (discarded 20% of the highest and 20% 
of the lowest means) were averaged to generate the value of signal intensity for 
a given genotype. Standard deviation was then calculated by Microsoft Excel.  
5.2.6  Co-immunoprecipitation assays  
HEK293T cells were transiently transfected by constructs carrying the 
DRAG-1 mature region (pCXT239) or the UNC-40 FNIII 5-6 region (pCXT245). 
Cell media were collected after five days. Anti-c-Myc conjugated sepharose 
beads (5ul beads per 1.5ml media) were first incubated with the UNC-40 FNIII 5-
6 expressing cell media for 4 hours at 4°C, then with the DRAG-1 expressing cell 
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media for another 4 hours at 4°C. The beads were then subjected to 5 time of 
wash with 50 mM Tris, pH 8.0, 150 mM NaCl, and 1% Triton X-100, and ran on a 
10% of SDS-PAGE gels. The presence of DRAG-1 in the immunoprecipitates 
was detected by western blotting using mouse anti-FLAG (M2) antibodies 
(4mg/ml, 1:10000). 
5.3  RESULTS  
5.3.1  unc-40/neogenin mutants exhibits Sma/Mab pathway mutant 
phenotypes 
We have already shown that C. elegans RGM protein DRAG-1 positively 
modulates the Sma/Mab pathway (Tian et al., 2010). Because neogenin is a 
receptor for RGM proteins in mouse and in cultured cells (Rajagopalan et al., 
2004) and UNC-40 is the sole DCC and neogenin homolog in C. elegans, I 
wished to determine whether UNC-40 plays a role in the Sma/Mab pathway. I 
first examined unc-40 mutants for Sma/Mab pathway phenotypes. Previous 
studies suggested that mutants of the Sma/Mab pathway components exhibit at 
least three phenotypes: (1) suppression of sma-9 in patterning the M lineage 
(Foehr et al., 2006), (2) aberrant body size (Foehr et al., 2006;Savage-Dunn, 
2005), and (3) altered expression level of the Sma/Mab responsive reporter 
RAD-SMAD (Tian et al., 2010). I examined unc-40 null mutants for all three of 
these phenotypes.  
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Two previously published unc-40 null alleles, e1430 and ev457 
(Hedgecock et al., 1990;Chan et al., 1996), as well as a previously published null 
or strong loss-of-function allele e271 (Brenner, 1974), could suppress the M 
lineage phenotype of sma-9(cc604) mutants at over 70% efficiency (Figure 5.1A, 
Table 5.1). Furthermore, unc-40(e1430) mutant worms have a significantly 
smaller body size when compared to N2 worms at the same developmental 
stage (Figure 5.1B). Notably, unc-40 (e1430) worms are also significantly smaller 
than drag-1(jj4) worms (Figure 5.1B). Finally, the expression level of the RAD-
SMAD reporter is lower in unc-40(e1430) background compared to wild type 
background (Figure 5.2 column 5 from left). It is worth mentioning that RAD-
SMAD reporter expression level in unc-40(e1430) worms is lower than that in 
drag-1(jj4) worms. This is in consistent with the body size assay, which is also 
indicative of Sma/Mab signal activity, in which unc-40(e1430) worms are smaller 
than drag-1(jj4) worms. Taken together, these results suggest that UNC-40 might 
function as a positive modulator of the Sma/Mab pathway.  
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Table 5.1: Mutations in unc-40 suppress the M lineage defects in the sma-9 
mutants. 
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Figure 5.1: unc-40, but not unc-6 or unc-5, mutants exhibit a small body 
size phenotype. 
 
(A) A schematic of UNC-40 protein. It contains four Ig-like and six FNIII domains 
on the extracellular region and three conserved motifs P1, P2, and P3. The 
molecular lesions of different mutant alleles are shown in the diagram. (B-C) 
Body size measurement of different genotypes at the early L4 stage (See 
materials and methods). unc-40(e1430) mutant worms are significantly shorter 
than wild-type N2, unc-5(e53), unc-6(ev400), and unc-40(tr115) worms. unc-
40(e1430); lon-1(e185) and unc-40(e1430); lon-2(e678) worms are significantly 
shorter than lon-1(e185) and lon-2(e678), respectively, though to different extent. 
Error bars represent 95% confidence intervals for the mean body length. The 
significance of difference between double mutants and the corresponding single 
mutants was statistically analyzed via Student's t-test. ***, P<0.0001. N.D., not 
statistically significantly different. 
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Figure 5.2: Quantification of RAD-SMAD reporter expression in different 
genetic backgrounds. 
 
Y axis is the signal intensity value. See Materials and Methods for the 
experimental procedure. Controls include lon-2(e678) worms, which have 
hyperactive Sma/Mab signaling, and dbl-1(wk70) worms, which have no 
Sma/Mab signaling. Error bars represent 95% confidence intervals for the means 
of relative intensity. The significance of difference among different genotypes 
was statistically analyzed via Student's t-test. *, P<0.01; **, P<0.001; ***, 
P<0.0001. 
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5.3.2  unc-6/netrin and unc-5 mutants do not exhibit Sma/Mab pathway 
mutant phenotypes 
Besides RGM, neogenin and DCC are also netrin receptors (Hedgecock 
et al., 1990;Kennedy et al., 1994;Chan et al., 1996). However, it is not known if 
netrin or a netrin receptor UNC-5 is involved in BMP signaling.  Therefore, I 
examined the null mutants unc-6(ev400) and unc-5(e53), for Sma/Mab pathway 
phenotypes, including the suppression of sma-9 M lineage defects and body size 
phenotypes. Unlike unc-40 null mutants, unc-6(ev400) and unc-5(e53) null 
mutants did not suppress the sma-9 M lineage defects (Table 5.1) and were not 
significantly different from wild type worms in body length (Figure 5.1B). Together, 
these results suggest that UNC-40/neogenin may have a role in Sma/Mab 
signaling that is independent of UNC-6/netrin and UNC-5 in C. elegans. 
5.3.3  unc-40 genetically interacts with Sma/Mab pathway components 
To place UNC-40 in the Sma/Mab pathway, I generated double mutants 
between unc-40(e1430) and mutations in the Sma/Mab pathway and measured 
their body length. e678 represents a null allele of lon-2, which encodes a 
member of the glypican family of heparan sulfate proteoglycans and negatively 
regulates Sma/Mab signaling (Gumienny et al., 2007). e185 is a strong loss-of-
function mutant of lon-1, which encodes a downstream target gene of the 
Sma/Mab pathway that is negatively regulated by the pathway (Maduzia et al., 
2002;Morita et al., 2002). However, there is also evidence that lon-1 may interact 
with lon-2 and dbl-1 via a negative feedback mechanism (King Chow, personal 
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communication). As shown in Figure 5.1C, unc-40(e1430); lon-1(e185) double 
mutants were significantly smaller than lon-1(e185) mutants; unc-40(e1430); lon-
2(e678) double mutants were also significantly smaller than lon-2(e678) mutants. 
Although lon-1(e185) and lon-2(e678) mutants are of similar size, lon-1(e185); 
unc-40(e1430) worms are much longer than lon-2(e678); unc-40(e1430) worms, 
suggesting that unc-40 may function upstream of lon-1 and in parallel to lon-2 in 
the Sma/Mab pathway. A more definitive conclusion requires that additional 
double mutants, such as unc-40; sma-3 double, be generated and examined. 
Since UNC-40 is a transmembrane protein, it likely functions as a modulator of 
the Sma/Mab pathway at the ligand-receptor level. A possible reason that lon-
1(e185); unc-40(e1430) double mutants are not as long as lon-1(e185) mutants 
is the proposed negative feedback role of lon-1 in the Sma/Mab pathway 
described above.  
5.3.4  UNC-40 is expressed in the Sma/Mab signal-receiving cells 
To further test the hypothesis that UNC-40 might function as a modulator 
for the Sma/Mab pathway, we asked whether unc-40 is expressed in the 
Sma/Mab signaling-receiving cells. It has been shown that Sma/Mab pathway 
receptors and Smads function in the hypodermal cells to regulate body size 
(Yoshida et al., 2001;Wang et al., 2002). We obtained a transgenic line that 
expresses an integrated functional UNC-40::GFP transgene (Chan et al., 1996). 
UNC-40::GFP is expressed primarily in neuronal as previously reported (Chan et 
al., 1996), but is also expressed in the hypodermal cells outlined by anti-AJM-1 
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staining (Figure 5.3A-C). Thus, assuming that the transgene faithfully reports 
expression, UNC-40 is present in the Sma/Mab pathway signal-receiving 
hypodermal cells.  
We also know that the Sma/Mab pathway functions cell-autonomously in 
the M lineage to control M lineage dorsoventral patterning (Foehr et al., 
2006;Tian et al., 2010). Consistent with UNC-40 being a modulator in the 
Sma/Mab pathway, UNC-40::GFP is expressed in the M lineage at 1-M (Figure 
5.3D-F), 2-M (Figure 5.3G-I), 4-M (Figure 5.3J-L), and 8-M (Figure 5.3M-O) 
stages, which are the critical stages when sma-9 functions in dorsoventral 
patterning (Foehr and Liu, 2006). This expression pattern also overlaps with the 
expression pattern of drag-1 in the M lineage (Tian et al., 2010).   
I am currently testing if forced expression of unc-40 only in the Sma/Mab 
signaling-receiving cells can rescue the unc-40 mutant phenotype in body size 
regulation and M lineage patterning.  
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Figure 5.3: unc-40 is expressed in the hypodermal and M lineage cells 
 
Images shown are side views with anterior to the left and posterior to the right for 
all panels. UNC-40::GFP (green) is expressed in the hypodermal seam cells (A). 
Anti-AJM-1 antibody staining (red) labels the apical surface of the hypodermal 
cells (B). (D-O) The M lineage expression pattern of UNC-40::GFP (green). Anti-
MLS-2 antibody staining (red) was used to mark the M mesoblast at the 1-M 
stage (E). Anti-FOZI-1 antibody staining (red) was used to mark M lineage cells 
from the 2-M to the 8-M stages (H,K,N). Only one focal plane was shown for the 
8-M (N) stage worms. UNC-40::GFP is present from the 1-M to the 8-M stages 
(D,G,J,M).  
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5.3.5  UNC-40 modulates Sma/Mab signaling through its extracellular 
domain 
UNC-40 and its homolog neogenin and DCC have conserved protein 
domains, including four conserved Immunoglobulin(Ig)-like domains and six 
Fibronectin type III (FNIII) domains on the extracellular region, a transmembrane 
domain, and three conserved motifs P1, P2, and P3 intracellularly (Figure 5.1A). 
The intracellular domain (ICD) of neogenin is known to mediate netrin and RGMa 
signaling by initiating intracellular signal cascades (Li et al., 2004;Liu et al., 
2004;Xie et al., 2005;Ren et al., 2008;Conrad et al., 2007;Hata et al., 2006;Kubo 
et al., 2008). It is not known whether or not neogenin requires its ICD to mediate 
BMP signaling. To address this, I tested three hypomorphic unc-40 alleles, ev546, 
ur304 and tr115, for their ability to suppress the sma-9 M lineage defects (Figure 
5.1A, Tabel 5.1). Among them, ev546 and ur304, have missense mutations 
located in the extracellular region (Figure 5.1A).  ev546 is a partial loss-of-
function allele in mediating muscle arm extension (Alexander et al., 2010). ur304 
mutant was identified in a suppressor screen and has no defect on its own in cell 
or axon migration (Xu et al., 2009). I found that ev546 weakly suppressed, while 
ur304 failed to suppress, the sma-9 M lineage phenotype (Table 5.1). These 
observations suggest that while the G774R mutation partially compromises the 
function of UNC-40 in Sma/Mab signaling, the A1056V mutation does not affect 
the function of UNC-40 in Sma/Mab signaling. 
The nonsense mutation (W1107stop) changes the last residue in UNC-40 
transmembrane domain into a stop codon, truncating the entire ICD (Figure 5.1A; 
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Alexander et al., 2009). The mediation of axon and cell movement is dependent 
on the ICD of UNC-40 (550 Blelloch,R. 1999; 551 Hong,K. 1999), thus unc-
40(tr115) mutant exhibits an uncoordinated phenotype similar to the unc-40 null 
mutants. Surprisingly, tr115 failed to suppress the sma-9 M lineage phenotype 
(Table 5.1), suggesting that the ICD is not required for UNC-40 function in 
mediating Sma/Mab signaling. Consistent with this result, the body size of tr115 
mutant is not detectably different from that of wild-type, or unc-5(e53) and unc-
6(ev400) null mutants (Figure 5.1B). Taken together, these results indicate that 
the intracellular domain of UNC-40 is dispensable for its function in Sma/Mab 
signaling and that the function of UNC-40 in mediating Sma/Mab signaling is 
independent of its function in axon guidance and cell migration. 
5.3.6  UNC-40 interacts with DRAG-1 via its FNIII 5-6 domains and 
synergizes with DRAG-1 in regulating body size  
To understand how UNC-40 functions in modulating Sma/Mab signaling, I 
examined its biochemical interaction with various components in the Sma/Mab 
pathway. RGM proteins are known to directly interact with neogenin. This 
interaction is required not only for multiple roles of RGMa, including axon 
repulsion (Monnier et al., 2002) and neuronal survival (Koeberle et al., 2010), but 
also for RGMc/HJV regulating hepcidin expression downstream of BMP signaling 
(Zhang et al., 2009). Neogenin is known to bind to RGMc/HJV through its FNIII 
(5,6) domains (Yang et al., 2008;Yang et al., 2011). Therefore, I tested if UNC-40 
interacts with the sole C. elegans RGM protein DRAG-1 by co-
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immunoprecipation assays (see materials and methods). Flag-DRAG-1 and Myc-
UNC-40 FNIII 5-6 were transfected into mammalian HEK293 cells. IP using anti-
Myc antibodies successfully pulled down Flag-DRAG-1 (Figure 5.4A). While I still 
need to repeat the co-IP experiment in the reciprocal direction and using worm 
extracts, these results suggest that the DRAG-1 mature domain physically 
interacts with the FNIII(5,6) domain of UNC-40 protein. I am currently generating 
truncations and point mutations in UNC-40 to further map the specific residues 
mediating interaction with DRAG-1.  
DRAG-1 is likely a co-receptor of the Sma/Mab pathway (Tian et al., 2010). 
The physical interaction between DRAG-1 and UNC-40 places both of them in 
the same complex. Since both of them positively modulate Sma/Mab signaling, I 
wondered whether they synergize with each other in promoting Sma/Mab 
signaling. I therefore generated double mutants between drag-1(jj4) and unc-
40(e1430) and determined their body sizes. drag-1(jj4) unc-40(e1430) double 
mutant worms are significantly smaller than either of the single mutant alone 
(Figure 5.4B). Furthermore, the double mutant has a significantly lower RAD-
SMAD reporter activity compared to either of the single mutants (Figure 5.2). 
Taken together, my biochemical and genetic data suggest that UNC-40 and 
DRAG-1 likely function in a complex and synergize with each other in modulating 
Sma/Mab signaling. 
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Figure 5.4: UNC-40 physically and genetically interacts with DRAG-1. 
 
(A) UNC-40 co-immunoprecipitates with DRAG-1 via its FNIII(5,6) domain. 
Please refer to material and methods for experiment procedues. (B) body size 
measurement of drag-1(jj4), unc-40(e1430), and drag-1(jj4) unc-40(e1430) 
worms. The double mutant is significantly smaller than either single mutant. Error 
bars represent 95% confidence intervals for the means of relative intensity. The 
significance of difference between the double mutant and unc-40(e1430) was 
statistically analyzed via Student's t-test. ***, P<0.0001. 
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5.4  DISCUSSION 
5.4.1  UNC-40 is a positive modulator of the BMP-like Sma/Mab pathway 
As a close homolog of DCC, neogenin was initially recognized as an axon 
guidance receptor that is required for axon and cell migration (Wilson and Key, 
2006;Srinivasan et al., 2003;Kang et al., 2004;Park et al., 2004). Recent in vitro 
and in vivo evidence suggests that neogenin is also involved in modulating BMP 
signaling. Neogenin has been shown to have both positive and negative roles in 
modulating BMP signaling. Neogenin positively potentiates BMP signaling to 
regulate the expression of hepcidin for body iron metabolism (Lee et al., 
2010;Zhang et al., 2009) and endochondral ossification in mice (Zhou et al., 
2010). Neogenin negatively modulates BMP signaling by binding to BMP ligands 
and activating RhoA signaling in cell cultures (Hagihara et al., 2011). Neogenin 
also increases the secretion of HJV, which may cause downregulation of BMP 
signaling (Zhang et al., 2005;Zhang et al., 2007). My data demonstrate that the 
sole C. elegans DCC/neogenin homolog UNC-40 is a positive modulator of the 
BMP-like Sma/Mab pathway: (1) unc-40 mutants behave similarly to mutants of 
all the core members of the Sma/Mab pathway with respect to both body size 
and suppression of sma-9 M lineage patterning phenotypes; (2) unc-40 mutants 
exhibit reduced activity of the Sma/Mab reporter, RAD-SMAD; (3) genetic 
epistasis analysis placed unc-40 at the ligand-receptor level; (4) unc-40 is 
expressed in the same cells as the Sma/Mab signal-receiving cells to regulate 
body size (in hypodermal cells) and mesoderm patterning (in the M lineage); (5) 
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UNC-40 synergizes with the sole RGM protein DRAG-1 to modulate Sma/Mab 
signaling and UNC-40 and DRAG-1 likely form a complex by directly interacting 
with each other. Thus, this study provides in vivo evidence that UNC-
40/neogenin is a positive modulator of BMP signaling and that this function of 
neogenin is evolutionarily conserved. 
Neogenin is a receptor of RGMa in axon repulsion and the two proteins 
function in two adjacent cells, or in trans, in this process (Rajagopalan et al., 
2004). Whether RGM and neogenin function in neighboring cells (in trans) or in 
the same cells (in cis) in modulating BMP signaling is also unclear. In this study, I 
showed that both UNC-40/neogenin and DRAG-1/RGM are expressed in the 
signal receiving cells, including the hypodermal cells and the M lineage cells. 
Even though I haven’t demonstrated that UNC-40/neogenin functions in these 
cells, my findings are consistent with UNC-40/neogenin and DRAG-1/RGM 
functioning in the same cells. 
 Neogenin is also a receptor for netrin (Wilson and Key, 2006), raising that 
possibility that netrin or netrin receptors might function in BMP signalling. It hasn’t 
been reported whether netrin or other netrin receptors also participate in BMP 
signaling. In this study, I showed that C. elegans UNC-6/netrin and another netrin 
receptor UNC-5 do not function in the Sma/Mab pathway: unc-6 and unc-5 null 
mutant have a wild type body size and do not suppress the M lineage defects of 
sma-9 mutants. I further showed that UNC-40 protein lacking the ICD exhibits 
wild-type activity in mediating Sma/Mab signaling. Since this mutant form of 
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UNC-40 is defective in axon guidance and cell migration mediated by netrin 
signaling, my results suggest that UNC-40/neogenin exerts its function in 
mediating BMP signaling via its extracellular domain and that neogenin’s role in 
modulating BMP signaling is independent of its role in netrin signaling. 
Consistent with this, the netrin-binding motif and the RGM binding motif in 
neogenin have been mapped to two independent regions of neogenin 
(Rajagopalan et al. 2004).  
5.4.2  A model for how UNC-40 and DRAG-1 function to modulate 
Sma/Mab signaling 
Both UNC-40 and DRAG-1 positively modulate Sma/Mab signaling at the 
ligand-receptor level (Tian et al., 2010; this study). UNC-40, like its homolog 
neogenin, appears to directly bind to the RGM protein DRAG-1 through its 5th 
and 6th FNIII domains. Neogenin-RGM binding has been shown to be required 
for hepcidin expression by regulating BMP signaling in cell culture (Lee et al., 
2010;Zhang et al., 2009). Cell culture experiments have also shown that 
Neogenin-RGM interaction helps to recruit the BMP receptors to the lipid raft 
microdomain where signaling occurs (Zhou et al., 2010). Consistent with this 
notion, the G320V mutation in RGMc/HJV, which disrupts neogenin-HJV 
interaction, causes juvenile hemochromatosis in humans (Kuns-Hashimoto et al., 
2008).   
The specific residues in neogenin that are involved in RGM binding 
haven’t been identified. The crystal structure for the 5th and 6th FNIII domains of 
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neogenin has been solved (Yang et al., 2011). Because neither the 5th FNIII 
domain in neogenin nor DCC binds RGM (Yang et al., 2008), residues in the 6th 
FNIII domain of neogenin that are different from those in both the 5th FNIII 
domain of neogenin and the 6th FNIII domain of DCC are likely to be involved 
RGM binding. Two loop regions in the 6th FNIII domain of neogenin enriched in 
these residues are therefore predicted to be involved in neogenin-RGM 
interaction (Yang et al., 2011). We are now in a position to test the importance of 
these residues in vivo.  
It is unlikely that UNC-40/neogenin functions in the BMP-like Sma/Mab 
pathway by binding to DRAG-1 alone. Recently neogenin has been shown to 
directly bind to BMP ligands (Hagihara et al., 2011) but not BMP receptors (Zhou 
et al., 2010). My work provides genetic evidence that unc-40/neogenin and drag-
1/RGM function synergistically, suggesting that unc-40 may have drag-1 
independent roles. It will be important to find out if UNC-40 also interacts with the 
ligand and/or receptors of the Sma/Mab pathway. UNC-40/neogenin may be a 
part of an accessory complex, which at least includes DRAG-1/RGM, which 
potentiates ligand-receptor binding through local enrichment of the ligand and 
receptors, which at least includes DRAG-1 (Figure 5.5).  
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Figure 5.5: A model for how UNC-40/neogenin may function in modulating 
the BMP-like Sma/Mab pathway 
 
In this model, UNC-40/neogenin positively modulates the BMP-like Sma/Mab 
pathway through its extracellular domain. The FNIII(5,6) domains of UNC-
40/neogenin directly interact with DRAG-1/RGM, which physically interacts with 
both the DBL-1/BMP ligand and the type I and type II receptors (See Appendix 3). 
It is unclear if UNC-40/neogenin also physically interacts with the ligand and/or 
receptors. Similarly, UNC-40/neogenin may also interact with other proteins. Red 
dots represent directly physical interaction.  
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Chapter 6:  Conclusions and Future Perspectives 
The proper formation of a complex multicellular organism requires precise 
coordination among many cellular events, including cell proliferation, cell fate 
specification and differentiation. I have used the C. elegans postembryonic 
mesodermal lineage, the M lineage, as a tool to study mechanisms coordinating 
these events at the cellular and molecular resolution, including transcription 
factor networks and signaling pathways. This thesis has two focuses, uncovering 
a pro-proliferation regulatory network that is centered with sem-2/SoxC, and 
identifying and characterizing new components in the BMP-like Sma/Mab 
pathway.  
6.1  Identifying a pro-proliferation network in the M lineage (Chapter 2 and 
Appendix 1) 
6.1.1  Summary 
In Chapter 2, I described the characterization of the sole SoxC family 
member in C. elegans. I found that SEM-2/SoxC is both necessary and sufficient 
to promote a proliferating blast cell fate, the sex myoblast fate, over a 
differentiated striated bodywall muscle fate. This function of sem-2 is directly 
regulated by PBC/HOX factors in the M lineage, as demonstrated by 
computational, in vivo functional and in vitro electrophoretic mobility shift assays 
(EMSA). I also identified the positional cues that dictate the specific expression of 
sem-2 in the sex myoblast precursors and their descendants, which include 
SMA-9 antagonism of BMP signaling, Notch signaling and the Wnt/-catenin 
asymmetry pathway. The crucial nature of the HOX/PBC factors in directly 
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enhancing expression of this proliferative factor in the C. elegans M lineage 
suggests a possible more general link between Hox-PBC factors and SoxC 
proteins in regulating cell proliferation (Tian et al. 2011). In Appendix 1, I 
described that sem-4/SALL functions together with sem-2/SoxC in specifying the 
SMs. Mutations in either sem-2 or sem-4 lead to the same SM to BWM fate 
transformation phenotype, yet they do not regulate each other’s expression in the 
SM mother cells or the SM lineage. SALL proteins are known stem cell factors 
and regulate differentiation and proliferation in mice. SoxC factors also have 
roles in proliferation in mice. However, the relationship between SALL and SoxC 
factors haven’t been studied. The result that sem-2/SoxC and sem-4/SALL 
together specify the proliferative SMs provides crucial in vivo evidence in any 
organisms that they may function together. 
6.1.2  Future directions 
Future directions for understanding how sem-2 regulates proliferation over 
differentiation include two parts: understanding the mechanism on how sem-4 
functions together with sem-2, and identifying sem-2 and sem-4 downstream 
target genes in the M lineage.  
SEM-4 and SEM-2 may physically interact with each other and function as 
a complex. Yeast two hybrid assays can be used to test for direct interaction. 
SALL family members are known to interact with NuRD (Nucleosome 
Remodeling and Deacetylase) and NODE (Nanog- and Oct4-associated 
Deacetylase) chromatin remodeling complexes (Cox et al., 2010;Kiefer et al., 
2002;Liang et al., 2008;van den Berg et al., 2010). Therefore, we can test if the 
NuRD complex in C. elegans is involved in specifying the SMs. To start, we can 
examine RNAi phenotypes of each component in the NuRD complex. The NuRD 
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complex may have multiple roles in the M lineage. An early role in general M 
lineage proliferation and patterning may mask any later roles in specifying the 
SMs. Therefore, it may be critical to knockdown the NuRD complex components 
in the M lineage at or before the 8-M stage, when sem-4 expression is first 
evident. We can start RNAi treatment at different M lineage stages. We can also 
use tissue-specific RNAi that employs an RNAi resistant rde-1 mutant and M 
lineage-specific rescue with rde-1 cDNA (Qadota et al., 2007).  
SEM-4 and SEM-2 may also regulate the same subset of target genes 
that are required for the SM fate. To isolate direct target genes of SEM-2 and 
SEM-4, we can perform Chip-seq on SEM-2 and SEM-4 in isolated M lineage 
nuclei. The technical hurdle is how to isolate nuclei from C. elegans larvae. SM 
cells from dissociated larvae precociously differentiate, thus the gene expression 
profiles from such cells wouldn’t represent the in vivo situation, which makes cell 
dissociation not ideal for studying regulatory networks. Our lab is currently 
working on adapting the INTACT (isolation of nuclei tagged in specific cell types) 
method (Deal and Henikoff, 2011) to isolate M lineage nuclei, which appears very 
promising (Vik Ghai, personal communication). In this method, nuclei are biotin-
labeled through transgenic expression of a biotinylated nuclear envelope protein 
in the cell type of interest. Total nuclei are isolated from transgenic worms and 
biotin-labeled nuclei are then purified using streptavidin-coated magnetic beads. 
INTACT gives high yield and purity of nuclei from the desired cell types, allowing 
genome-wide analysis of gene expression and chromatin features. INTACT 
method has worked for isolating body wall muscle nuclei from C. elegans adults 
(Steiner et al., 2012). If the INTACT method works in the M lineage, we can 
isolate M lineage nuclei at 8-16M stages in gfp::sem-2 and gfp::sem-4 worms. 
Then we can perform Chip using anti-GFP antibodies on the isolated nuclei and 
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subject the isolated DNA to high throughput sequencing. We can identify the 
commonly regulated downstream target genes by both SEM-2 and SEM-4. Gene 
ontology will be characterized. Those genes whose products belong to protein 
families that have roles related to proliferation will be subjected to further 
examination. We will first generate transcriptional and translational reporters to 
investigate if they are expressed in the M lineage and especially in the 
proliferating SM cells. The expression will also be examined in sem-2 and/or 
sem-4 mutant background. Loss-of-function and overexpression studiess will 
then be performed. Those whose expression is regulated by sem-2 and/or sem-4 
and who have M lineage phenotypes, especially SM proliferation phenotypes are 
likely the true M lineage specific direct targets of sem-2 and sem-4. 
6.2  Identifying and characterizing novel BMP-like Sma/Mab pathway 
components 
6.2.1  Summary 
Members of the BMP like signaling pathway in C. elegans have been 
identified from a sma-9 suppressor screen (Foehr et al. 2006). drag-1(jj4) was 
identified from the same screen. DRAG-1, as the focus of Chapter 3 and Chapter 
4, is the sole member of the repulsive guidance molecule (RGM) family of 
proteins in C. elegans. One vertebrate DRAG-1 homolog that is associated with 
juvenile hemochromatosis (HFE2), Hemojuvilin (Hjv), regulates iron homeostasis 
by modulating BMP signaling. Using a combination of molecular genetic and 
biochemical analyses, I demonstrated that DRAG-1 is a membrane-associated 
protein that functions by interacting with the ligand DBL-1, type I receptor SMA-6, 
and type II receptor DAF-4 to modulate the Sma/Mab pathway in a cell-type-
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specific manner. I further showed that DRAG-1 positively modulates this BMP-
like pathway by using a novel Sma/Mab-responsive reporter. I also established 
that vertebrate Hjv is partially functional in C. elegans and three tested HFE2-
associated mutations hamper DRAG-1 function in vivo. Therefore, my results 
provide a direct link between RGM proteins and BMP signaling in vivo and a 
simple and genetically tractable system for mechanistic studies of RGM protein 
regulation of BMP pathways. 
 In Chapter 5, I described the role of UNC-40, the sole Neogenin/DCC 
protein, in the Sma/Mab pathway. This role of neogenin has been shown in a 
couple of BMP-mediated processes in mice and cultured mammalian cells; 
however, mechanistically how neogenin functions in BMP signaling is still not 
clear. I genetically placed unc-40 in the BMP-like Sma/Mab pathway. I showed 
that UNC-40 positively regulates Sma/Mab signaling with the RAD-SMAD 
reporter. Furthermore, my results demonstrated that modulation of Sma/Mab 
signaling by UNC-40 is independent of its role in axon and cell migration: 
mutations in UNC-6/netrin and UNC-5, factors that are related to the axon 
guidance role of UNC-40, do not exhibit the Sma/Mab pathway phenotypes. 
Interestingly, I found that the ectodomain of UNC-40 is sufficient to mediate its 
role in BMP signaling because a mutant allele of unc-40 carrying an early stop 
codon that truncates the entire intracellular region could function perfectly in BMP 
signaling but not in axon guidance. UNC-40 physically interacts with DRAG-1 
through UNC-40’s FNIII (5,6) domains in the extracellular region, which suggests 
that the UNC-40-DRAG-1 complex may be required for modulating Sma/Mab 
signaling. Consistent with this notion, I showed that one HFE2-associated 
mutation in Hjv, known to interrupt HJV binding to neogenin, almost completely 
abolished DRAG-1 function in C. elegans. 
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6.2.2  Future directions 
The main future focus will be investigating the mechanisms on how UNC-
40 and DRAG-1 modulate Sma/Mab signaling.  
One hypothesis is that UNC-40 and DRAG-1 interaction is required for 
their function in Sma/Mab signaling. We can identify the critical residues in both 
UNC-40 and DRAG-1 proteins that are mediating the interaction. The Neogenin-
interacting region in RGMa protein has been mapped (Itokazu et al., 2012). 
Synthesized peptide consisting of aa 284-293 of RGMa directly binds to the 
extracellular domain (ECD) of recombinant neogenin. The homologous sequence 
in DRAG-1 is aa238-247, among which 5 out of the 10 residues are identical to 
RGMa (Figure 4.1, blue underline). Therefore, this stretch of amino acids 
provides us with a starting point to test critical residues in DRAG-1 that are 
required for DRAG-1-UNC-40 binding. Missense mutations will be made in 
DRAG-1 protein in the critical residues. Mutated DRAG-1 will be tested for 
function regarding body size and sma-9 M lineage suppression phenotypes. One 
human JH mutation, G320V, is known to interrupt HJV binding to neogenin (ref). 
G320 corresponds to G271 in DRAG-1. I have already shown that the G271V 
mutation in DRAG-1 almost completely abolished DRAG-1 function in mediating 
Sma/Mab signaling. Notably, G271 is located outside of the 10-residue motif 
(aa238-247). We will test if G271VDRAG-1 is able to bind to UNC-40.  
I already showed that UNC-40 binds to DRAG-1 through its FNIII(5,6) 
domains. The crystal structure of neogenin FNIII(5,6) domains has been solved 
(Yang et al., 2011a). Because neither the neogenin 5th FNIII domain nor DCC 
directly binds RGM (Yang et al., 2008), residues in the neogenin 6th FNIII domain 
that are different from residues in both the neogenin 5th FNIII domain and the 
DCC 6th FNIII domain are likely the ones required for RGM binding. Two loops 
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enriched with the differential residues were therefore predicted to mediate 
neogenin-RGM interaction (Yang et al., 2011b). Since UNC-40 is a homolog for 
both DCC and neogenin, the residues in UNC-40 that are conserved with 
neogenin but not DCC in those loops are most likely to be candidates for 
neogenin-RGM interaction. These candidate residues could be subjected to 
combined biochemical interaction and in vivo function tests to investigate if 
DRAG-1-UNC-40 interaction is important for UNC-40 function.  
It is likely that UNC-40 and/or DRAG-1 mediate Sma/Mab signaling not 
just through DRAG-1-UNC-40 interaction, because unc-40(e1430); drag-1(jj4) 
double mutants have more severe Sma/Mab pathway phenotypes. Neogenin has 
been shown to directly interact with the BMP ligands (Hagihara et al., 2011). 
Therefore, we would like to test if UNC-40 also binds to the ligand DBL-1, if so, 
we will determine which part of UNC-40 is required for such interaction. We 
would also like to study the functional relevance of this interaction.  
If DRAG-1-UNC-40 interaction is required for them to mediate Sma/Mab 
signaling, the next question will be how they promote the signaling. DRAG-1 can 
physically interact with the ligand and both type I and type II receptors in the 
Sma/Mab pathway (Chapter 4). The hypothesis is that the formation of a 
supercomplex comprised of the ligand, type I, II receptors, DRAG-1, and UNC-
40, will cause local enrichment of both the ligand and receptors on the 
membrane, which can lead to efficient signaling. One recent study in cultured 
cells suggested that neogenin can recruit the receptors to the lipid rafts 
microdomain where the signaling takes place, with the help of RGM proteins 
(Zhou et al., 2010). We would like to test if UNC-40 and DRAG-1 also help the 
receptors enter the lipid rafts in C. elegans. We will first examine the presence of 
receptors, DRAG-1 and UNC-40 in lipid rafts in wild type animals by isolating lipid 
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rafts from transgenic animals that express gfp fusions for each protein. If they are 
present in lipid rafts in wild type animals, we will then isolate lipid rafts from drag-
1(jj4), and unc-40(e1430) mutants and examine the presence of receptors in lipid 
rafts. 
The Liu lab has performed a large scale sma-9 suppressor screen (Jun, 
Liu, unpublished results). We have identified many mutations that are not located 
in the known Sma/Mab pathway genes. The long term goal will be identifying and 
characterizing the new components using methods similar to those I used in 
Chapters 3-5. The new components, especially ones that are localized to the 
cellular membrane, will add to our current understanding of RGM-neogenin 
complex in modulating BMP signaling.  
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APPENDIX I:  
Determine the relationship between sem-2/SoxC and sem-4/SALL in the M 
lineage  
A1.1 INTRODUCTION  
sem-2 encodes the sole C. elegans group C Sry-related HMG box (Sox)-
containing transcription factor . Previous study has shown that SEM-2 is 
necessary to promote a proliferating sex myoblast (SM) fate over a differentiated 
striated body wall muscle (BWM) fate (Tian et al., 2011). sem-2 expression in the 
sex myoblast precursors and their descendants is under the control of a number 
of factors, including direct activation by a Hox-PBC complex, regulation by the 
Wnt/-catenin asymmetry pathway along the anterioposterior axis, as well as 
regulation by the dorsoventral cues: SMA-9 antagonism of the Sma/Mab 
signaling that patterns the dorsal M lineage and Notch signaling that patterns the 
ventral M lineage, both of which converge on a FoxF/C factor LET-381 that 
represses sem-2 expression. The function of SEM-2 in the M lineage suggests 
that SoxC proteins have an evolutionarily conserved role in promoting the 
proliferation of multipotent progenitor cells. It is crucial for our understanding of 
SoxC function to identify the co-factors and downstream target genes through 
which SoxC proteins exert their function in regulating progenitor cell proliferation.  
It has been shown that sem-4 mutants share the same SM to BWM fate 
transformation phenotype as sem-2 mutants; in addition, sem-4 mutants exhibit 
an extra division in the coelomocyte (CC) precursor cells, which then give rise to 
two BWMs (Basson and Horvitz, 1996). SEM-4 is the sole member of the Spalt 
or SALL family of C2H2 zinc finger-containing transcription factors in C. elegans 
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(de Celis and Barrio, 2009). The SALL family contains four members in 
vertebrates, SALL1-SALL4. SALL family members have been shown to play 
roles in regulating proliferation in vertebrates. Mutations in SALL1 and SALL4 in 
humans cause Townes-Brocks syndrome and Okihiro syndrome, respectively, 
where patients exhibit hypoplastic phenotypes in multiple tissues/organs (de 
Celis and Barrio, 2009;Sweetman and Munsterberg, 2006). Both SALL1 and 
SALL4 have been shown to regulate pluripotency of stem or progenitor cells 
(Karantzali et al., 2011;Neff et al., 2011;Oikawa et al., 2009;Rao et al., 
2010;Wang et al., 2011;Yang et al., 2008;Yang et al., 2010;Yang et al., 2012;Yuri 
et al., 2009). Mechanistically, SALL proteins function by interacting with NuRD 
(Nucleosome Remodeling and Deacetylase) and NODE (Nanog- and Oct4-
associated Deacetylase) chromatin remodeling complexes (Cox et al., 
2010;Kiefer et al., 2002;Liang et al., 2008;van den Berg et al., 2010). SoxC 
proteins share similar roles in the self-renewal of multipotent progenitor cells 
(See Chapter 1). However, the functional link between SoxC and SALL proteins 
in regulating proliferation is unknown. The shared M lineage phenotype between 
sem-2/SoxC and sem-4/SALL mutants suggests an exciting possibility that the 
functions of these two factors are linked. 
A1.2 MATERIAL AND METHODS 
A1.2.1 C. elegans strains 
The following strains were used in this study: LG I: sem-2(n1343); sem-
4(n1378). Analyses were performed at 20°C. 
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A1.2.2 Immunofluorescence staining 
Animal fixation, immunostaining, microscopy and image analysis were 
performed as described previously (Amin et al., 2007). Guinea pig anti-FOZI-1 
(Amin et al., 2007) (1:200) and goat anti-GFP (Rockland Immunochemicals; 
1:1000) were used.  
A1.3 RESULTS 
A1.3.1 sem-4 shares overlapping expression pattern with sem-2 in the 
M lineage 
I examined sem-4 expression in the M lineage using a sem-4::gfp 
transgene (Grant et al., 2000). On the ventral side, sem-4::gfp expression was 
first detected at the 8-M stage in the M.v(l/r)p cells, or the SM grandmother cells 
(50%, N=6). This expression persisted in the SM mother cells (61.5%, N=39), the 
sister cell of the SM mother cell (56.4%, N=39), and the SMs (100%, N=8, Figure 
A1.2A,B). The expression in SM descendants hasn’t been investigated. The 
differentiating BWMs and CCs gradually lose sem-4::gfp expression. Thus sem-
4::gfp expression precedes that of sem-2::gfp expression by one cell division in 
the ventral M lineage, where they subsequent share overlapping expression 
patterns (Figure A1.2A,B., Tian et al., 2011). On the dorsal side, sem-4::gfp 
expression was first observed in the M.d(l/r)p cells, or the CC mother cells (60%, 
N=10) and subsequently in their daughter cells, or the undifferentiated CCs 
(54.5%, N=11) and BWMs (45,5%, N=11, Figure A1.2B). sem-4::gfp expression 
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was not detectable in the differentiating CCs and BWMs. Interestingly, this loss of 
sem-4::gfp expression in the differentiating cells appeared to be transient, as 
sem-4::gfp expression came back on in the fully differentiated BWMs and CCs 
(data not shown). The functional significance of this later expression of sem-
4::gfp is not known.  
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Figure A1. 1: sem-4(n1378) M lineage phenotypes. 
 
(A-B) On the dorsal side, sem-4 mutant has the CC precusors going through an 
extra division and give rise to a pair of BWMs. On the ventral side, sem-4 mutant 
has a fate transformation from SMs to BWMs. 
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Figure A1. 2: In the M lineage, sem-2 and sem-4 share over lapping 
expression patterns, but they do not regulate each other’s expression. 
 
The expression patterns of sem-4::gfp and gfp::sem-2 in the M lineage are 
summarized in panels A and B respectively. On the ventral side, gfp::sem-2 is 
expressed in the SM mother cells and the SM lineage; sem-4::gfp expression is 
detected a cell division earlier than that of sem-2 and overlaps with sem-2 in the 
SM mother and SM cells. sem-4::gfp expression hasn’t been examined in the SM 
descendants, as shown in the dotted lines in panel B. sem-4::gfp is also 
expressed on the dorsal side in CC mother cells, CC precursors and their sister 
BWM precursor cells, while gfp::sem-2 is not expressed on the dorsal side. M 
lineage cells are labeled with anti-FOZI-1 antibody (C, F, I, L). Expression 
patterns of sem-4::gfp are similar in wild-type and sem-2(n1343) worms (C-H), 
while expression patterns of gfp::sem-2 are similar between wild-type and sem-
4(n1378) worms (I-N). Arrows point to the GFP positive M lineage cells.  
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A1.3.2 sem-4 and sem-2 do not regulate each other’s expression in the 
ventral M lineage 
Because sem-4 shares the same ventral M lineage phenotype and 
expression with sem-2, I determined whether they regulate each other’s 
expression in the ventral M lineage. I used the sem-4(n1378) allele, which 
showed 98% SM to BWM fate transformation (Basson et al., 1996), and the sem-
2(n1343) allele, which showed 100% SM-to-BWM fate transformation (Tian et al., 
2011). To my surprise, the expression of gfp::sem-2 was still detectable in sem-
4(n1378) mutants in the M lineage at the 16-M stage (93.75%, N=32) and the 18-
M stage (100%, N=6), in the same pattern and intensity as compared to wild type 
(Figure A1.2 I-N). Similarly, the expression of sem-4::gfp was also present in 
sem-2(n1343) mutants in the M lineage at the 16-M stage (100%, N=8) and the 
18-M stage (100%, N=3), in the same pattern and intensity as compared to wild 
type (Figure A1.2 C-H). These results suggest that sem-2 and sem-4 do not 
regulate each other’s expression.  
sem-2::gfp is not expressed in the dorsal M lineage in wild type worms. 
Interesting, it is expressed in the M.d(l/r)pa cells in sem-4(n1378) mutants 
(34.7%, N=23). sem-4(n1378) mutant worms exhibit a 30% dorsal CC-to -BWM 
fate transformation phenotype (Basson et al., 1996). Taken together, these 
observations suggest that sem-2 is normally repressed by sem-4 in the dorsal M 
lineage.  
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A1.4 DISCUSSION 
Both sem-2 and sem-4 are expressed in the proliferating SM precursors 
and descendants (Tian et al., 2011; this work), while sem-2 and sem-4 mutants 
fail to make the proliferating SM cells (Tian et al., 2011; Basson et al., 1996). I 
have shown that these two genes do not regulate each other’s expression in the 
ventral M lineage. These findings suggest that SEM-2 and SEM-4 are required 
together to specify the proliferative SM fate. It is important to determine how they 
function together. One possibility is that SEM-2 and SEM-4 directly physically 
interact with each other in regulating gene expression; another possibility is that 
they regulate the same set of target genes involved in SM specification and 
proliferation. Despite the lack of mechanistic details, these studies begin to 
connect the SoxC factors with the SALL stem cell factors. Since SALL protein 
function involves the NuRD complex (Cox et al., 2010;Kiefer et al., 2002;Liang et 
al., 2008;van den Berg et al., 2010), it also be interesting to investigate if the C. 
elegans NuRD complex is involved in SEM-4 and SEM-2 function in SM 
specification.  
In addition to the SM-to-BWM phenotype, sem-4 mutants also share 
similar but not identical phenotypes as let-381(RNAi) animals in the dorsal M 
lineage. let-381 encodes the sole FoxF/C factor in C. elegans, and in let-
381(RNAi) worms the M.d(l/r)pa cells (which differentiate into CCs in wild-type 
worms) behave as their ventral counterparts, the M.v(l/r)pa cells that divide to 
produce a SM and a BWM each (Amin et al., 2010). In sem-4 mutants, the 
M.d(l/r)pa cells divide an extra time like their ventral counterparts (a phenotype 
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shared by let-381(RNAi) and sem-4 mutants), but give rise to 4 BWMs, rather 
than 2 SMs and 2 BWMs like in let-381(RNAi) animals (Figure A1.1). It is known 
that let-381 represses sem-2 expression on the dorsal M lineage (Tian et al., 
2011). sem-4 also appears to repress sem-2 in the dorsal M lineage (data not 
shown). Thus, the extra division phenotype of the M.d(l/r)pa cells in both let-
381(RNAi) and sem-4(n1378) animals might be due to the ectopic expression of 
sem-2 in these cells. The reason that the anterior daughters of these cells 
become the SMs in let-381(RNAi) animals is probably because both sem-2 and 
sem-4 are present in these cells. However, the lack of sem-4 in sem-4(n1378) 
mutants will render these cells to become BWMs because both sem-2 and sem-4 
are required for the proper specification of SMs. Therefore, it is important to 
study the relationship between sem-4 and let-381 in the dorsal M lineage. One 
prediction is that sem-4 either positively regulates let-381 expression or works in 
parallel to let-381, while let-381 does not regulate the expression of sem-4.  
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